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ABSTRACT OF DISSERTATION 
 
 
 
 
MODULATION OF INFLAMMATORY CYTOKINE, CHEMOKINE, AND TOLL-
LIKE RECEPTOR GENES AND TRANSCRIPTOME ANALYSIS OF EQUINE 
ENDOTHELIAL CELLS FOLLOWING INFECTION WITH EQUID HERPESVIRUS-
1, AND EQUINE ARTERITIS VIRUS. 
 
EHV-1 is a double-stranded DNA virus whereas EAV is a positive sense, single-
stranded RNA virus. Therefore, genetically, they are very different from one another. 
However, both these viruses are endotheliotropic and thus, infect and replicates in equine 
endothelial cells resulting in vasculitis. Vasculitis is central to the pathogenesis of these 
two viruses. Thus, the main objective of this thesis was to investigate the inflammatory and 
innate immune responses of EECs that contributes towards the development of vasculitis 
following infection with EHV-1 and EAV in-vitro. Since proinflammatory cytokines and 
chemokines produced by endothelial cells play a significant role in the development of 
vasculitis, we investigated their gene expression as well as secretion. Results from this 
study showed that the proinflammatory response of EECs induced by EAV is relatively 
less when compared with the corresponding results from EHV-1 infected EECs. 
Furthermore, EAV elicits a lower type I interferon response in EECs when compared with 
EHV-1. Further investigations revealed an active role played by TLR 3 in inducing the 
proinflammatory response in EHV-1 infected EECs during the first 6 hours of infection but 
not in EAV infected EECs. Analyzing the whole transcriptome of EHV-1 and EAV 
infected EECs revealed a complex pattern of gene regulation and cellular pathways related 
to cellular immune, inflammatory and apoptotic responses. Finally, we investigated host 
genetic factors associated with EHV-1 induced myeloencephalopathy but found no 
evidence for a recessive allele influencing the development of EHM following EHV-1 
infection for any genetic locus was identified. However, more complex host-pathogen 
interactions are possible. 
Key words: EHV-1, EAV, TLR3, Type I interferons, RT-qPCR, Luminex, si-RNA, RNAi, 
GWAS, RNA-seq 
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CHAPTER ONE 
Literature Review 
1.0.Introduction 
1.1 History of horses 
Fossil records of horses (family Equidae) dates back to 55 million years [7]. However, 
it is believed that at the end of the Pleistocene period around 11,000 years ago, wild horses 
of the New World went extinct but the Old-World wild horses and their relatives (zebras, 
onagers and asses) survived. Horses were re-introduced to the New World during the 16th 
century by Spanish explorers [8]. A key aspect in the progression of the human civilization 
is the domestication of plants and animals. Among the animal species domesticated by 
humans throughout the course of history, the dog and the horse hold major importance 
since they were not bred mainly as a food source [9; 10]. Throughout history, the main 
usage of horses was for transportation and warfare [9]. The common consensus is that the 
first instance of horse domestication took place between the 5th  and 4th  millennium BC in 
the Eurasian steppes [11]. Arguably, these domesticated horses descended from either 
Tarpan or Przewalski’s horses [8]. Out of these two truly wild horse groups the Tarpans 
became extinct in the wild in the late 1800s but the Przewalski’s horses are still extant in 
the wild in the steppe regions of east Asia [8]. The domestication of horses became a 
popular and common practice among ancient human civilizations of the Old-World. 
Evidence for the close association between horses and Old-World human cultures can be 
identified in the linguistics of proto-Indo-European cultures where the words for “horse” 
and “foal” were part of their vocabulary. Furthermore, petroglyphs from the bronze age, 
such as the ones found in central Asia depicts horses and horse drawn chariots 
demonstrating the importance of horses in human civilizations. Likewise, the 22-century 
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old Qin “terracotta” army discovered in China contains sculptures of horses bearing 
similarities to the Przewalki’s horses. This spectacular find indicates the importance and 
the usage of horses in Chinese culture. Therefore, since the second millennium, utilization 
of horses for draught work, transportation, sports and in warfare was wise spread in ancient 
Asian and European cultures and since then until the industrial revolution horses have 
contributed immensely to the progression of the human civilization.  
1.2. Equine Industry of the United States of America 
The equine industry of the United States (U.S.) is a large, economically diverse 
industry with a significant contribution to the US economy. According to the results of the 
2017 economic impact study carried out by the American Horse Council Foundation 
(AHCF), the U.S. equine industry has generated approximately $122 billion in total 
economic impact which is an increase from $102 billion since 2005. The U.S. equine 
industry contributes around $50 billion in direct economic impact to the U.S. economy. It 
amounts to a direct employment impact of 988,394 jobs and a total employment impact of 
1.7 million jobs. Furthermore, it contributes approximately $38 billion in direct wages, 
salaries, and benefits. Approximately there are around 7.2 million horses in the U.S., and 
they are being used for recreation, showing, racing and as draught horses. The states of 
Texas, California and Florida occupy the first three spots respectively as the states with the 
greatest number of horses in the U.S. Moreover, around 32 million acres of land is owned 
by the U.S. horse industry while approximately 49 million acres of land is leased for horse-
related uses (https://www.horsecouncil.org/resources/economics/). Kentucky is considered 
as horse country and the city of Lexington is considered as the horse capitol of the world. 
The horse population in Kentucky is approximately 242,400 and it boasts $23.4 billion in 
 
3 
 
equine and equine-related assets. Furthermore, the state of Kentucky is associated with 
35,000 equine operations and 1.1 million acres devoted to the equine industry 
(https://www.horseproperties.net/state/kentucky). 
1.3. Impact of infectious diseases on the equine industry  
Horses in the U.S. are affected by a vast array of infectious agents including viral, 
bacterial, fungal and protozoal infectious agents. These infectious agents have the capacity 
to causes disease conditions in horses ranging from mild diseases which the horse recover 
fairly quickly to fatal conditions that may spread rapidly among horse populations and 
develop into outbreaks [12]. A direct consequence of infectious diseases in horses is the 
detrimental effect it can have on the U.S. equine industry, which is estimated to be around 
$122 billion as well as the U.S. economy as a whole 
(https://www.horsecouncil.org/resources/economics/). Infectious diseases such as West 
Nile, Potomac Horse Fever, and equine herpesvirus myeloencephalopathy (EHM) imparts 
economic losses to the equine industry by causing fatalities in adult horses [13-16]. 
Abortions induced by infectious agents such as the equine herpesvirus-1 (EHV-1) and the 
equine arteritis virus (EAV) imparts severe economic losses by causing the elimination of 
valuable progeny as well as reproductive complications following infection [5; 6; 17-19]. 
Respiratory disease conditions caused by infectious agents such as EHV-1, EHV-4, EAV, 
and the equine influenza virus reduces the performance of race and show horses which in 
turn affects the economy of the equine industry [5; 6; 19; 20]. EHV-1 and EAV are two of 
the most prominent viruses causing reproductive and respiratory disease conditions in 
horses around the world. Collectively, these two viruses are a significant threat to the U.S. 
and the global equine industry as well as the focus of this dissertation.   
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1.4. Viruses that cause respiratory and reproductive diseases of the horse 
As mentioned above, acute and chronic respiratory and reproductive diseases 
resulting from contagious infectious agents have a significant negative effect on the $122 
billion equine industry of the U.S. (https://www.horsecouncil.org/resources/economics/) 
[21]. The most prominent viral respiratory infectious agents of horses in North America 
include equine influenza virus (EIV), equine rhinovirus types 1 (ERhV1) and type 2 
(ERhV-2), equine herpesvirus type-5 (EHV-5), equine herpesvirus type-4 (EHV-4), equine 
herpesvirus type-1 (EHV-1), equine herpesvirus type 2 (EHV-2), equine arteritis virus 
(EAV), and the equine adenovirus while EHV-1, EHV-3 and EAV remains as major virus 
infections of the horse that results in reproductive consequences [21].  
1.4.1. Equine Influenza virus (EIV) 
Influenza viruses belong to the family Orthomyxoviridae and the horse is 
considered a “dead-end” host for influenza A viruses. Being a member of the influenza A 
viruses, equine influenza viruses are considered to be relatively stable in their natural host 
the horse [22]. Recent EIV outbreaks have been caused by the subtype H3N8 which was 
first isolated in 1963. However, prior to the emergence of this strain, the now extinct H7N7 
subtype was considered the major cause of epidemics [23]. Horses of all ages are 
susceptible to equine influenza infections, but foals have a higher resistance towards 
infections due to the presence of maternal antibodies [20; 22]. The clinical signs of equine 
influenza usually include pyrexia, anorexia, nasal discharge and cough [22]. Equine 
influenza infections are rarely lethal but can be accompanied with complications such as 
secondary bacterial pneumonia, myositis, myocarditis, and limb edema [24]. Since 2000, 
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several major equine influenza outbreaks have taken place in the United Kingdom, South 
Africa, India, Japan and Australia [22].   
1.4.2. Equine rhinitis virus (ERV) 
Equine Rhinitis virus (ERV) infections are a major cause of acute respiratory 
diseases in horses all around the world. ERVs belong to the family Picornaviridae and 
genus Aphthovirus. The seropositive nature of horses to ERVs vary depending on their age 
with horses over 12 months of age being more seropositive to the virus. The clinical signs 
of Equine rhinitis A (ERAV) and B (ERBV) viruses include fever, anorexia, nasal 
discharge, coughing, pharyngitis, and lymphadenitis of the head and neck and viremia [25]. 
Moreover, subclinical ERAV and ERBV infections may occur as well. Persistent virus 
shedding in urine and feces may occur following ERAV infections. If left untreated, ERAV 
and ERBV infections can lead to secondary bacterial infections of the upper respiratory 
tract. [26].     
1.4.3. Equine arteritis virus (EAV) 
Similar to EHV-1, EAV too is one of the most important viruses causing 
reproductive and respiratory diseases in horses and has the capacity to severely impact the 
U.S. and the global equine industry [5; 6; 19; 27]. EAV belongs to the order Arteriviridae 
and genus Alphaarterivirus (https://talk.ictvonline.org/taxonomy/) and induces a flu-like 
syndrome as well as abortions. Furthermore, EAV establishes persistent infection in the 
reproductive tract of sexually matured stallions [5; 6; 19; 27]. The pathogenesis and disease 
conditions caused by EHV-1 is discussed in more detail in subsequent chapters.  
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1.4.4. Equine herpesvirus-1 
EHV-1 belongs to the subfamily Alphaherpesvirinae and genus Varicellovirus [28]. 
It is one of the most important viruses causing reproductive and respiratory diseases in 
horses and has the capacity to severely impact the U.S. and the global equine industry [15; 
17; 18]. The respiratory disease caused by EHV-1 is similar to the disease condition caused 
by EHV-4. But unlike EHV-4, EHV-1 can also induce abortions and equine herpesvirus 
myeloencephalopathy (EHM) [15; 17; 18]. Furthermore, EHV-1 establishes latent 
infections in the sensory nerves of the trigeminal ganglia and lymphocytes of the peripheral 
circulation as well as in lymph nodes [29-31] of infected horses. The pathogenesis and 
disease conditions caused by EHV-1 is discussed in more detail in subsequent chapters.  
1.4.5. Equine herpesvirus-2 (EHV-2) 
EHV-2 is a slow growing virus in the subfamily Gammaherpesvirinae and the 
genus Percavirus [28]. It is ubiquitous among horse populations and has been isolated from 
horse populations from many different countries including United Kingdom, Japan, 
Australia, New Zealand, Switzerland, Germany, United States, Canada, Hungary and 
Poland [32]. The significance of EHV-2 as an equine upper respiratory tract pathogen has 
not been studied extensively. However, several studies have implicated EHV-2 with upper 
respiratory tract disease, inappetence, lymphadenopathy, immunosuppression, 
keratoconjunctivitis, general malaise and poor performance [32]. A study done in 
Argentina has revealed that 79.7% of horses were sero-positive for EHV-2 while a similar 
study has revealed that 67% of horses displaying signs of clinical respiratory diseases were 
positive for EHV-2 [32]. Furthermore, an experimental infection study has shown that 
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unvaccinated adult horses as well as foals develop respiratory symptoms following 
infection with EHV-2 [33]. 
1.4.6. Equine herpesvirus-4 (EHV-4) 
Equine herpesvirus-4 belongs to the subfamily Alphaherpesvirinae and genus 
Varicellovirus [28]. It is closely related to EHV-1 which belongs to the same genus sharing 
a nucleotide similarity between 55 - 84% and an amino acid similarity between 55 – 96% 
with EHV-1 [3; 4]. EHV-4 is one of the most important herpesviruses infecting horse 
populations around the world as well as a major cause of respiratory diseases in horses [17; 
18]. It imparts severe economic losses to the global equine industry through the respiratory 
illness it causes as well as due to the lost time for training and performance [34]. 
Furthermore, it is reported that on rare occasion EHV-4 may cause isolated incidents of 
abortions [4]. Serological studies from around the world has attested to the relatively high 
prevalence of EHV-4 among horse populations [18; 35]. The pathogenesis of EHV-4 is 
quite different than that of EHV-1 and is most often limited to the upper respiratory tract 
resulting in mild rhinopneumonitis [17; 18; 36]. Even though rare, abortions due to EHV-
4 infections have been reported in the United States (US) and in the United Kingdom [18]. 
Studies have shown that EHV-4 can also infect and replicate in endothelial cells of local 
capillaries of lymph nodes and pulmonary vessels, and therefore, it has been suggested that 
the pathogenesis of EHV-4 abortions might be following a vasculitis-based mechanism 
similar to that of EHV-1 [37]. However, even though EHV-4 incidences are relatively 
higher than EHV-1 in Kentucky, abortions due to EHV-4 in the US are considerably low 
(less than 1%) [38]. Interestingly, in Japan, it is believed that prior to 1967, only EHV-4 
strains were responsible for abortions and respiratory diseases in horses. Clinical signs of 
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EHV-4 induced respiratory disease include pyrexia, anorexia, nasal and ocular discharge. 
Secondary bacterial infections in the upper respiratory tract may be a contributory factor 
in the development of rhinopneumonitis [17; 18].  
1.4.7. Equine herpesvirus-5 (EHV-5) 
EHV-5 is a member of the subfamily Gammaherpesvirinae and the genus 
Percavirus [28]. Interestingly, studies done on EHV-2 lead to the discovery of EHV-5 from 
horses in Australia with upper respiratory tract disease [39]. Following the initial discovery 
of EHV-5, several countries including New Zealand, Switzerland, Argentina and Germany 
has reported EHV-5 infections [40]. Apart from the upper respiratory tract disease caused 
by EHV-5, it is also implicated in the development of equine multinodular pulmonary 
fibrosis (EMPF), which causes pulmonary fibrosis in adult horses [41].  
1.4.8. Equine Adenovirus type-1 (EAdV-1) 
EAdV-1 is a nonenveloped, icosahedral, double-stranded DNA viruses of the 
family Adenoviridae and genus Mastadenovirus (https://talk.ictvonline.org/ictv-
reports/ictv_9th_report/dsdna-viruses-2011/w/dsdna_viruses/93/adenoviridae).  EAdVs 
were first isolated in the U.S. in 1969 and since then, two EAdV serotypes have been 
identified (EAdV-1 and EAdV-2) [42]. EAdV-1 is a major causative agent of upper 
respiratory tract infections in horses while EAdV-2 is associated with gastrointestinal tract 
infections in horses [42]. EAdV-1 has a worldwide prevalence and has been isolated 
frequently from nasopharyngeal secretions from foals and adult horses with or without 
respiratory disease [43]. In particular, several reports have indicated that EAdV-1 
infections cause severe respiratory tract infections in Thoroughbred and Arabian foals 
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which can become life threatening [42; 43]. Fatal pneumonia has been reported in Arabian 
foals and Fell pony foals with severe combined immunodeficiency. However, EAdV-1 
induced pneumonia has been reported in immunocompetent foals as well [42; 43].  
1.5.Viruses that cause neurological conditions in horses 
1.5.1.  West Nile Virus (WNV) 
West Nile virus was initially isolated in 1937 from the West Nile district of Uganda 
[44]. WNV belongs to the family Flaviviridae and genus Flavivirus. It is an arbovirus 
transmitted by mosquitos and usually maintained in a bird-mosquito-bird transmission 
cycle [45]. However, occasional WNV transmission occur to other vertebrates such as 
horses and humans who are considered as “dead-end” hosts. These “dead-end” hosts do 
not develop sufficient viremia to re-infect mosquito species to sustain infectivity cycles.  
Within the U.S., only a few species of Culex mosquito drive the transmission of the virus 
even though the virus has been detected in 65 different mosquito species and 326 bird 
species [44; 45]. WNV infected horses, in most cases, do not display a clinical illness other 
than fever. However, during recent WNV outbreaks, around 10% of infected horses 
displayed neurological disorders. The most common symptoms in horses include ataxia, 
paresis or paralysis of the limbs, recumbency, skin fasciculations, muscle tremors and 
rigidity, hyperesthesia and even aggressiveness [44].  
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1.5.2. Equine Rabies 
Rabies belongs to the family Rhabdoviridae and genus Lyssavirus and it is an 
uncommon neurological disease of horses [46; 47]. However, human and animal rabies 
remains a notifiable condition in the U.S. since 1944 [46]. In the U.S., equine rabies is not 
a significant cause of equine deaths as it is in Central and South America. In 2017, 13 rabid 
horses and donkeys have been reported in the U.S. which is a significant decrease from the 
23 reported in 2016. However, England, New Zealand, Hawaii, Australia, and some 
Caribbean and Pacific Islands are reported as free from the disease. Most often, rabies gets 
transmitted to horses via a bite from a rabid dog although transmission due to encounters 
with rabid wild animals have also been reported. In North America, racoons, foxes and 
skunks are the main reservoir for rabies although bats have also been reported to transmit 
rabies to horses. Rabies is almost always fatal once clinical signs develop and in horses 
these symptoms include neurological signs, behavioral changes, lameness and colic. 
Unlike in dogs, the furious form of rabies, which makes rabid animals aggressive, is not 
common in horses but the dumb form is. However, most cases of equine rabies exhibits 
fever, hyperesthesia, ataxia followed by recumbency and loss of anal sphincter tone and 
death is often due to cardiorespiratory failure [46; 47]. 
1.5.3. Equine herpesvirus myeloencephalopathy (EHM) 
As mentioned above, EHV-1 is one of the most important equine herpesviruses that 
poses a significant threat to the U.S. and the global equine industry. One of the pathological 
manifestations of EHV-1 infection is EHM, which is a rare and fatal neurological condition 
that has a a 15-50% case-fatality rate [48; 49]. In Recent years, the occurrence of EHM has 
increased dramatically with outbreaks reported in the United States, South Africa, New 
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Zealand and several European nations, including the United Kingdom. Susceptibility to 
EHM appears to be determined by several host factors including age, physical condition, 
immune status and whether the infection is a primary exposure [48; 50]. Furthermore, there 
is some evidence to suggest that a single point mutation in the DNA polymerase gene of 
some EHV-1 strains increase their ability to induce EHM following infection [51]. In most 
cases, horses that develop EHM display neurological signs which include dysmetria, ataxia 
and paresis of limbs, toe dragging, hypotonia of the tail and recumbency [15; 52]. 
1.6. Persistent viral infections 
During persistent infections, the infected virus is not cleared and remains in cells of the 
infected host. Silent as well as productive infections are associated with persistent virus 
infections in the absence of host cell death or even extensive cell damage. Persistent virus-
host interaction maybe of three types defined as latent, chronic and slow infections [53]. 
Several host organ systems are targeted by viruses that has the capacity to establish 
persistent infections [53]. Herpes viruses such as the Herpes simplex-1 (HSV-1), EHV-1 
and varicella-zoster viruses establishes lifelong latent infections in the host nervous system. 
HSV-1 and varicella-zoster viruses establishes latent infections in the dorsal root ganglia 
while EHV-1 utilizes the sensory nerves of the trigeminal ganglia, lymphocytes of the 
peripheral circulation as well as in lymph nodes. [29-31; 54]. Following reactivation, 
infectious virus particles travel along peripheral nerves to body surface and may initiate 
lesion (cold sore or zoster) [53; 54]. However, some viruses choose to persist in the central 
nervous system (CNS). Such sites of virus persistence can be regarded as a “dead-end” due 
to the little to no opportunity the virus has in shedding infectious virus particles to the 
outside. One reason why some viruses choose the CNS to establish persistent infections 
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maybe because host anti-viral mechanisms have restricted access to the CNS and therefore, 
persistent infection can be easily established [54]. Subacute sclerosing panencephalitis 
caused by the measles virus, progressive multifocal leukoencephalopathy caused by the 
human polyomavirus 2 establish persistent infection in the CNS [54; 55]. 
There is evidence to suggest the filoviruses such as the Ebola virus persists in the 
reproductive tract of infected individuals. However, in the case of the Ebola virus the host 
immune system clears virus material over time which may take from a few months to years 
[55]. In more recent years, it was reported that individuals infected with the Zika virus may 
shed virus particles in semen for about 80 days while viral nucleic acids maybe detected 
for a period up to 6 months [56; 57].  Similarly, EAV persists in the male reproductive tract 
as well and virus infected stallions may shed the virus for a few months to lifelong [5; 6; 
19].  
Some viruses choose the renal system of the host to establish persist infection which 
enables them to readily spread to the outside when reactivated. The human 
cytomegalovirus utilizes the tubular epithelial cells in the kidney to establish persistent 
infection [54]. In addition, the renal epithelium is utilized by several other polyomaviruses 
such as the simian virus 40 (SV40), the K virus of mice, and the JC and BK viruses of 
humans to establish persistent infection [58].  
The lymphoreticular system is another host system targeted by viruses to establish 
persistent infection. The Epsteen-Bar virus targets memory B cells which are long lived 
immune cells to establish persistent infection. Furthermore, the human immunodeficiency 
virus utilizes resting CD4+ T cells to maintain a dormant reservoir [54; 58].  
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The murine leukemia virus and the mouse mammary tumor virus which are retrovirus 
integrates its genome into the hematopoietic progenitor cells and mammary epithelial stem 
cells respectively. Since these viruses infects and integrates the viral genome into host stem 
cells the virus can persist for an indefinite period, providing a continuous supply of 
infectious virions [54; 58].  
Interestingly, the bovine viral diarrhea virus (BVDV) establishes persistent infection in 
the fetus of cattle. BVDV infected bovine fetuses develop immunocompetence towards 
BVDV which helps the virus to evade the host immune response and maintain persistent 
infection [59].  
1.6.1. EAV persistent infection 
Following infection via the respiratory or venereal routs, EAV establishes 
persistent infection in the reproductive tract of stallions which results in the continuous 
shedding of the virus in semen [5; 6; 19]. Furthermore, this establishment of persistent 
infection is androgen dependent [60]. In some cases, virus shedding of these persistently 
infected carrier stallions may stop within a few weeks or months post infection. However, 
in 10-70% of infected stallions, virus shedding may persist for many years to lifelong [5; 
6; 19; 27; 61]. Carrier stallions do not display any clinical signs of equine viral arteritis 
(EVA) or a decrease in reproductive capacity [27; 62; 63]. Furthermore, studies have 
demonstrated that there is a correlation between the EAV carrier status of stallions and the 
susceptibility of a subpopulation of CD3+ T cells of those stallions to in-vitro EAV 
infection. Furthermore, the same studies demonstrated that this correlation has a strong 
association with the CXCL16 gene on equine chromosome 11 [64; 65].  
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Interestingly, the virus persists in the male reproductive tract despite the presence 
of very high neutralizing antibodies in the serum [27; 62; 63]. Studies have demonstrated 
that there is a negative correlation between the increase in serum neutralizing antibody 
titers and the host viremia titers suggesting neutralizing antibodies play a role in virus 
clearance, except in the case of carrier stallions [66]. Even though the mechanisms utilized 
by EAV to evade the host immune responses has not been fully identified, several previous 
studies have demonstrated the importance of host factors in the development EAV 
persistent infections in stallions. Recent work has demonstrated that establishment of long-
term persistent infection correlates with the in vitro susceptibility of a subpopulation of 
CD3+ T lymphocytes to EAV infection [64; 65; 67-69]. As such, stallions with the 
susceptible phenotype for CD3+ T lymphocytes are at a greater risk of becoming long-term 
persistently infected carriers compared to stallions with the resistant phenotype. It has been 
demonstrated through a genome-wide association study that these susceptible/resistance 
phenotypes are associated with the CXCL16 gene located in equine chromosome 11 [67]. 
Subsequent studies have further demonstrated that the CXCL16 gene consists of two allelic 
variants and the stallions with the susceptible phenotype (CXCL16S) establishment of long-
term persistence whereas stallions with the resistant phenotype (CXCL16R) is associated 
with early viral clearance [70]. Interestingly, the CXCL16S isoform functions as an entry 
receptor for EAV while the CXCL16R isoform does not [69; 70]. Furthermore, Carossino 
et.al. (2018) has demonstrated the microRNA eca-mir-128 present within seminal 
exosomes, which is also a putative regulator of CXCL16, is downregulated in horses with 
persistent EAV infections. The downregulation of this microRNA promotes the 
upregulation of CXCL16 at anatomical sites where EAV establishes persistent infection 
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[71]. Taken together, CXCL16 and eca-mir-128 are important host factors that play 
significant roles in the complex mechanism utilized by EAV to establish persistent 
infection in stallions [72]. 
It has been demonstrated that the ampullae is the primary sites of EAV persistent 
infection [73; 74]. Within these glands, EAV shows a strong tropism towards vimentin-
positive stromal cells of the lamina propria as well as T (CD2+, CD3+, CD5+, and CD8+) 
and CD21+ B lymphocytes  [74]. Moreover, transcriptome analysis of the accessory sex 
gland ampullae from stallions with persistent EAV infections has demonstrated CD8+ T 
lymphocyte infiltrations suggesting a predominant CD8+ T lymphocyte response [73]. 
However, EAV infected cells usually localize within inflammatory infiltrates suggesting 
EAV has the capacity to replicate regardless of this host anti-viral response [74]. 
Transcriptome analysis of the ampullae of persistently infected stallions further revealed 
the upregulation of inhibitory receptor molecules such as PDCD1 and transcriptional 
factors EOMES, NFATC2 and PRDM1 which maybe resulting in CD8+ T lymphocyte 
dysfunction which can hinder the virus clearance process by these lymphocytes [73]. 
Furthermore, T regulatory cells, which have been implicated in the suppression of local 
immune responses following virus infections, have also been detected among 
inflammatory infiltrates. These factors may contribute to the local immunosuppression in 
the ampullae and other accessory sex glands which may promote viral persistence [74]. 
Furthermore, only a small fraction of the CD8+ T lymphocytes infiltrates express granzyme 
B or interferon gamma which indicates a local suppression of the CD8+ T cell mediated 
immune response at these accessory sex glands [74]. Additionally, studies have 
demonstrated that in persistently infected stallions EAV undergoes antigenic drift that may 
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contribute to immune evasion [74]. The importance of androgens in the establishment of 
EAV persistent infection is evident by the fact that the only successful method of clearing 
the virus in persistently infected stallions is through castration [60; 74]. The local 
immunosuppression induced by androgens maybe another factor influencing the 
establishment of EAV persistence. As such all these factors point towards a multifaceted 
mechanism at play during the development of EAV persistence [74].  
1.6.2. EHV-1 latent life cycle 
Herpesviruses are among the most successful viral pathogens affecting both humans and 
animals and one key reason for their success is their ability to establish latent infections 
and periodically reactivate [75]. As mentioned before, the order Herpesvirales has 3 
subfamilies and all these subfamilies include viruses that can establish latency. Following 
the initial lytic cycle of infection in horses, EHV-1 establishes latent infection in about 
60% of naturally infected horses [29]. During this time the infected animals show no 
apparent clinical signs, virus shedding or viremia [1]. In HSV-1, latency is established in 
sensory neurons innervating the site of primary infection [76]. Many different studies has 
looked into elucidating the specific site of EHV-1 latency and they have reported the 
sensory nerves of the trigeminal ganglia and lymphocytes of the peripheral circulation as 
well as in lymph nodes as possible candidate sites [29-31]. Furthermore, reactivation of 
latently infected EHV-1 from leukocytes has been demonstrated but not from the 
trigeminal ganglia [29]. The reasons and the mechanisms that drive herpesviruses towards 
latency is not fully understood. However, the prevailing consensus regarding latency is that 
(a) the failure to initiate the expression of viral IE genes promote latency; (b) The 
herpesvirus genome exists in a non-replicating “endless” state during latency; (c) only the 
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latency associated transcripts (LATs) are transcribed during latency; (d) cellular signals 
that can activate the expression of viral IE genes induce herpesvirus reactivation [76]. With 
these characteristics, the latent herpesvirus particles escape the immune system and the 
host becomes a life-long carrier of the virus [1].   
 
 
 
 
 
 
 
Figure 1.1: EHV-1 latent cycle. (A) Following the production of progeny virions, virus particles 
enter innervating sensory neurons and migrates to the nucleus of the neuron. The viral DNA gets 
released and circularized once inside the nucleus and latency associated transcripts are expressed. 
(B) During reactivation, the genes that promote the lytic life cycle are expressed promoting the 
production of infectious virus particles. Infectious virus particles are released from the axon resulting 
in recurrent infection and virus shedding. Adapted and reproduced with permission from Springer 
Nature: Nature Reviews Microbiology [2], copyright 2008.   
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1.7. Equine arteritis virus  
1.7.1. EAV classification 
The equine arteritis virus (EAV) is a positive sense single stranded RNA virus in 
the order Nidovirales. The order Nidovirales is a relatively large group of positive sense 
RNA viruses [77]. According to the previous classification, the order Nidovirales consists 
of three families: Coronaviridae, Arteriviridae, and Roniviridae. The family Arteriviridae 
contained the single genus Arterivirus to which EAV belonged [78]. However, according 
to the latest ICTV classifications, the order Nidovirales contains 7 sub orders, 9 families, 
20 subfamilies, 33 genera, 59 sub genera and 88 virus species. Within this large collection 
of RNA viruses, EAV belongs to the suborder Arnidovirineae, family Arteriviridae, 
subfamily Equarterivirinae, and the genus Alphaarterivirus 
(https://talk.ictvonline.org/taxonomy/). In contrast to the family Herpesviridae, virion 
morphology of the nidoviruses do not share significant similarities. Furthermore, they 
differ in their host specificity and genome size as well. The basis for classifying viruses 
under the order Nidovirales lies with the similarities in genome organization, mechanisms 
of gene expression, and in sharing a common ancestry for the key replicase gene [77-81]. 
1.7.2. EAV virion architecture 
EAV is the prototype virus of the family Arteriviridae and the causative agent of equine 
viral arteritis (EVA) [5; 6; 19; 77]. Arteriviruses are enveloped, spherical virus particles 
containing glycoprotein projections on their envelope. The EAV virion has a spherical 
morphology with a 40 to 60 nm diameter [82]. The genome size and the number of encoded 
genes vary considerably among the members of the order Nidovirales [78; 80; 83]. 
Arteriviruses have relatively smaller genomes when compared to other members of the 
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order Nidovirales and the genome size of EAV varies between 12,704 and 12,731 kilobases 
(kb) between different viral strains (kb) [5; 6; 19; 84]. 
 
 
 
 
 
The EAV genome is encapsidated by an icosahedral core composed of the nucleocapsid 
protein and this core particle is wrapped around by a smooth lipid bilayer envelope lacking 
large projections. However, it contains 7 envelope proteins (Figure 1.2) [5; 6; 80; 82]. 
1.7.3. EAV genome organization 
EAV has at least 10 open reading frames (ORFs) encoding for 13 non-structural proteins 
(nsps) and 8 structural proteins (Figure 1.3) [5; 6; 80; 82]. The EAV genome, as it is with 
all the members of the family Arteriviridae has a capped structure at its 5' end and a 
polyadenylated (poly A) tail at the 3' end. In addition to that, the 5' and the 3' ends of the 
genome contains untranslated regions (UTRs). 
Figure 1.2: Virion architecture of EAV consists of a nucleocapsid and 7 envelope 
proteins. Major envelope proteins (GP5 and M) forms dimers while 3 of the 5 minor 
envelope proteins (GP2, GP3 and GP4) forms trimers. E and ORF5a are also minor 
envelope proteins. Adapted and reproduced with permission from Elsevier: [Vet Clin 
North Am Equine Pract.][5], copyright 2014.  
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The 5' proximal three-quarters of the genome is occupied ORF1a and ORF1b which 
are the two largest ORFs in the EAV genome (Figure 1.3) [5; 6; 82; 84]. ORF1a and ORF1b 
are connected to each other with a -1 ribosomal frameshift site (RFS) and they encode for 
two replicase polyproteins which gets extensively processed post-translation by 3 viral 
proteases (nsp1, 2 and 4) to produce at least 13 nsps (nsp1-12, including nsp7 α/β) [5; 6; 
82; 84]. The 8 structural proteins of EAV are encoded by a nested set of segmented mRNAs 
located at the 3' proximal quarter of its genome and not from its genomic RNA (Figure 1.3) 
[5; 6; 82; 84]. The 8 structural proteins of EAV include 7 envelope proteins (E, GP2, GP3, 
GP4, ORF5a protein, GP5 and M) and the nucleocapsid protein (N) [5; 6; 82; 84]. Out of 
the 7 envelope proteins 3 (GP2, GP3 and GP4) are considered minor envelope proteins and 
Figure 1.3: Genome organization of EAV depicting the ORFs and the respective proteins 
coded by them. The 5' proximal three-quarters of the genome is occupied ORF1a and 
ORF1b which gets translated into two polyproteins which gets autocatalytically 
processed by three viral proteases (nsp1, 2 and 4) to generate EAV nonstructural proteins. 
The nested set of mRNAs are also indicated. RNA 1 is identical to the EAV genome and 
RNAs 2-7 code for the EAV structural proteins. The pink boxes represent the body TRS 
sequences and the light blue box at the 5' end of each sg mRNA represents the common 
leader sequence. The sgmRNAs 2 and 5 are bicistronic while the rest are functionally 
monocistronic. Adapted and reproduced with permission from Elsevier: [Veterinary 
Microbiology][6], copyright 2013.   
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they form a heterotrimer while the major envelope proteins, M and GP5 form disulfide-
linked heterodimers [5; 6].  
1.7.4. EAV viral proteins 
Compared to EHV-1, EAV is a relatively small virus with a smaller genome [3-6]. 
While the EHV-1 genome contains 76 genes coding for a total of 77 viral proteins, the 10 
ORFs of EAV codes for a mere 21 viral proteins [1; 3; 5; 6; 28]. Proteins encoded by the 
EAV genome is classified into two groups as structural and non-structural proteins. EAV 
structural proteins consists of the 7 envelope proteins E, GP2, GP3, GP4, ORF5a protein, 
GP5, and M encoded by ORFs 2a, 2b, 3-4, 5a, 5b, and 6, and a nucleocapsid protein (N) 
encoded by ORF7. The 3' proximal quarter of the EAV genome contains the ORFs that 
code for the structural proteins (Figure 1.4). The minor envelope proteins GP2, GP3 and 
GP4 form heterotrimers while the major envelope proteins GP5, and M form a disulfide-
linked heterodimer in the EAV particle (Figure 1.3). The structural proteins of EAV takes 
part in the formation of the EAV virion [5; 6; 82; 84].   
EAV non-structural proteins (nsps) are synthesized by the autoproteolysis of the 
large polyproteins pp1a and pp1ab which are the products of ORF1a and ORF1ab 
respectively [85]. ORF1a and ORF1b together is known as the replicase gene and it 
occupies 75% of the 5’ end of the EAV genome.  Translation of replicase gene results in 
the production of pp1a (1728 aa) and pp1ab (3175 aa) which gets auto-catalytically cleaved 
at 11 sites by 3 internal proteinases (nsp1, nsp2, and nsp4) resulting in the production of 
the EAV non-structural proteins (nsps) 1-12 [86; 87]. Expression of pp1ab occurs through 
a -1 ribosomal frameshift mechanism in the overlapping region of ORF1a and ORF1b 
(Figure 1.5)  [80]. 
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1.8. Equine viral arteritis 
Equine viral arteritis (EVA) is a respiratory and reproductive disease of the family 
Equidae caused by EAV [5; 6; 19; 27; 88-90]. It was first isolated in 1953 from a fetal lung 
following a respiratory disease outbreak which also accompanied abortions [91; 92]. Since 
then EAV outbreaks have been reported from countries [61; 93-95]. Furthermore, 
serological studies done using different horse populations around the world has 
demonstrated that EAV has a worldwide prevalence [61]. Horses in almost every country 
in the European continent is seropositive to EAV. However, the percentage of 
seroconverted horses in European countries vary between 6 and 90% [96-100]. 
Furthermore, the seropositivity for EAV among different breeds of horses such as the 
European Haflingers, Norikers, Warmbloods, and Lipizzans and the American 
Standardbreds were between 50 and 94% [95; 99]. The seropositivity for EAV among 
American Quarter horses and thoroughbreds were around 0.6% and <5,4% respectively 
[61; 95; 101]. This indicates the seroprevalence for EAV varies among different countries 
and breeds [19].  Only a hand full of countries such as Iceland, Japan, and New Zealand 
are free from the disease [27; 102]. Interestingly, the seroprevalence for EAV increases 
with the age of the horse suggesting a repeated exposer to EAV as the horses age [61; 100]. 
Recent studies have demonstrated that the difference of seroprevalence among horse breeds 
have a genetic origin. Among stallions, the trait of becoming long term carriers or clearing 
EAV shortly after infection is linked to the in-vitro susceptibility of a subset of CD3+ T 
lymphocytes to EAV infection. As such, stallions with this subset of susceptible CD3+ T 
lymphocytes are at a higher risk of becoming long term carriers [67; 68; 103].  
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Transmission of EAV occurs via two main routs which are the venereal and respiratory 
routs [61; 92]. During the acute phase of infection, horses shed the virus in nasal secretions 
7-14 days post infection [104]. Aerosolization of virus particles in respiratory secretions 
facilitate horizontal transmission of the virus from infected to non-infected horses [19]. 
Aerosolized virus particles originating from urine and other bodily secretions, as well as 
from aborted fetuses and fetal membranes from infected horses can also transmit the virus 
via the respiratory rout [98; 99; 105]. In addition, the virus can be present in the feces of 
acutely infected animals up to 8 days post infection [106] as well as in the female 
reproductive tract for a short time following infection [105]. Transmission of EAV via the 
venereal rout occurs with semen from acutely or chronically infected stallions during 
natural or artificial breeding [63]. Virus shedding via the venereal rout can occur during 
the acute phase of the infection or when an acutely infected stallion becomes a carrier 
animal. It is estimated that around 10-70% of the acutely infected stallions become carriers 
that continuously shed the virus in their semen ranging from several weeks (short term 
carriers) to life long (long term carriers) [61; 63]. The establishment of persistent infection 
in stallions by EAV is similar to the establishment of latent infections by EHV-1 in that it 
allows the virus to establish a natural reservoir that is responsible for the survival of the 
virus as well as its perpetuation and evolution [61; 62; 107] 
1.8.1. Clinical signs 
Following EAV infection via the respiratory rout, the initial virus replication takes 
place in alveolar macrophages and bronchiolar epithelial cells within 24 hours post-
infection (hpi) [108]. Within the first 48 after infection the virus drains into regional lymph 
nodes, especially the bronchial lymph nodes [109]. This is followed with virus shedding in 
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nasal secretions and typically lasts up to 7-21 days [109]. Once inside the lymph nodes the 
virus infects Peripheral blood mononuclear cells (PBMCs) and initiates cell associated 
viremia (CAV) within 72 hpi which may last up to 3-19 days post infection. Development 
of CAV is essential for the pathogenesis of the virus since it allows the virus to spread 
throughout the body and replicates in 2ry replication sites such as the vascular smooth 
muscle cells and endothelial cells, and cause systemic panvasculitis [6; 88; 110]. 
Furthermore, the characteristic histological lesion associated with EVA is severe 
necrotizing panvasculitis of small vessel. Therefore, abortions, which is one of the main 
reproductive consequences of EAV infections is a result of the vasculitis and thrombosis 
induced by EAV in the myometrial blood vessels of the pregnant uterus [88].  
The severity of the clinical signs displayed during the acute phase of EAV infection 
varies according to the age, genetics and the physical condition of the horses as well as the 
viral strain,  challenge dose and the route of infection [111; 112]. The horse adapted, highly 
virulent Bucyrus strain of EAV causes high mortality in healthy mature horse. However, it 
is a laboratory derived experimental virus variant with an extreme form of pathology that 
is not seen in EAV field isolates. The field isolates of EAV can be categorized into three 
groups according to the severity of clinical signs and the following disease manifestations. 
As such, strains such as EAV KY84 and EAV KY77 cause a severe and a moderate disease 
of EVA respectively. Strains such as EAV SWZ64 and EAV AUT68 cause a mild form of 
EVA and EAV KY63, and EAV CA95 infections are asymptomatic [113-115].  
1.8.2. Acute infection 
Most acute EAV infections are subclinical or produce barely detectible symptoms [98]. 
Usually it is the very young, old and the stressed horses that develop a clinically apparent 
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illness following acute infection with EAV [98]. Clinical signs usually develop 3 to 14 
days following exposure to virus and may last up to 5 to 9 days [98]. Acutely infected 
horses initially show a flu-like illness followed with fever up to 41°C, depression, anorexia 
limb and ventral edema, periorbital edema, conjunctivitis, lacrimation, nasal discharge, and 
urticaria [27; 92]. Onset of fever is accompanied with leucopenia involving both 
neutrophils and lymphocytes [116]. In fact fever and leukopenia are considered the two 
most consistent clinical signs [92; 117]. Severe clinical signs are usually seen with foals 
and neonates and these include respiratory distress, colic, and diarrhea and may result in 
mortality [112; 118]. However, other than with foals and neonates, infections with EAV 
field isolates are rarely fatal to adult horses [61; 114]. As mentioned earlier, the virus can 
establish persistent infections in the reproductive tract of the stallion but in geldings and 
mares, the virus gets cleared within about a month after infection [61].  
1.8.3. Reproductive consequences      
Abortions in pregnant mares is one of the main reproductive consequences of EAV 
infections. A pregnant mare may abort starting from 3 months to over 10 months into 
gestation either with or without displaying any clinical signs. Furthermore, EAV induced 
abortions may occur at the end of the acute phase or during the convalescent phase of 
infection [61; 119; 120]. The incidence of abortions during natural EAV outbreaks range 
from <10% to 71% and this could be due to the differences in the abortigenic potential of 
different EAV strains [19; 61; 91; 121]. The aborted fetuses, in most cases are partially 
autolyzed but may be expelled fresh as well [61; 120; 122]. EAV infections in the late 
gestation period may result in a premature delivery of a weak foal that may not survive or 
a foal that develops the clinical disease within a short period of time [112].  
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EAV infections in stallions may result in a period of subfertility during the acute phase 
of the infection ranging from 6 to 11 weeks after infection. This sub-fertile period is usually 
associated with decreased sperm motility, concentration and percentage of 
morphologically normal sperm cells as well as a decrease in libido [123]. Furthermore, 10–
70% of EAV infected stallions and sexually mature colts become carriers of the virus by 
establishing persistent infection and continuously shed the virus in their semen ranging 
from several weeks (short term carriers) to months, years or lifelong (long term carriers) 
that shows no changes in their semen quality [19; 61; 63; 124]. There is evidence to suggest 
that the carrier state is androgen-dependent and this explains the lack of it in mares geldings 
or prepubertal colts [61; 125]. Virus shedding in semen usually starts around 5 days post 
infection and the sperm-rich fraction of semen contains the virus [63; 123]. 
1.8.4. EAV vaccination and management 
Several studies have investigated the use of antiviral compounds against EAV 
infections but none of them have been proven to be successful in treating acute EVA [126; 
127]. As such vaccination and proper management applications are one of the best methods 
to prevent and control this disease. Currently, in the US and Canada, a modified live 
vaccine (MLV) is being used against EAV (ARVAC®) [62]. However, this MLV vaccine 
is not licensed in European countries and Japan. An inactivated EAV vaccine (Artervac®) 
is used in several European countries instead of the MLV vaccine. Compared to the MLV 
vaccine, Artervac® has a reduced immunogenicity and needs to be re-vaccinated semi-
annually. Furthermore, its efficacy in preventing clinical EVA is not well characterized 
[19; 98].  
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The intra-muscular MLV vaccine has been in use in the US since 1985 and has been 
proven to be safe as well as induce protective immunity against EVA [105; 128; 129]. 
Studies have shown that the vaccine elicits the production of neutralizing antibodies 5-8 
days post vaccination and this antibody titer peaks 7-14 days post-vaccination [105; 128-
130]. The protective antibody response may last up to 2 years and annual revaccination is 
recommended to maintain the protective level of neutralizing antibodies titers which is 
estimated to be 1:64 [19; 131; 132]. Even though vaccination with the MLV can prevent 
clinical EVA as well as prevent virus shedding in semen as well as persistent infection, it 
does not prevent re-infection and therefore, it is possible for vaccinated horses to display 
viremia or shed the virus is nasal secretions if they get exposed to and re-infected with 
EAV post vaccination [61; 105; 130]. 
It is not recommended to vaccinate pregnant mares with the MLV vaccine especially 
during the last 2 months of gestation since there is a high chance for abortions [133]. 
Furthermore, it is not recommended to vaccinate dams with foals <6 weeks of age. Foals 
should be vaccinated only when they are 6 months of age or older. This is to prevent the 
neutralization of the MLV vaccine by maternal antibodies against EAV. Moreover, 
vaccination of foals before the onset of puberty is highly recommended to prevent them 
from becoming carriers of the virus [19; 98].      
Management practices to control and prevent EVA are aimed at preventing the spread 
of EAV through  Identification of  carrier  stallions,  the  quarantine  of  new  arrivals,  the 
segregation of pregnant mares and foals from other horses,  implementation of biosecurity 
measures, and enforcement of vaccination programs [19; 101]. It is recommended to assess 
a stallion’s vaccination history, serological status and the virological status of their semen 
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prior to breeding or introduction into a new farm in order to prevent new EAV outbreaks. 
Furthermore, 60 days prior to breeding, stallions should be assessed for the presence of 
neutralizing antibodies against EAV. Virological assessment of semen should be 
performed in unvaccinated yet seropositive stallions in order to determine their infection 
status and potential carrier state. If a stallion is confirmed as a carrier it should be kept 
isolated from other non-infected stallions, however, it can be bred with a seropositive mare 
[105]. Furthermore, it is highly recommended to vaccinate horses that frequently travel to 
competitions or come into close contact with other horses on a regular basis.  
During EAV outbreaks, the state veterinarian should be immediately notified, and the 
premises placed under strict quarantine. Horses with symptoms or in close contact with 
affected horses should be isolated and all animal movements should be suspended 
(http://www.aaep.org/info/guidelines).  Furthermore, breeding programs at the affected 
premises should be put on hold and at-risk horses should be vaccinated immediately. 
Following quarantine, it is important to decontaminate stalls and equipment on the affected 
premises with any disinfectant. Usually disinfectants containing phenolic, chlorine, iodine, 
and quaternary ammonium compounds are adequate to inactivate EAV [5; 19].  
1.9. Host immune response against EAV 
1.9.1. Innate immune response 
As mentioned earlier, EAV infects horses in two main ways, either via the 
respiratory rout or the venereal rout [61; 92]. Therefore, during the infection process, the 
EAV particles first encounter the mucosal lining of the upper respiratory tract or the 
reproductive tract and the host mucosal immune response acts as the first line of defense 
against EAV. The host innate immune response against EAV has not been extensively 
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studied, however, the available information provide insights in to the interactions between 
the virus and the innate immune system [19].  
EAV is an endotheliotropic virus and during its pathogenesis it mainly infects 
equine endothelial cells (EECs) and PBMCs [6; 88; 110]. Infection of these cells induce 
the production of various anti-viral compounds as well as proinflammatory cytokines and 
chemokines. One of the major anti-viral compounds produced by the triggering of the 
innate immune system are the type I (IFNα and IFNβ) interferons [134-136]. Binding of 
IFN molecules with their cell surface receptors triggers a cascade of signaling events 
through the Janus kinase signal transducer and activator of transcription (JAK-STAT) 
pathway which induces the transcription of hundreds of IFN regulated genes (IRGs) [137]. 
Investigations into the host interferon response induced by EAV has shown that in EECs, 
EAV suppresses the production of IFNβ which is one arm of the type I interferon system 
[138]. The same study demonstrated that nsp1, nsp2, and nsp11 of EAV exerts strong 
inhibition on the IFNβ promoter and that nsp1 interferes with the host IRF-3 and signaling 
via NF-𝜅B to inhibit IFNβ production [138]. Similar to EAV, PRRSV which is another 
member of the order Nidovirales is also known to elicit an attenuated type I interferon 
response. Upregulation of TNF-α, IL-1β, IL-6, and IL-8 mRNA in EECs have been 
demonstrated following in-vitro infection of virulent and avirulent strains of EAV. 
Furthermore, the secretion of biologically active TNF-α has also been detected in EAV 
infected EECs [139]. Studies have demonstrated that the virulent Bucyrus strain (VBS) of 
EAV could in-vitro infect CD3+ T lymphocytes of only some horses [103]. In-vivo 
infection of horses belonging to both the susceptible and resistant phenotypes have 
demonstrated that horses in both groups upregulated the mRNA production of IL-1β, TNF-
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α, IL-8 and IFNɣ following infection with EAV. However, IFNα and IL-10 gene 
expression was observed only in horses with the resistant phenotype [64].  
Following the respiratory rout of infection, EAV infects alveolar macrophages 
(AMΦ) but in-vitro studies have shown that EAV is unable to replicate in them. However, 
EAV is capable of both infecting and replicating in blood-derived equine macrophages 
(BMΦ) [139]. In-vitro infection of both AMΦ and BMΦ by virulent and avirulent strains 
of EAV stimulate the mRNA production from TNF-α, IL-1β, IL-6, and IL-8 genes as well 
as the production of biologically active TNF-α secretion [139].  
1.9.2. Humoral immune response 
The host humoral immune response against EAV is characterized by the production 
of complement-fixing (CF) and virus-specific neutralizing (VN) antibodies [129; 140]. 
Several studies have demonstrated that the EAV structural proteins GP5, M and N as well 
as the nsps nsp2, nsp4, nsp5 and nsp12 contribute to induce the humoral response in the 
host [141; 142]. However, several studies have demonstrated that the major neutralization 
sites for EAV-specific antibodies are located on the GP5 protein and these include 4 major 
neutralization sites [143; 144]. Similarly, Chirnside et. al. (1995) identified another epitope 
on the GP5 protein [145]. Moreover, another study done by Glaser et.al. (1995) 
demonstrated that mutations on the GP5 neutralization sites render EAV resistant to 
neutralization with VN antibodies [146].  
Both CF and VN antibodies appear between 7-14 days post infection. CF antibody 
titers peaks around 2-3 weeks and declines around 8 months post infection while VN 
antibody titers peak around 2-4 months post infection and may persist for 3 years or more 
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[104; 134; 140; 147]. Avirulent strains of EAV such as the MLV strain is shown to induce 
a stronger CF antibody response in the host than virulent EAV strains [140]. The induction 
of CF antibodies is important because EAV neutralization is thought to be complement 
dependent and the heat inactivation of host sera decreases its capacity to inactivate EAV. 
Furthermore, the IgG fraction of late antiserum is responsible for EAV neutralization [148; 
149]. A recent study done by Carossino et.al. (2018) has demonstrated that following EAV 
infection a short-lived IgM response is initially triggered followed by a long-lasting IgG1 
response in infected horses. The appearance of this humoral response correlates with the 
reduction of viremia and subsequent viral clearance except in the case of carrier stallions 
[66; 74]. Furthermore, EAV infections also triggers an IgG1 and IgG4/7 antibody response 
in the seminal plasma [74].  
Seropositive dams transfer their EAV-specific VN antibodies to foals via colostrum 
and they protect the foal from EAV infections during the first few months of their life. The 
fact that maternal antibodies are not detected in the serum of foals prior to nursing suggests 
that the transfer of the EAV-specific passive immunity is through colostrum and not via 
the placenta in-utero [150; 151]. As mentioned earlier, the maternal antibodies against 
EAV remains in the sera of foals up to 6 months and foals should be vaccinated during the 
time of weaning to maintain this EAV-specific immunity [19; 98; 129]. The half-life of 
EAV-specific maternal antibodies in serum of foals is 32 days [150; 151].     
1.9.3. Cell mediated immune response 
Cell mediated immunity, similar to the humoral immunity plays a key role during 
infections. A study done by Castillo-Olivares et al has demonstrated the presence of an 
EAV-specific cytotoxic T-lymphocyte (CTL) responses in experimentally infected ponies. 
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The study shows that the cytotoxicity displayed by EAV stimulated PBMCs was virus 
specific and was mediated by CD8+ T lymphocytes. Furthermore, this CTL response lasted 
for period between 4 months to more than 1-year post-infection [152]. 
1.10 Equine herpesvirus-1 (EHV-1) 
1.10.1 EHV-1 classification 
With the isolation of more than 80 different herpesviruses from different animal species 
during the past 50 years necessitated a scientific classification for the Herpesviridae family. 
The first attempt of organized scientific classification of the herpesviruses came in 1971 
by ICTV [153]. However, this classification was updated in 2009 to form the currently 
used ICTV classification of herpesviruses [28]. During the 2009 update, the former family 
Herpesviridae was split into 3 families and they were incorporated into the new order 
Herpesvirales [28]. The three new families created were the family Herpesviridae which 
contains the mammal, bird and reptile herpesviruses, family Alloherpesviridae which 
contains the fish and frog herpesviruses and the family Malacoherpesviridae which 
contains a bivalve herpesvirus [28]. The family Herpesviridae is divided into 3 sub 
families; namely Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae and the 
two equine herpesviruses used in this study, EHV-1 and the equine herpesvirus-4 (EHV-
4) are included in the subfamily Alphaherpesvirinae [28].  
1.10.2 EHV-1 virion architecture 
Members of the family Herpesviridae share similar virion structural features. The 
virion of the members of this family has a spherical morphology and it contains four major 
components which are the capsid, the core, the tegument and the envelope [28; 153; 154]. 
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The core contains the genetic material of the virus which is a double stranded 
deoxyribonucleic acid (DNA) molecule of 125-290 kbp arranged into unique long and 
short regions with internal and terminal repeats. It is a fibrillar spool in which the viral 
DNA is wrapped around [17; 18; 28; 154]. Encasing the core is an icosahedral capsid which 
is composed of 12 pentameric and 150 hexameric capsomeres. The external diameter of 
this 162 capsomere capsid is 200 nm. The capsid of the Herpesviridae family members is 
surrounded by an asymmetrically arranged proteinaceous matrix containing over 30 viral 
proteins called the tegument [28; 153-155]. Surrounding this entire structure is an envelope 
or a lipid bilayer which contains viral and some host glycoproteins embedded in it (Figure 
1.4) [28; 153-155].  
 
 
 
 
 
 
 
 
Figure 1.4: Virion architecture of EHV-1 consists of a core containing viral genomic 
DNA, a capsid, tegument and an envelope with 12 embedded glycoproteins. Adapted 
and reproduced with permission from Bentham Open: [The Open Veterinary Science 
Journal][1], copyright 2008.   
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1.10.3 EHV-1 genome organization  
EHV-1 together with its closely related cousin EHV-4 are two of the most important 
herpesviruses affecting horse populations worldwide and up until 1981, both EHV-1 and 
EHV-4 were considered two subtypes of the same virus [156]. However, the complete 
genome sequencing of EHV-1 and EHV-4 paved the way in separating them as two 
different virus species [3; 4]. Just as all the other herpesviruses, EHV-1 has a linear dsDNA 
genome encapsidated by a thick walled, spherical to pleomorphic icosahedral capsid of 
about 120 nm in diameter and 162 capsomeres [28; 154; 155]. The genome of EHV-1 is 
approximately 150,224 bp in size [3; 4] and can be divided into a unique long (UL) region 
(112,871 bp) and a unique short (US) region (11,861 bp) which are covalently linked to 
each other. The UL region is flanked by two inverted repeat sequences of 32 bp in EHV-1 
called the internal repeat (IRL) and the terminal repeat (TRL) [3; 4; 17; 28].  
 
 
 
 
 
 
 
 
Similarly, the US region is also flanked by two inverted repeat sequences of 12,714 bp 
called internal repeat (IRS) and the terminal repeat (TRS) (Figure 1.5) [3; 4]. EHV-1 
genome consists of 80 ORFs and they code for at least 76 individual genes of which four 
(genes 64, 65, 66 and 67) have been duplicated [3; 4; 17]. The average G+C content of the 
 
Figure 1.5: Genome organization of EHV-1. The UL region is flanked by TRL and IRL 
sequences. The US region is flanked by TRS and IRS sequences. The UL region contains 
ORFs 1-63 and the US region contains ORFs 68-76. The TRS and IRS regions contain copies 
of ORFs 64-67 [3; 4]. 
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EHV-1 genome is 56.7% [3; 4]. Furthermore, similar to other herpesviruses, the genome 
of EHV-1 contains 20 sets of tandemly reiterated DNA sequences in which 8 are located 
in the UL region, 2 in the US region and 5 each in the TRS and IRS regions. Interestingly, 
most of these sequences are in non-coding regions of the genome. Even though, EHV-1 
and EHV-4 has some very close similarities in genome arrangement and composition they 
share with their alphaherpesvirus cousins, EHV-1 is assumed to contain five distinct genes 
encoded by ORF 1, ORF 2, ORF 67, ORF 71 and ORF 75 which have not been found in 
any other herpesviruses to date.    
1.10.4. EHV-1 viral proteins 
As mentioned previously, the components of an EHV-1 virion includes a 
nucleocapsid core, an icosahedral capsid, the tegument and a lipid envelope [28; 154]. 
Several EHV-1 viral proteins contribute to the formation of the nucleocapsid core and 
among them are the gene products of EHV-1 genes 22, 25, 35, 42, 43 and 56. These genes 
encode for “capsid triplex subunit 1”, “capsid protein”, “capsid maturation protease”, 
“major capsid protein”, “capsid triplex subunit 2” and the “capsid portal protein” 
respectively. The function of the capsid portal protein is the encapsidation of viral DNA 
while the major contribution of the other nucleocapsid core proteins is in capsid 
morphogenesis.  
The gene products of the genes 8, 11, 12, 23, 40, 46, 48 and 51 which are the 
“tegument protein UL51”, “tegument protein VP22”, “transactivating tegument protein 
VP16”, “tegument protein UL37”, “tegument protein UL21”, “tegument protein UL16”, 
“tegument protein UL14” and the “myristylated tegument protein” respectively, contribute 
in the virion morphogenesis of EHV-1. The gene products of the EHV-1 genes 13 and 14 
 
36 
 
which are the “tegument protein VP13/14” and “tegument protein VP11/12” take part in 
gene regulation by modulating the gene expression of VP16. Gene products of the genes 
15, 19, 45, and 49 which are the “membrane protein UL45”, “Tegument host shut-off 
protein”, “DNA packaging tegument protein UL17” and the “Tegument serine/threonine 
protein kinase” takes part in the membrane fusion of the virion, host mRNA degradation, 
DNA encapsidation and protein phosphorylation respectively.  
The EHV-1 virion is surrounded by a lipid envelope with 12 glycoprotein 
projections. The 12 glycoproteins of EHV-1 are conserved in all other alpha herpesviruses 
as well and therefore, named according to the nomenclature adopted for the prototype 
member of this family which is HSV-1 [1]. These envelope glycoproteins play a major role 
in inducing an immune response from the host following infection as well as in virus 
adsorption, penetration, and cell-to-cell spread [1; 157]. The 12 EHV-1 glycoproteins are 
encoded by the genes 6, 10, 16, 33, 39, 52, 62, 70, 71, 72, 73 and 74 and termed gK, gN, 
gC, gB, gH, gM, gL, gG, gp2, gD, gI and gE respectively [1]. EHV-1 gC is essential for 
host cell binding of the virus as it assists in binding heparan sulphate moieties on the host 
cell surface as well as virus egression from host cells [1]. However, most of the EHV-1 
glycoproteins play roles in cell to cell spread and these include gB, gD, gE, gI, gK and gM 
[1]. The glycoproteins gD and gM is also important in entry into the host cell [1]. Apart 
from these functions, gC, gE, gG, gI, gM and gp2 are important in the virulence of EHV-
1 while gB, gD, gH, gL and gK play key roles in EHV-1 replication [158]. The 
glycoproteins gp2, gC, gB, gD and gM represent the most glycosylated proteins in the 
EHV-1 virion and they function as immunogens inducing a humoral as well as a cell 
mediated immune response from the host [1; 157]. The fact that sera obtained from rabbits 
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and mice injected with purified EHV-1 virions contain polyclonal antibodies directed at 
this set of glycoproteins demonstrate their importance in stimulating a host immune 
response [157]. 
1.11. EHV-1 infection in horses and diseases 
1.11.1. EHV-1 respiratory disease 
EHV-1 infections are one of the major causes of acute viral upper respiratory tract 
(URT) diseases in horses. Furthermore, it has been suggested that the viruses isolated from 
respiratory infections differ in antigenicity, host range, plaque size and growth rate in-vitro 
and in-vivo from the abortigenic isolates [159]. In the absence of mucosal antibodies, 1ry 
infection of EHV-1 takes place at the upper respiratory tract epithelium in horses, though, 
transmission is also possible through the conjunctival epithelium upon direct contact with 
aerosols containing the virus [160; 161]. The incubation period of the respiratory form of 
EHV-1 infections vary depending on the strain of virus, infecting dosage and immune 
condition of the host, but in most cases its between 1-3 days [162]. Experimental intra-
nasal infections done on ponies have revealed that infectious virus particles and virus 
antigen expression can be detected in the nasal and nasopharyngeal epithelium of infected 
animals as early as 12 hpi. The URT infections by EHV-1 results in the erosion of the nasal 
and nasopharyngeal epithelial cell around 4-7 days post infection and during this time the 
infected animals also shed the virus from epithelial surfaces. The erosion of epithelial cells 
expose the underlying lamina propria to which the virus readily spreads and infects the 
leukocytes and endothelial cells of the blood and lymphatic vessels around 4 days post 
infection [163]. Once inside the circulatory system, the virus amplifies itself by going 
through the lytic cycle of replication which results in cell-associated viremia and the spread 
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of the virus to its secondary sites of replication such as the pregnant uterus, CNS, testes 
and endocrine organs [15; 17; 18; 163-165]. The cell-associated viremia is a critical 
development in EHV-1 induced abortions and EHM and can develops as early as 3 days 
post infection and last up to 22 days [163].  
The respiratory form of EHV-1 infections usually results in rhinopharyngitis and 
tracheobronchitis [17; 18; 166]. In young horses, the respiratory form of EHV-1 usually 
results in depression, fever, anorexia, coughing, and nasal discharge. However, 
neutropenia, lymphopenia, and progressive lymphadenopathy may also be visible [162]. 
The nasal discharge appears serous for the first few days of infection and may become 
mucopurulent with development of 2ry bacterial infections. The infected horses may 
develop bronchopneumonia when the virus infects the lower part of the respiratory tract 
[1]. Virus clearance is takes about 1-3 weeks, however, bronchial hypersensitivity, chronic 
obstructive pulmonary disease syndrome or compromised athletic performance may still 
persist and this condition is called “poor performance syndrome” [162; 167].  
1.11.2. Abortion and neonatal diseases 
With highly virulent EHV-1 strains, endothelial cell infection, vasculitis and 
thrombosis in the tale pregnant uterus is critical for abortions to occur [18; 168]. Following 
experimental intra-nasal infection, endothelial infection of the blood vessels in the pregnant 
uterus has been detected as early as 6 days post infection and it gets widespread over 9-13 
days post infection, and as mentioned before, the development of cell-associated viremia 
is critical for this [163; 168]. The interaction between viremic leukocytes and endothelial 
cells appears to be tissue selective suggesting the micro-environmental factors such as 
cytokines and hormones may influence endothelial cell activation and the subsequent 
 
39 
 
interaction with leukocytes to facilitate virus transfer [1; 18; 163; 168]. The principal 
determinant of abortion is the degree of thrombosis in the pregnant uterus. Endothelial cell 
infection in blood vessels of the late pregnant uterus leads to inflammation and thrombosis. 
Severe and wide-spread thrombosis results in rapid placental thrombo-ischemic necrosis 
leading to the expulsion of a fresh virus negative fetus. Less severe and less wide-spread 
thrombosis do not cause rapid placental separation providing more time for the virus to 
leak into and infect the fetus via the placenta [163; 169; 170]. In some instances, the fetuses 
may be born alive after virus-induced expulsion but develops interstitial pneumonia shortly 
after birth [17; 18]. Early pregnancy abortions are rare with EHV-1 infections. several 
possible reasons maybe at play making the late gravis uterus more susceptible for abortions 
by EHV-1. One such reason could be that during mid to late pregnancy, the placenta 
releases progesterone which causes local immunosuppression. Furthermore, the 
development of individually vascularized micro cotyledons in the placenta makes these 
micro cotyledons susceptible to single vessel thrombi infarction [17; 18; 163; 168; 171].  
1.11.3. Equine herpesvirus myeloencephalopathy (EHM) 
EHV-1 infections usually result in mild respiratory diseases in young horses, neonatal 
foal death and abortion storms in pregnant mares and establish lifelong latent infection in 
horses which allows viral perpetuation in equine populations [18; 172]. Interestingly, some 
of the EHV-1 strains can cause a fatal neurological disease called equine herpes 
myeloencephalopathy (EHM) [15; 18]. The association between EHV-1 and a severe form 
of myeloencephalopathy was first discovered in Norway in 1966 [173]. EHM has a 15-
50% case-fatality rate and poses a significant threat to the $102 billion equine industry in 
the United States. Unfortunately, the occurrence of EHM has increased dramatically over 
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the past fifteen years, with extensive outbreaks reported in the United States, South Africa, 
New Zealand and several European nations, including the United Kingdom [14; 52; 164; 
165; 174; 175]. Similar to EHV-1, other alpha herpesviruses such as HSV-1 and VZV too 
induces a neurological disease form. However, unlike HSV-1 or VZV, EHV-1 does not 
have a neurotropism [176; 177]. EHM is a result of vasculitis and thrombosis caused by 
EHV-1 following infection of the endothelial cells of the vasculature of the CNS [15; 52; 
164; 165; 175; 178]. (8). It has been demonstrated that following experimental EHV-1 
infection in foals, the initial viral replication takes place in the epithelial cells and local 
lymph nodes of the upper respiratory tract [18; 166]. which result in leukocyte-associated 
viremia [18; 166; 179]. Subsequently, the virus infects the endothelium of the vasculature 
specifically located in the CNS and the uterus resulting in the development of an 
inflammatory process that leads to vascular damage (vasculitis and micro thrombosis) 
promoting the development of EHM and abortions [15; 18; 166].  
The ability to establish EHM by EHV-1 strains is linked to a single nucleotide 
polymorphism (SNP) in the DNA polymerase gene (open reading frame 30 [ORF 30]). 
This relationship was established by analyzing a panel of 131 EHV-1 field isolates [51]. 
As such, EHV-1 strains that has a Guanine (G) residue at the nucleotide position 2254 in 
the open reading frame 30 (ORF 30) are considered neuropathogenic while strains that has 
an Adenine (A) residue at this position are considered non-neuropathogenic [51]. This SNP 
results in the replacement of Asparagine (N) with Aspartic acid (D) at the amino acid 
position 752 in the DNA polymerase gene [51]. As such, it highlights a genetic basis 
associated with the virus in establishing EHM. However, this SNP of the pathogen’s 
genome cannot explain all the EHM cases resulting from EHV-1 infections since 16-24% 
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of the EHM cases are caused by EHV-1 strains that do not have this mutation on the DNA 
pol gene [175]. Therefore, it can be hypothesized that the development of EHM is 
multifactorial.  
Clinically, horses with EHM display ataxia, paresis, swelling of hind limbs and urinary 
incontinence [52; 165; 180] while histopathological examinations often reveal perivascular 
cuffing in some areas of the central nervous system (CNS) together with axonal swelling 
and/or malacia, areas of microscopic hemorrhage, vasculitis and thrombosis [52; 178; 180]. 
EHM has no specific treatment and the prognosis is directly related to the severity of the 
neurological signs exhibited by affected horses [165]. Supportive medical care provided to 
such horses focus on treatments to reduce CNS inflammation due to vasculitis. 
Corticosteroids such as prednisolone and dexamethasone, NSAIDS such as Flunixin 
megalumine and Dimethyl sulfoxide is often used as treatments to counter CNS 
inflammation together with Acyclovir [165]. Since 1941 many different vaccines have 
been developed to protect horses from EHV-1 infections as well as disease manifestations 
[172]. However, these vaccines have not been successful since their protective efficacy is 
largely unknown or unsatisfactory [17]. Currently there are inactivated as well as modified 
live vaccines (MLV) available against EHV-1 but none of them seem to be able to prevent 
the development of EHM.  
1.11.4. Vaccination and management 
Vaccination, together with management measures remains as one of the best measures 
to control EHV-1 infections [1]. Vaccines against EHV-1 infections were first introduced 
in the 1950s and since then the main types of vaccines commercially available against 
EHV-1 infections have been either inactivated whole virus or subunit vaccines [1]. The 
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earliest attempt at producing a vaccine against EHV-1 resulted in the development of a 
killed EHV-1 vaccine prepared using infected tissues from foals or hamsters. This was 
followed with the development of a partially purified, formaldehyde inactivated EHV-1 
vaccine [181-183]. Likewise, inactivated whole EHV-1 vaccines are widely used during 
current times as well. Duvaxyn EHV-1/4 is an inactivated whole EHV-1 and -4 vaccine 
currently being used. This vaccine has been shown to induce both virus neutralizing as well 
as complement fixing antibodies in foals and mares [1]. Vaccination with Duvaxyn EHV-
1/4 significantly reduced the clinical signs of disease and the duration of both cell-
associated viremia and virus shedding in foals and virus shedding was also reduced in 
vaccinated mares when compared with control ponies [1] upon experimental infection with 
EHV-1. However, Response of foals and mares to inactivated EHV-1 vaccines in the field 
conditions have not been very efficient. A study carried out in Australia has demonstrated 
that the seroconversion of foals and mares vaccinated with inactivated whole EHV-1 
vaccines are 50% and less than 30% respectively [184].  
Apart from inactivated whole EHV-1 vaccines, the only other type of vaccine 
commercially available in the market are modified live vaccines (MLV) [17]. The vaccine 
Rhinomune is an MLV licensed for the use in US and Europe (as Prevaccinol in Europe) 
[1; 17]. Rhinomune has been demonstrated to have an excellent safety record and studies 
have demonstrated that this vaccine can provide protection against EHM under 
experimental conditions and against abortions in field conditions [185; 186]. Foals are 
usually protected against EHV-1 infections until 5-6 months of age due to the transfer of 
maternal antibodies. Therefore, during the time of weaning, it is recommended for foals to 
be vaccinated against EHV-1 followed with booster doses at every 3-6 months to prevent 
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the respiratory form of disease [187]. It is also recommended to vaccinate pregnant mares 
to reduce the risk of EHV-1 induced abortions [187].  
Good managemental practices coupled with proper vaccination has shown to reduce 
the risk of EHV-1 induced abortions by about 75% [15]. One important aspect of proper 
management is to segregate the horse population in a farm to distinct categories such as 
weanlings, yearlings and new arrivals [187]. Horses arriving newly should be kept in 
quarantine or isolation for a period of 21 days before introducing to the herd. Since stress 
can reactivate the latently infected EHV-1 as well as immunosuppress animals making 
them more susceptible to various forms of pathogenic infections including EHV-1, it is 
important to control factors that cause stress in horses. Over-crowding, poor nutritional 
conditions, heavy parasite infestations, disruption of established social groups or exposure 
to inclement weather are some of the controllable factors that can induce stress in horses 
[187]. Proper disinfection practices on tools and utensils as well as proper hygienic 
practices must also be followed to prevent EHV-1 infections and the spread of EHV-1 
infection during outbreaks [188]. 
1.12. Host immune response against EHV-1 
1.12.1. Innate immune response 
EHV-1 initially infects the respiratory mucosal surface and the epithelium of the 
upper respiratory tract and as such this is the initial site of immune resistance against the 
virus [189] [190]. A recent study by Hussey et.al 2014 using primary equine respiratory 
epithelial cells has investigated the innate immune response against EHV-1 infections 
[190]. The study revealed that upon infection the gene expression of the proinflammatory 
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cytokines and chemokines IFNα, Ilβ, TNFα, IL8 and IL6 was upregulated whereas the gene 
expressions of IFNβ, GM-CSF, MCP-1 and IL10 did not show a significant upregulation 
[190]. Furthermore, the same study demonstrated that in-vitro EHV-1 infected equine 
respiratory epithelial cells suppress the secretion of IFNɣ. Even though the gene 
expressions of IFNα and TNFα was upregulated following EHV-1 infections, the secretion 
of these cytokines from equine respiratory epithelial cells was not detected. Furthermore, 
the secretion of IL-1, IL-17, IL-4, and IL-10 was also not detected [191]. However, a study 
done by Edington et al. 1986 has demonstrated an increased production of IFNα in nasal 
secretions as well as in serum following in-vivo EHV-1 infection of Welsh mares and 
ponies [192].  
Interestingly, Hussey et.al 2014 revealed that EHV-1 infections of equine 
respiratory epithelial cells suppress MHC-1 and MHC-II expression. MHC-I and MHC-II 
molecules are antigen presenting cells and they are essential molecules in bridging the 
innate and the adaptive immune responses [193]. In the case of EHV-1 infections, the 
downregulation of MHC-1 molecules are of importance since they are responsible for the 
activation of CD8+ cytotoxic T-lymphocytes (CTLs) which plays a key role in EHV-1 
clearance [194; 195]. As such, the downregulation of MHC-1 may play as a survival tactic 
by the virus to delay an EHV-1-specific immune response. Furthermore, the 
downregulation of MCH-I molecules by EHV-1 had been reported in several previous 
studies which identified it as an entry receptor for EHV-1 [196-198]. There is also enough 
evidence to conclude the secretions of equine respiratory epithelial cells which includes 
the proinflammatory cytokines and chemokines induces the chemotaxis of monocytes 
towards the site of infection and the EHV-1 pUL56 plays a role in suppressing this 
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chemotaxis[190; 199]. However, Edington et al. 1986 has shown that the phagocytic 
function and the killing efficiency of monocytes in EHV-1 infected mares and yearlings 
was reduced [192]. Furthermore, PBMCs in-vitro infected with EHV-1 has been shown to 
upregulate the gene expression of type I interferons (IFNα and IFNβ), TNFα, and IL8 while 
TGFβ expression was downregulated.   
1.12.2. Humoral immune response 
As mentioned earlier, EHV-1 establishes latent infections in about 60% of infected 
horses [29]. Primary infection with EHV-1 is known to induce a protective yet short lived 
immune response, making hosts susceptible for reinfection within 3-4 months of the initial 
infection [200]. However, horses suffering multiple reinfection incidences gradually 
develop an immunity capable of preventing clinical signs of re-infection [201]. The 
mucosal humoral response against EHV-1 is an important aspect in EHV-1 pathogenesis 
since it is the first site of contact during natural EHV-1 infections. Experimental infection 
of foals has demonstrated the production of EHV-1-specific mucosal antibodies which was 
absent following vaccination. Furthermore, these EHV-1-specific mucosal antibodies were 
predominantly of the IgA isotype and also was the most long lasting. Furthermore, the 
same study demonstrated that mucosal IgA has virus neutralizing capability and may play 
an important role in reducing virus shedding. For brief moments during the acute phase of 
infection EHV-1-specific IgGa and IgGb were in excess of IgA but these IgG isotypes did 
not have any virus neutralizing capability [202].  
There is evidence to suggest that the immunity bestowed on the host following an 
EHV-1 induced abortion incidence is more durable than the immunity gained by 
contracting the EHV-1 induced respiratory disease [200]. Natural as well as experimental 
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EHV-1 infections of horses stimulate the production of both VN and CF antibodies starting 
around 2 weeks post infection by which time the CF antibody titer showed a peak. The VN 
antibodies, however, required another week to acquire peak titers [202-204]. Antibodies 
against EHV-1 targets the envelope glycoproteins gB, gC, gD, gH and gp2 while gC and 
gD glycoproteins contain neutralizing epitopes. EHV-1 specific VN antibodies lasts up to 
a year and is considered more protective against reinfection than CF antibodies which lasts 
only up to 10 weeks [204-208]. However, several studies have demonstrated that high titers 
of serum VN antibodies are more protective against the respiratory disease induced by 
EHV-1 than abortions or EHM [209-211].   
1.12.3. Cell mediated immune response 
Cytotoxic activity against virus infected host cells is mainly carried out by CD8+ T 
lymphocytes and this is true in the case of EHV-1 infections as well [193-195; 212]. 
Following infection, EHV-1 internalizes itself into host cells and sequentially works its 
way into developing CAV which may last up to 3 weeks [213]. This intra-cellular nature 
of EHV-1, as with all viruses helps it in evading destruction via VN and CF antibodies. As 
such, the CLT response generated against EHV-1 is essential for virus clearance [163; 195]. 
Allen et al 1995 has demonstrated that the EHV-1-specific CTL response is carried out 
mainly by MHC-1 restricted CD8+ T lymphocytes and the maximum lysis of virus infected 
target cells through this CTL activity happens between 2-3 weeks post infection. 
Furthermore, this generated EHV-1-specific CTL response may persist up to a year [212]. 
Other Experimental infection studies have demonstrated that ponies with repeated EHV-1 
exposure contains a higher number of EHV-1-specific CTLs in their circulation and 
exhibited significantly reduced or no clinical and virological signs following infection 
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when compared to naive ponies with little to no EHV-1-specific CTLs in their circulation 
and displayed a more severe form of the infection [195; 213]. Furthermore, studies have 
also shown that following EHV-1 infection, the number of CD8+ T lymphocytes increase 
in lungs as well as in the peripheral circulation of mares significantly [214; 215].  
A study done by Kydd et al 2003 using experimental infection of pregnant mares 
with EHV-1 has demonstrated that mares with EHV-1-specific CTLs in the circulation 
immediately before and approximately 1 month after experimental infection did not abort 
whereas the mares that did not have circulating EHV-1-specific CTLs did [195]. This 
protection granted by EHV-1-specific CTLs against EHV-1 induced abortions maybe 
through the prevention of CAV which is essential for the virus to reach the pregnant uterus 
after initial infection of the upper respiratory tract [195]. Findings from these studies 
indicate that the rise and recruitment of CD8+ T lymphocytes coincide with the recovery 
from EHV-1 infections and hence might play an important role in clearing the virus [195]. 
Dendritic cells transfected with the EHV-1 IE protein has shown to increase the EHV-1-
specific CTL activity in-vitro indicating a possible epitope that might be useful in the 
development of an EHV-1 specific vaccine. Furthermore, dendritic cells transfected with 
the EHV-1 glycoproteins gC, gD, gI and gL has also shown increased EHV-1-specific CTL 
activity in individual horses suggesting these proteins may also act as inducers of a CTL 
response against EHV-1 [216]. 
1.13. Inflammation and its mediators   
The term inflammation is derived from the Latin word “inflammare” which means 
“to burn” and it is one of the most important processes utilized by host cells against injury 
or infections [217]. During the inflammation process a series of highly organized events 
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takes place involving cellular and vascular events as well as specific humoral secretions 
[217]. These organized events induce a multitude of cellular and vascular pathways that 
induces vasodilation, migration of white blood cells, capture and adhesion of inflammatory 
cells and the secretion of mediators and signaling molecules which contribute to the 
development of inflammation [217]. Inflammation is characterized as acute and chronic. 
During the acute phase of inflammation increase in blood flow to the affected tissue, 
vascular permeability as well as accumulation of fluid, leukocytes, and inflammatory 
mediators such as cytokines is observed. The chronic phase of inflammation is 
accompanied with the development of specific adaptive (humoral and cellular) immune 
responses to the infection [218].   
1.13.1. Cytokines 
Cytokines are one of the most important mediators of acute and chronic 
inflammation [217; 219]. This group of relatively small signaling proteins act on a variety 
of host cells at picomolar or nanomolar concentrations to impart their inflammatory effects 
[219; 220]. A total of 44 chemokines and 23 chemokine receptors and over 50 cytokines 
have been identified in humans to date [221]. Cytokines can be divided as either pro or 
anti-inflammatory, based on their structural homology or receptor utilization [220]. Many 
host cells has the capacity to secrete cytokines including stromal, fibroblasts, and 
endothelial cells and the binding of a particular cytokine with its receptor triggers a 
signaling cascade that induces many events associated with inflammation such as adhesion, 
phagocytosis, and apoptosis [217; 220]. The most prominent proinflammatory cytokines 
are TNFα, IL-1β, IL6 and type I interferons while IL12, IL23 and IL10 have anti-
inflammatory properties [219].  
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An interesting as well as an important group of cytokines are the interferons which 
are a subset of the class 2 α-helical cytokines. Interferons can be subdivided into two 
classes as type I and type II interferons and members of both classes play important roles 
in providing protection against invading pathogens [222]. In particular, IFNα and IFNβ of 
the type I interferon group imparts antiviral effects on a variety of cells and prevents the 
replication and the spread of viruses. Furthermore, type I IFNs stimulate the cytotoxic 
activity of T-cells, natural killer cells, monocytes and macrophages which facilitates the 
clearance of virus infected cells [222].           
1.13.2. Chemokines 
Together with cytokines, chemokines play an important role in the inflammatory 
process. The attraction of inflammatory cells towards sites of injury or infection is an 
integral part of inflammation which is mediated by chemokines [219; 220; 223]. Around 
40 chemokines that play roles in inflammation has been identified up to date. Chemokines 
are around 8-10 kDa in size and they share an amino acid homology between 20-70%. 
Chemokines are divided into families based on relative position of their cysteine residues 
[223; 224]. Based on this classification there are 4 subfamilies of chemokines but only two 
have been extensively characterized [223; 224]. The α-chemokines, based on the presence 
of a glutamic acid–leucine–arginine near the N terminal can be chemo attractive to 
neutrophils or lymphocytes [223; 224]. In contrast, β- chemokines are not chemo attractive 
to neutrophils. Instead they act on monocytes, eosinophils and basophils [223; 224]. 
Chemokines impart their chemo attractive action on immune cells by binding with specific 
G-protein–coupled cell-surface receptors [225]. These receptors are constitutively 
expressed on some cell types whereas they are inducible on some cell types [223]. A wide 
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variety of injury and disease conditions require the activation and accumulation of 
inflammatory cells and this requires the secretion of chemokines [224]. The different 
subgroups of chemokines that are being secreted during a tissue injury or an infection 
determines, in part, the inflammatory infiltrates. The ability to control the movement of 
inflammatory cells by chemokines present novel opportunities to develop therapeutics that 
may be effective in controlling and managing inflammatory disease conditions [223; 224].  
1.13.3. Toll-like receptors 
The selective pressure imposed on multi-cellular organisms by pathogens has 
advanced the evolution of the immune system [226]. Traditionally, the mammalian 
immune system has been categorized in two arms: The innate immune system and the 
adaptive immune system [227]. The adaptive immune system utilizes antigen receptors 
present on effector cells such as T and B lymphocytes to detect and mount an immune 
response against foreign antigens [228]. The innate immune was first described over a 
century ago and it is the first line of defense against invading pathogens [226; 228; 229]. 
The innate immune system senses these invaders through pathogen associated molecular 
patterns (PAMPs) or damage associated molecular patterns (DAMPs) present on them 
[226; 229]. The host cells uses a specialized group of structurally diverse cell surface and 
intra-cellular receptors known as pattern recognition receptors (PRRs) to sense these 
PAMPs or DAMPs and one such extensively studied group of PRRs are the Toll-like 
receptors (TLRs) [229].  
The discovery of Toll receptors were first done in Drosophila as a receptor involved 
in the establishment of dorso-ventral polarity in the developing embryo [230]. However, 
later it was discovered that the absence of Toll receptors made Drosophila susceptible to 
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fungal infections [231; 232] suggesting its importance in the host immune response. In 
mammals, 12 different homologs have been identified for the Drosophila Toll receptors 
and they play crucial roles in the host immune response [233; 234]. Mammalian TLRs can 
be structurally characterized based on the presence of an extra-cellular a leucine rich repeat 
(LRR) domain and an intra-cellular TIR domain [228]. Human TLRs can be grouped into 
5 sub families based on their amino acid sequences: the TLR2, TLR3, TLR4, TLR5, and 
TLR9 subfamilies. The TLR2 subfamily is composed of TLR1, TLR2, TLR6, and TLR10 
while the TLR9 subfamily is composed of TLR7, TLR8, and TLR9 [228]. Furthermore, it 
has been demonstrated that different TLRs recognizes different categories of ligands. In 
general, TLR2 recognizes peptidoglycan, bacterial lipoproteins, and zymosan, TLR3 
detects double-stranded RNA, TLR4 can detect lipopolysaccharide and heat-shock 
proteins, TLR5 is associated with flagellin detection, TLRs 7 and 8 can detect single-
stranded RNA and TLR9 is involved with the detection of CpG motifs of unmethylated 
bacterial DNA [235]. 
1.13.3.1 Equine Toll-like receptors  
As mentioned earlier, mammalian cells express 12 different TLRs [233; 234]. However, in 
most cases a particular cell type may not express all 12 TLRs. There isn’t much data on the 
expression of different TLRs in equine tissues. Only a handful of studies have reported the 
expression of different TLRs in equine cells [234; 236-239]. A study done by Gornik et. al 
(2011) has demonstrated the expression of TLR 2, 3, 4, 6 and 9 mRNA in equine corneal, 
conjunctival and limbal tissue [237]. A study done by Berndt et. al. (2006) has 
demonstrated a correlation between TLR4 and IL8 mRNA expression in bronchial 
epithelial cells of horses with recurrent airway obstruction due to neutrophilic airway 
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inflammation [236]. Furthermore, LPS treated equine lung tissue has been shown to 
increase the expression of TLR2 and TLR4 mRNA [239].  
The expression of TLR9 in equine pulmonary intravascular macrophages, 
Neutrophils in pulmonary capillaries and type-II epithelial cells of alveolar septa by 
Schneberger et. al. (2009) [238]. Furthermore, the same study demonstrated the expression 
of TLR9 in pulmonary vascular endothelial cells, airway epithelial cells and in alveolar 
macrophages [238]. Another study using equine tissue samples from the kidney, jejunum, 
liver, spleen and mesenteric lymph nodes detected TLR transcripts for TLRs 1-4, -9 6 and 
TLR10 [240]. However, not much data is available on the expression of TLRs in equine 
endothelial cells and this is one aspect which has been addressed by chapter 3 of this thesis.    
Moreover, a study done by Soboll-Hussey et.al. (2014) has demonstrated in-vitro EHV-1 
infection of equine respiratory epithelial cells result in the increased expression of TLR3 
and TLR9 mRNA [190]. Furthermore, the same study demonstrated the upregulation of 
INFα, IFNβ, IL1, IL6, TNFα, GM-CSF, MCP-1 and IL8 mRNA suggesting an involvement 
in TLRs 3 and 9 in upregulating these cytokines and chemokines [190].  
1.14. Genomics in infectious diseases   
With the advances made in sequencing since 1995, the global analysis of genomes, 
epigenomes, transcriptome, proteome and the metabolome with regards to various diseases 
conditions has advanced the knowledge of disease pathology as well as disease diagnostics. 
Furthermore, it has shed light into the different ways a host responds to infections [241; 
242]. One advantage of genomics information is that it offers the opportunity for 
personalized medicine in clinical and public health settings [243]. Such efforts are now 
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being utilized to control and prevent diseases such as cancers, heart disease and 
neurodegenerative diseases as well as in the management of infectious diseases and 
epidemics [243]. As such, genomic analysis is fast becoming an indispensable tool in 
therapeutics and diagnostics.   
1.14.1. Transcriptome in infectious diseases 
The transcriptome is defined as the complete set of transcripts in a cell, and their 
quantity, for a specific developmental stage or physiological condition [244]. With the 
advances made in sequencing, investigating the transcriptome has become an essential 
aspect in understanding the functional elements of the genome as well as the molecular 
constituents of cells that play key roles during disease progression [244].    
To determine the transcriptomes of various samples multiple technologies have 
been utilized thus far. Theses including hybridization-or sequence-based approaches [244]. 
Hybridization-based approaches usually involve the incubation of fluorescently labelled 
cDNA with custom-made microarrays or commercial high-density oligo microarrays. 
Hybridization-based approaches are high throughput and relatively inexpensive however 
they require an existing knowledge of gene sequences of the target organism. Furthermore, 
this method is inefficient at accurately quantifying low or high levels of gene expression 
[244; 245]. Tag-based sequencing methods such as serial analysis of gene expression and 
cap analysis of gene expression were utilized to overcome the limitations of hybridization- 
based approaches. Indeed, the tag-based methods were much more accurate in quantifying 
gene expression microarrays. However, these methods were relatively expensive while 
requiring laborious methodology and relatively large input RNA amounts [244; 245]. The 
recent technological advancements in high-throughput DNA sequencing paved the way for 
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the development of a novel method for mapping and quantifying transcriptomes. This 
method, named RNASeq (RNA sequencing), is both qualitative and quantitative and is 
capable of accurately measuring both low as well as high levels of gene expression [244; 
245]. Furthermore, it can be used to quantify the expression levels of isoforms [244; 245].  
Precision or personalized medicine is a new and emerging area in modern medicine 
that provide personalized diagnosis, treatment, and prevention of disease conditions by 
taking into account an individual’s genetic information, environment, and lifestyle [246]. 
Since the genetics and therefore, the gene expression varies considerably among 
individuals, the response towards infections and injuries may also show considerable 
variations among different individuals. These differences in gene expressions can be 
quantified and analyzed with RNAseq which may provide valuable information in 
diagnosing, controlling as well as preventing disease conditions taking into account 
individual variations among patients [247].   
Infectious diseases are one of the main causes of morbidity and mortality 
worldwide amassing up to approximately 15 million of 57 million (over 25%) annual 
deaths [241]. Newly emerging as well as re-emerging pathogens contribute to a significant 
portion of these deaths while the frequent use of antibiotics is driving the emergence of 
antibiotic resistant bacterial strains that pose a grave public health risk. Furthermore, with 
regards to conventional anti-viral therapies, the repertoire of druggable viral proteins are 
extremely limited and also promotes the development of resistance [241]. Due to these 
drawbacks in conventional treatments against pathogens, modern drug discovery strategies 
are focused on identifying and manipulating host-oriented molecules that play key roles in 
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host-pathogen interactions during disease progression. As such, transcriptomics is an 
indispensable tool in the future of drug discovery and therapeutics [241; 248].  
1.14.2. Genome-wide association studies (GWAS) in infectious diseases 
Genome-wide association studies (GWAS) is utilized to screen hundreds of 
thousands to millions of genetic variants across the genomes of many individuals to 
identify genotype–phenotype associations. This genomics approach, which share 
similarities with the transcriptomics-based approach, has revolutionized field of complex 
disease genetics over the past decade [249]. The first publication of a GWAS was in 2005 
for age-related macular degeneration and since then over 50,000 GWAS studies have 
reported significance between genetic variants and common diseases traits [249; 250]. In 
more detail, GWAS has been successfully utilized to identify risk loci for a vast number of 
complex disease phenotypes such as anorexia nervosa, major depressive disorder, cancers 
and diabetes mellitus, among others [249; 251-253]. Furthermore, the identification of 
SNPs on genes which implicates risk loci often leads to the discovery of genes of 
unidentified functions or of previously unsuspected relevance. Additionally, it also leads 
to the discovery of novel biological pathways and mechanisms underlying disease 
phenotypes [249; 250; 254]. Indeed, a GWAS done in Dr. U.B.R. Balasuriya’s lab has also 
demonstrated significance between the development of persistent EAV infection in 
stallions and the presence of the CXCL16s receptor variant. Furthermore, this study was 
the first GWAS study done to investigate genotype–phenotype associations in horses [64; 
65; 67].  
As such, GWAS is an important tool for the identification of novel mutations in 
genes in the form of single nucleotide polymorphisms (SNPs) which may predispose 
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individuals towards developing diseases. It is also an important tool in clinical care as it 
helps in identifying novel drug targets and disease biomarkers which, together with 
transcriptomics techniques has the potential to advance personalized medicine [249].   
1.15. Scope and outline of dissertation 
EHV-1 is a double-stranded DNA virus whereas EAV is a positive sense, single-
stranded RNA virus. Therefore, these two viruses are genetically very different from one 
another. However, they share some interesting similarities in their pathology and disease 
outcomes. EHV-1, similar to most alpha herpesviruses, establishes latent infection 
following primary infections while EAV establishes persistent infection in the male 
reproductive tract of the horse. Furthermore, following primary infection, the development 
of CAV is an essential step for both EHV-1 and EAV to spread from its 1ry site of infection 
to secondary replication sites. Characteristic to both these viruses is their endotheliotropic 
nature and thus, following CAV, they infect and replicates in equine endothelial cells 
resulting in vasculitis. Induction of vasculitis in the blood vessels of the pregnant uterus is 
the underlying reason for abortions in pregnant mares following EHV-1 or EAV infections. 
Moreover, EHV-1 infections can infect the endothelial cells supplying the CNS and the 
resulting vasculitis induces EHM in affected horses, which is the neurological form of 
EHV-1. As such, vasculitis plays an important role in the pathogenesis and disease 
outcomes of these two viruses.  
The main objective of this thesis was to investigate the innate immune response of 
EECs that contributes to the development of vasculitis following infection with EHV-1 and 
EAV in-vitro as well as to compare the innate immune responses induced by the two virus 
strains. In particular, we investigated the involvement of the pro-inflammatory cytokines, 
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chemokines and Toll-like receptors as well as the biological pathways that may play a role 
in the induction of vasculitis. The central hypothesis of this study was whether in-vitro 
infection of EECs with EHV-1 and EAV virus strains will induce similar combinations of 
pro-inflammatory cytokines, chemokines and Toll-like receptors.   
Vasculitis is the inflammation of the walls of the blood vessels and a vast number 
of mechanisms contribute to the  development of vasculitis [255]. However, the production 
of pro-inflammatory cytokines and chemokines by immune and endothelial cells play a 
significant role in the development of vasculitis [255]. Since the upregulation of pro-
inflammatory cytokines and chemokines occur frequently in vasculitis syndromes [255; 
256], understanding the pro-inflammatory cytokine and chemokine profile of EECs 
infected with EHV-1 and EAV is important in determining the pathogenesis of these two 
viruses. The characterization of the innate immune response of EECs against EHV-1 and 
EAV has not been done extensively, in particular the pro-inflammatory cytokine and 
chemokine response towards viral infections. As such the second chapter of this thesis was 
focused on elucidating the gene expression as well as the secretion of pro-inflammatory 
cytokines and chemokines from virus infected EECs to determine their contribution in 
promoting vasculitis. 
The proinflammatory cytokine and chemokine response by endothelial cells is part 
of the innate immune response and it mediates this response by sensing pathogen associated 
molecular patterns (PAMPs) or damage associated molecular patterns (DAMPs) [226; 
229]. Toll-like receptors (TLRs) sense PAMPs and DAMPs and initiate an innate immune 
response via proinflammatory cytokines and chemokines. However, no extensive study has 
been carried out to definitively confirm the full repertoire of TLRs expressed by EECs or 
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to determine the involvement of TLRs in inducing an inflammatory response from EECs 
following infection with EHV-1 or EAV. Therefore, chapter 3 of this thesis was focused 
on filling this gap of information on EHV-1 and EAV pathogenesis in EECs.  
Chapter 4 of this thesis utilized RNA-seq to further investigate the transcriptome of 
EHV-1 and EAV infected EECs. The differential expression of host genes following 
infection with EHV-1 and EAV provides insights into the biological pathways that are 
affected during the infection process.  
Chapter 5 of this thesis was focused on identifying host genetic factors associated 
with EHV-1 induced myeloencephalopathy (EHM) in horses. The development of EHM 
in horses following EHV-1 infections has been linked with the neuropathogenic phenotype 
of EHV-1 which is a result of a single nucleotide substitution within ORF30 [51]. Since 
the development of EHM in horses cannot be explained solely by this factor, we 
investigated the involvement of host genetic factors influencing EHM using a genome-
wide association study (GWAS). 
 
 
 
 
 
 
 
 
 
 
 
59 
 
CHAPTER TWO 
 
COMPARISON OF THE PROINFLAMMATORY GENE MODULATION IN 
EQUINE ENDOTHELIAL CELLS BY EQUID HERPESVIRUS-1, EQUID 
HERPESVIRUS-4 AND THE EQUINE ARTERITIS VIRUS 
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2.1. SUMMARY 
Equid herpesvirus-1 (EHV-1) and equid herpesvirus-4 (EHV-4) are closely related 
DNA viruses while EAV is an RNA virus. All three viruses are endotheliotropic viruses of 
the horse with a global presence and having a significant economic impact on the equine 
industry. Even though genetically very different, all these viruses share close similarities 
in their disease outcomes. The infection of endothelial cells with these viruses results in 
vasculitis that is the underlying etiology for the disease conditions caused by these three 
viruses. Here we in-vitro infected EECs with either the two EHV-1 strains (T953 and 
T262), EHV-4 (T445) or EAV and utilized RT-qPCR, Luminex and flow cytometry to 
investigate the proinflammatory cytokine and chemokine profile. In-vitro infection of 
EECs with the two EHV-1 strains (T953 and T262) and EAV produced higher viral titers 
when compared with EHV-4 (T445). However, based on relative gene expression and 
Luminex findings the proinflammatory cytokine and chemokine response of EECs induced 
by EAV is relatively less than the corresponding values for EECs infected with the three 
herpesviruses. Furthermore, EAV downregulates the type 1 interferon response in EECs 
by comparison with the EECs infected with the three herpesviruses.  
Key words: EHV-1, EAV, RT-qPCR, Luminex, Flow cytometry, IFNα,   
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2.2. INTRODUCTION 
Equid herpesvirus–1 (EHV-1) and Equid herpesvirus–4 (EHV-4) are double 
stranded DNA viruses of the subfamily Alphaherpesvirinae and genus Varicellovirus [28] 
that are endemic in horse populations in most continents [18]. Furthermore, these two 
viruses have striking similarities in nucleotide (55-84%) and amino acid (55-96%) 
sequences [257; 258]. Equine arteritis virus (EAV) is a positive sense, single stranded RNA 
virus belonging to the order Arteriviridae and genus Alphaarterivirus 
(https://talk.ictvonline.org/taxonomy/)[259] and it also has a worldwide distribution [5; 6].  
Collectively, these viruses are a significant threat to the global equine industry, as well as 
the $122 billion US equine industry (https://www.horsecouncil.org/resources/economics/). 
Even though reproductive consequences following EHV-4 infections are relatively rare, all 
three viruses are associated with respiratory and reproductive diseases in horses and have 
a tropism for equine endothelial cells (EECs) of the small blood vessels in horses 
(endotheliotropic) [5; 6; 17; 18; 88]. Infection of EECs with these viruses results in cell 
injury which leads to thrombosis and vasculitis of small blood vessels [5; 6; 17; 19; 52; 
170]. Furthermore, some EHV-1 strains  [neuropathogenic (e.g. T953 strain)]  are capable 
of infecting endothelial cells of small blood vessels which supply the central nervous 
system (CNS) causing vascular thrombosis and vasculitis leading to a frequently fatal 
neurological disease called equine herpesvirus myeloencephalopathy (EHM) [15; 18; 52; 
178]. Recently, EHM outbreaks have been reported in an increasing number of countries 
including the USA, prompting the USDA to designate it as an emerging disease [175]. 
However, most of the strains of EHV-1 [non-neuropathogenic (e.g. T262 strain)] and 
occasionally EHV-4 strains cause thrombosis and vasculitis in small vessels of the late 
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pregnant uterus resulting in abortion [18; 260]. Thus, the underlining etiology for the 
disease conditions caused by all three viruses used in this study is the viral vasculitis of the 
CNS and the late gravid uterus.  
EAV was first isolated from the lung of an aborted fetus in a standardbred breeding 
farm near Bucyrus, Ohio in 1953 [121]. Since then, EAV outbreaks have occurred in the 
US and other parts of the world causing direct and indirect economic losses due to abortion 
in pregnant mares, increased mortality in young foals and establishment of persistent 
infection in stallions [27; 89; 90]. In contrast to neuropathologic EHV-1 strains, EAV 
infections do not cause neurological clinical signs but similar to non-neuropathogenic 
EHV-1 and some EHV-4 strains, they can cause abortion through endothelial cell injury 
which leads to severe necrotizing panvasculitis and increased vascular permeability [5; 19]. 
Therefore, the main factor associated with the pathological outcomes of these virus 
infections is vasculitis. Vasculitis is the inflammation of the walls of the blood vessels and 
a vast number of mechanisms contribute to its  development [255]. However, the 
production of cytokines and expression of adhesions molecules by immune and endothelial 
cells play a significant role in the development of vasculitis and thrombosis of the small 
blood vessels [255]. Since the up regulation of proinflammatory cytokines and chemokines 
occurs frequently in vasculitis syndromes [255; 256], understanding the proinflammatory 
cytokine and chemokine profile of equine endothelial cells (EECs) infected with EHV-1, 
EHV-1 (T262), EHV-4 (T445) and EAV is important in contributing to the understanding 
of the pathogenesis of vasculitis caused by each of these viruses. Furthermore, even though 
genetically very different, all four viruses share some close similarities in their disease 
outcomes and pathogenesis and the fact that vasculitis is a major factor in their 
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pathogenesis led us hypothesize that the proinflammatory cytokine and chemokine profile 
of  EECs infected with these viruses should also have some close similarities. Several 
studies have explored the cytokine and chemokine gene expression of immune cells, EECs 
and also the serum cytokine levels to EAV  [64; 261] and EHV-1 and -4 infections [191; 
262; 263]. The primary objective of this study however, was to compare the 
proinflammatory cytokine and chemokine gene expression as well as protein secretion by 
EECs following infection with these three endotheliotropic viruses in order to establish 
whether their similarities in disease outcomes and pathogenesis would be reflected in gene 
and protein expression in infected EECs. As such, we hypothesized that the 
proinflammatory cytokine and chemokine gene expression as well as secretion of these 
virus infected EECs would show similar combinations.   
2.3. MATERIALS AND METHODS 
2.3.1 Cell lines 
Equine endothelial cells (EECs) were derived from the pulmonary artery of a horse 
as previously been described [264]. The EECs were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Corning, New York, NY) with 10% bovine calf serum (BCS, 
Hyclone Laboratories, Inc., Logan, UT), 100 U/mL penicillin–streptomycin, 1 mM sodium 
pyruvate, 0.1 mM nonessential amino acids and 200 mM L-glutamine (Thermo Fisher 
Scientific, Waltham, MA) in a humidified incubator at 37 °C with 5% CO2. All experiments 
were performed in EECs between passage numbers 15-20.  
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2.3.2 Viruses 
Four viruses were used in this study. The horse adapted virulent Bucyrus strain of 
EAV (VBS; VR796; ATCC), the neuropathogenic T953 (Findlay) strain [14] and the 
abortigenic T262 strain [265] of equine herpesvirus 1 and the T445 strain of EHV-4. The 
EHV-1 and EHV-4 viruses were kindly provided by the late Dr. George Allen, Maxwell 
H. Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky. All 
viruses were propagated in EECs to generate high titer working stocks. Briefly, triple 
decker cell culture flasks (Nunc, Rochester, NY) containing EEC monolayers were infected 
with each of the four viruses. The flasks were frozen at -80°C when a 100% cytopathic 
effect (CPE) was observed. Cell lysates were clarified by centrifugation (2000 x g) at 4 °C 
for 15 min, followed by ultracentrifugation (Beckman Coulter, Miami, FL) at 121,600 x g 
for EAV and 100,000 x g for EHVs through a 20% sucrose cushion in NET buffer (150 
mM NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 7.5) at 4 °C for 4 h to pellet the virus. 
Purified preparations of each virus strain were resuspended in Dulbecco’s phosphate 
buffered saline (DPBS, Thermo Fisher Scientific, Waltham, MA), briefly sonicated and 50 
µL aliquots were frozen at -80 °C until further use. Virus stocks were titrated by standard 
plaque assay in EECs, and titers were expressed as the number of plaque forming units 
(PFU) per milliliter (PFU/mL).  
2.3.3 Antibodies 
To determine the presence of viral antigens in in-vitro infected EECs, the following 
monoclonal antibodies (mAbs) were used. To detect EAV antigens, mAb 12A4 against 
EAV non-structural protein 1 (nsp-1) [266] was conjugated with Alexa Fluor 488 (AF-488) 
[267]. To detect EHV-1 antigens in T953 and T262 infected cells, the mAb 14H7 against 
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EHV-1 glycoprotein 13 (gp13) was used [268; 269]. A Melon Gel IgG Spin Purification 
kit (Pierce, Rockford, IL) was used to purify mouse ascitic fluid containing mAb 14H7. 
Purified IgG was directly conjugated to AF-647 (Thermo Fisher Scientific, Waltham, MA) 
following the manufacturer’s protocol. Briefly, purified IgG from mAb 14H7 was diluted 
with phosphate-buffered saline (PBS, pH 7.4) to a concentration of 2 mg/mL. The diluted 
IgG solution was incubated with AF-647 reactive dye for 1 h at room temperature in the 
dark with slow stirring. The reaction mixture was loaded onto an exclusion purification 
resin column for separation of labeled antibodies from unincorporated dye. Fractions of 
AF-647 labeled antibodies were collected and stored at 4 °C. To detect nonspecific binding, 
an AF-647 conjugated mouse IgG2a [270] isotype control was used (BD Biosciences, San 
Jose, CA).  
2.3.4 Viral growth curves 
The one step growth curves in EECs for each virus strain used in this study in EECs 
were plotted over a period of 24 hours post infection (hpi) according to a standard 
laboratory protocol. Briefly, EECs were plated in 6 well plates (3×106 cells per well) and 
left overnight in a humidified incubator at 37 °C in the presence of 5% CO2 for the cells to 
attach and form a cell monolayer. Following this, the media was aspirated, and the 
monolayer was washed once with 1 mL of DMEM (Corning, New York, NY) without 
BCS. The EEC monolayer was then infected with 200 µL of Minimum Essential Media 
(MEM, Corning, New York, NY) containing virus strains (EHV-1 [T262 or T953], EHV-
4 [T445], or EAV) at a multiplicity of infection (MOI) of 2 and incubated in a humidified 
incubator at 37 °C in the presence of 5% CO2 for 1 h. After 1 hour the medium containing 
the virus was removed and the EEC monolayer was washed three times with pre- warmed 
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(37 °C) PBS. Following this, pre-warmed (37 °C) DMEM (Corning, New York, NY) with 
10% BCS (Hyclone Laboratories, Inc., Logan, UT), 100 U/mL penicillin–streptomycin, 1 
mM sodium pyruvate, 0.1 mM nonessential amino acids and 200 mM L-glutamine 
(Thermo Fisher Scientific, Waltham, MA) was added to the wells and the plates incubated 
in a humidified incubator at 37 °C in the presence of 5% CO2. Tissue culture fluid (TCF) 
supernatant from the virus infected EEC monolayers were collected at time points 3, 6, 9, 
12, 18 and 24 hpi. The collected TCF was used to plot the growth curves of the virus strains 
using the Reed and Muench 50% end point (TCID50) method. 
2.3.5 RNA extraction and quantitative real-time RT-PCR (RT-qPCR) 
EECs were seeded in 6 well plates (3×106 cells per well) and left overnight in a 
humidified incubator at 37 °C in the presence of 5% CO2 for the cells to attach and form a 
cell monolayer. Following this, monolayers were infected with the four virus strains as 
described above. Upon completion of infection, the virus containing MEM (Corning, New 
York, NY) was aspirated and pre-warmed (37 °C) DMEM (Corning, New York, NY) with 
10% BCS (Hyclone Laboratories, Inc., Logan, UT), 100 U/mL penicillin–streptomycin, 1 
mM sodium pyruvate, 0.1 mM nonessential amino acids and 200 mM L-glutamine 
(Thermo Fisher Scientific, Waltham, MA) was added into each well and re-incubated until 
6 or 12 hpi. EECs grown in identical conditions absent virus infection was used as the mock 
control.  TCF supernatants from each of the virus and mock infected EEC monolayers were 
collected and stored at -80 °C to be used later for Luminex assay (Millipore sigma, 
Burlington, MA) analysis. RT-qPCR was performed on total RNA extracted from EHV-1, 
EHV-1 (T262), EHV-4 (T445) and EAV infected EECs at 6 and 12 hpi using the miRNeasy 
mini kit (Qiagen, Hilden, Germany). Total RNA from uninfected EECs cultured under 
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identical conditions was used as the reference sample. Any contaminating genomic DNA 
present was removed by performing DNase I digestion (RNase free DNase set, Qiagen, 
Hilden, Germany). The total RNA quality and quantity was assessed using a Bioanalyzer 
(Agilent technologies, Santa Clara, CA). One micro gram of total RNA was reverse 
transcribed to generate cDNA using a High capacity reverse transcription kit (Thermo 
Fisher Scientific, Waltham, MA). Real-Time PCR amplification was carried out using 1:1 
diluted cDNA to assess the relative expression of different proinflammatory cytokine and 
chemokine genes using commercially available and custom made equine TaqMan™ 
primers and probes (Thermo Fisher Scientific, Waltham, MA) in a 7500 Fast Real-Time 
PCR system (Thermo Fisher Scientific, Waltham, MA). The panel of proinflammatory 
cytokine and chemokine genes investigated in this study are listed in Table 2.3. All 
reactions were performed in triplicate. Equine β- glucuronidase gene was used as an 
endogenous control to normalize the quantitative RT-qPCR data as has been described in 
previous studies [64]. PCR efficiency for all reactions was assessed using LinRegPCR 
[271]. For relative quantification, fold changes in gene expression were calculated using 
the ΔΔCT method [272].   
2.3.6 Cytokine and chemokine multiplex assay 
To screen for the proinflammatory cytokines and chemokines secreted by EECs 
infected with the viruses used in this study, Luminex technology based equine multiplex 
cytokine assays were carried out. Analysis of IFNα, IFNɣ, IL17, IL4 and IL10 content was 
performed using a horse cytokine 5 plex assay at the Animal Health Diagnostic Center at 
the University of Cornell, Ithaca, NY as described by Wagner et. al. 2009 [273]. All the 
other cytokine (IL1α, IL1β, IL12, IL18, TNFα, GM-CSF and G-CSF) and chemokine (IL8, 
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CCL2, CCL5, CXCL10, Eotaxin and Fractalkine) protein analyses were carried out using 
the MILLIPLEX MAP Equine Cytokine/Chemokine Magnetic Bead Panel - Immunology 
Multiplex Assay (Millipore sigma, Burlington, MA) in conjunction with the Luminex 
200™ System (Luminex Corporation, Austin, TX). TCF supernatant collected previously 
were used for the analysis. In brief, 25 µL of the TCF supernatants collected from virus 
infected EEC cultures at 6 and 12 hpi were treated with the primary antibody cocktail 
(IL1α, IL1β, IL8, IL12, IL18, CXCL10, CCL2, CCL5, Eotaxin, Fractalkine, TNFα, G-CSF 
and GM-CSF) according to the manufacturer’s protocol. The treated cell culture 
supernatants were loaded into a 96 well plate provided with the kit and incubated overnight 
at 4 °C on a shaker. Following incubation, the 1ry antibody cocktail is removed and the 
detection antibody was added and incubated with agitation on a plate shaker for 1 hour at 
room temperature. Streptavidin-Phycoerythrin was added to each well containing the 
detection antibody followed with a 30-minute incubation and washing. The plate was read 
using a Luminex 200™ System (Luminex Corporation, Austin, TX). 
2.3.7 Flow cytometry analysis of EECs 
In order to make certain that the difference in gene expression levels and cytokine 
production by EHV-1 and EAV infected EECs was not due to the differences in the 
infection levels of EECs, flow cytometry was performed. EECs were seeded in 6 well 
plates (3×106 cells per well) and left overnight in a humidified incubator at 37 °C in the 
presence of 5% CO2 for the cells to attach and form a cell monolayer. Following this, the 
monolayer was infected with either EHV-1 (T953 or T262) or EAV at a MOI of 2 as 
described above. Upon the completion of infection, the virus containing MEM (Corning, 
New York, NY) was aspirated and pre-warmed (37 °C) DMEM (Corning, New York, NY) 
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with 10% BCS (Hyclone Laboratories, Inc., Logan, UT), 100 U/mL penicillin–
streptomycin, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids and 200 mM L-
glutamine (Thermo Fisher Scientific, Waltham, MA) was added into each well and re-
incubated until a 12 hpi timepoint was reached. After 12 h of incubation, EECs were 
harvested from plates using a cell scraper. Up to 1×106 cells were incubated at room 
temperature in 200 µL of 2% paraformaldehyde for 30 minutes to fix the cells. 
Permeabilization of EECs was carried out by incubating EECs using 200 µL of 1% saponin 
at room temperature for 5 minutes. Following permeabilization, EHV-1 (T953 and T262) 
infected EECs were incubated with 14H7-AF647 mouse mAb and EAV infected EECs 
were incubated with 12A4-AF488 mouse mAb for 30 minutes at room temperature. After 
washing, cells were resuspended in flow buffer (PBS supplemented with 10% normal goat 
serum and 0.1% sodium azide) and acquisition was performed using a BD LSR II flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ). Data were analyzed using the BD 
CellQuest™ pro software (Becton Dickinson, Franklin Lakes, NJ). 
2.3.8. Statistical analysis 
The statistical analysis of the virus growth curves was performed using the natural 
log values (Ln) of the virus titers employing t tests. For RT-qPCR analysis, ANOVA was 
performed using the means of fold changes. Statistical analysis of Luminex data was 
performed using t tests as well. The significant level (p-value) for all experiments was set 
at 0.05 for all tests. Statistical analysis was performed using the JMP pro 13 software 
(JMP®, Version 13 SAS Institute Inc., Cary, NC, 1989-2019). 
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2.4. RESULTS 
2.4.1 Virus growth curve comparison 
First, the production of infectious progeny virus in EECs were analyzed using two 
EHV-1 strains (T953 and T262), EHV-4 (T445) strain and EAV over a period of 24 hours. 
The growth curves of the virus strains were plotted using the Reed and Muench 50% 
endpoint (TCID50) method [274].  
The growth patterns of the three herpesviruses were similar. The titers of the three 
herpesviruses shows a sharp increase from 12 to 18 hpi timepoints indicating the viruses 
might be completing one infectious cycle in EECs between these two timepoints (Figure 
2.1). Furthermore, the titer at the 18 hpi timepoint was statistically significantly higher than 
the titer at the 12 hpi timepoint for the two EHV-1 strains (T953 and T262) but not for 
EHV-4 (T445) (Tables 2.1 and 2.2). At the end of 24 h, of the three herpesviruses, the 
highest virus titer was achieved with EHV-1 (T262) followed by EHV-1 (Table 2.1). 
However, the virus titers of these two viruses at the 24 hpi timepoint were not statistically 
significant (Table 2.2). EHV-4 (T445) achieved the lowest virus titer after 24 hpi and the 
final titer was statistically significantly lower than all the other virus titers at the same 
timepoint (Tables 2.1 and 2.2).   
Compared to the three herpesviruses, EAV had a different growth pattern (Figure 
2.1). In the case of the growth curve of EAV the virus titer increases steeply from 6 to 9 
hpi timepoints indicating the virus might be completing one infectious cycle in EECs 
between these two timepoints (Figure 2.1). Furthermore, the titer at the 9 hpi timepoint was 
significantly higher than the titer at the 6 hpi timepoint (Table 2.1). Based on the virus 
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growth curves, it can be concluded that the two EHV-1 strains (T953 and T262) and EAV 
elicited a similar ability to replicate in EECs when compared with EHV-4 (T445) which 
generated a lower virus titer in EECs.  
2.4.2 Inflammatory cytokine and chemokine gene expression of EECs following virus 
infection 
We explored the gene expression profile of eight proinflammatory cytokines (IL6, 
IL17, IL18, TNFα, IFNα, IFNω, IFNɣ and GM-CSF) and eight proinflammatory 
chemokines (IL8, CXCL9, CXCL10, CXCL11, CXCL16, CCL3, CCL4 and CCL5) in 
virus infected EECs at 6 and 12 hpi timepoint using RT-qPCR. Gene expression values 
from 3 independent biological replicates are reported for the 4 virus strains used in this 
study. The relative quantification values of these genes in EECs infected with each virus 
are provided in Table 2.3. The gene expression levels of 4 proinflammatory cytokines 
(IL18, GM-CSF, CXCL16 and IFNɣ) and 2 proinflammatory chemokines (IL8 and CCL3) 
were upregulated less than 5-fold at both 6 and 12 hpi timepoints in EECs infected with 
these four viruses. All other genes showed a 5-fold or a greater gene expression, at least at 
one timepoint (6 or 12 hpi).  
Differences in gene expression in virus infected EECs between 6 and 12 hpi 
timepoints was investigated. In EHV-1 infected EECs, three cytokines (IL6, IL17c, IFNα) 
and one chemokine (CCL5) showed a statistically significant increase in gene expression 
from 6 to 12 hpi (Table 2.3). In EHV-1 (T262) and EHV-4 (T445) infected EECs, the gene 
expression of only IL17c increased significantly from 6 to 12 hpi (Table 2.3). In EAV 
infected EECs, three cytokines (IL17c, IFNα, IFNω) and one chemokine (CCL4) increased 
significantly from 6 to 12 hpi (Table 2.3). 
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Any differences in gene expression in EECs infected with the four virus strains 
were compared with each other. As mentioned previously, a 5-fold or greater change in 
gene expression was observed in the case of proinflammatory cytokines IL6, IL17, TNFα, 
IFNα, IFNω and the proinflammatory chemokines CXCL9, CXCL10, CXCL11, CCL4 and 
CCL5. Interestingly, the gene expression levels of these proinflammatory cytokines and 
chemokines in infected EECs were similar among the three herpesvirus and were not 
significantly different from one another. When compared with the gene expression levels 
of the EAV infected EECs however, the three herpesvirus infected EECs had a higher gene 
expression for all of the cytokines and chemokines and some of them were significantly 
different.  
When considering the EEC gene expression levels of EHV-4 (T445) vs EAV, at 
the 6 hpi timepoint, IL6, IFNα and CXCL11were significantly higher in the case of EHV-
4 (T445) infected EECs (Table 2.4). At the 12 hpi timepoint, IL17, CXCL10, CXCL11 and 
CCL5 gene expression were significantly higher in EHV-4 (T445) infected EECs (Table 
2.4). When considering the EEC gene expression levels of EHV-1 (T262) vs EAV, at the 
6 hpi timepoint, CXCL11 and IFNω gene expressions were significantly higher in EHV-1 
(T262) infected EECs (Table 2.5). At the 12 hpi timepoint, IFNα gene expressions was 
significantly higher in EHV-1 (T262) infected EECs (Table 2.5). When considering the 
EEC gene expression levels of EHV-1 vs EAV, at the 6 hpi timepoint, CXCL11, IFNα and 
CCL4 gene expressions were significantly higher in EHV-1 infected EECs (Table 2.6). At 
the 12 hpi timepoint, IL6 gene expressions was significantly higher in EHV-1 infected 
EECs (Table 2.6). As such, the gene expression data indicates that the three herpesviruses 
induce a higher proinflammatory response in EECs when compared with EAV. 
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During our analysis of virus growth curves in EECs we observed that, out of these 
4 virus strains, EHV-4 (T445) achieved the lowest virus titer during replication in EECs. 
However, during our analysis of the cellular response towards virus infection in terms of 
proinflammatory cytokine and chemokine gene expression, we do not see a statistically 
significant difference between EHV-4 (T445) and its two closely related EHV-1 cousins 
(T953 and T262). This indicates that EECs can mount a defense response against EHV-4 
(T445) infection in the same magnitude as in EHV-1 strains. Interestingly, EAV shows the 
lowest fold changes for proinflammatory cytokine and chemokine gene expression when 
compared with the three herpesviruses indicating that compared to the three herpesviruses 
used in this study, EAV suppresses the proinflammatory response of EECs. 
2.4.3 Inflammatory cytokine and chemokine production by EECs against virus 
infection 
Following RT-qPCR analysis of virus infected EECs, we observed that compared 
to the three herpesviruses EAV suppresses the proinflammatory gene response in EECs. 
Here, we investigated if this suppression at the mRNA level is also present at the protein 
level. We analyzed the levels of proinflammatory cytokines and chemokines produced by 
virus infected EECs using a Luminex assay. A total of 18 analytes were analyzed using the 
TCF supernatants collected from EEC monolayers infected with the four virus strains used 
in this study at both 6 and 12 hpi timepoints. TCF supernatant from uninfected EEC 
monolayers was used as the negative control. Here we present data from 3 independent 
experiments. Out of the 18 cytokines and chemokines analyzed, 15 (IL1α, IL1β, IL4, IL8, 
IL10, IL12, IL18, MCP1, CCL5, IFNɣ, Eotaxin, Fractalkine, TNFα, G-CSF and GM-CSF) 
did not show any detectable amounts at either of the two timepoints for any of the virus 
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infected EEC cultures. Out of these analytes, IL8, IL18, GM-CSF and IFNɣ showed very 
low levels of gene expression in RT-qPCR analysis at both 6 and 12 hpi timepoints as well 
suggesting that in vitro infection of EECs by these 4 virus strains do not influence their 
production at the mRNA as well as protein levels. CCL5 and TNFα showed gene 
expression levels over 5 folds in infected EECs in RT-qPCR analysis but their presence 
was not detected in the TCF supernatants of infected EECs suggesting that in vitro infection 
of EECs by these 4 virus strains induce their mRNA expression but not the secreted 
proteins. Only three analytes (IL17, CXCL10 and IFNα) were present in detectable 
amounts in the TCF supernatants of infected EECs.  
At the 6 hpi timepoint, only the TCF supernatants from EEC cultures infected with 
the three herpesvirus strains produced detectable levels of IFNα but didn’t show a 
statistically significant difference from the negative control (Figure 2.2). At the 12 hpi 
timepoint, IFNα levels produced by EECs infected with the three herpesviruses increased 
and this increase from 6 to 12 hpi was statistically significant for each of the three 
herpesviruses (Figure 2.2). However, the IFNα levels produced by the three herpesviruses 
at the 12 hpi timepoint were not significantly different from one another. In contrast, at 
both 6 and 12 hpi timepoints, the TCF supernatants from EAV infected EECs did not 
contain any detectable amounts of IFNα (Figure 2.2). This indicates that in vitro infection 
of EECs with EHV-1 and EHV-4 strains induce the secretion of IFNα while EAV 
suppresses IFNα production from EECs.  
At both 6 and 12 hpi timepoints, IL17 was detected in the TCF of EECs infected 
with all 4 virus strains (Figure 2.3). However, at both these timepoints, the levels of IL17 
was not significantly different from the negative control or between each other indicating 
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that in vitro infection of EECs by these 4 virus strains does not induce IL17 secretion 
(Figure 2.3). 
At the 6 hpi timepoint, CXCL10 levels produced by the two EHV-1 strains (T953 
and T262) was significantly higher than the level produced by EAV infected EECs (Figure 
2.4). CXCL10 levels produced by EHV-4 (T445) was higher though not statistically 
different from what was produced by EAV infected EECs (Figure 2.4). At the 12 hpi 
timepoint, the CXCL10 levels produced by EECs infected with the 3 herpesviruses were 
significantly higher than the negative control. However, the increase from 6 to 12 hpi was 
statistically significant only for EHV-4 (T445) infected EECs (Figure 2.4). Interestingly, 
CXCL10 produced by EAV infected EECs was not statistically different from the negative 
control at both 6 and 12 hpi timepoints. Furthermore, at the 12 hpi timepoint, The CXCL10 
produced by EHV-1 infected EECs was significantly higher than EAV infected EECs. 
EHV-1 (T262) and EHV-4 (T445) infected EECs produced CXCL10 levels higher than 
EAV infected EECs at 12 hpi even though no statistical significance was observed among 
them. 
2.4.4 Flow cytometry 
Based on the results of the RT-qPCR and Luminex assays the proinflammatory 
cytokine and chemokine production by the EAV infected EECs is lower than that of the 
herpesviruses. Therefore, in order to make sure this reduction is not due to reduced EEC 
infection levels by EAV we performed flow cytometry analysis of virus infected EECs. 
EECs were in-vitro infected with EHV-1 (T262), EHV-1 and EAV at MOI of 2 and 
incubated for 12 h. Following incubation, cells were stained with mAbs against EHV-1 
gp13 and EAV nsp-1. Flow cytometry analysis indicated that on average, EAV percentage 
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of infected EEC was 38.91 whereas the average for EHV-1 and EHV-1 (T262) was 29.35 
and 38.07 respectively (Figure 2.5). This would suggest that the reduced proinflammatory 
cytokine, chemokine and IFN gene expression as well as production by EAV infected 
EECs was not due to reduced EAV infection and confirms that compared with the 
herpesviruses, EAV suppresses the inflammatory response elicited by endothelial cells 
following infection.  
In conclusion, the proinflammatory cytokine and chemokine gene expression and 
secretion in EAV infected EECs appear to be lower when compared with the three 
herpesvirus infected EECs. 
2.5 DISCUSSION 
This study explored the growth characteristics and the proinflammatory cytokine, 
chemokine and interferon gene expression and production in EECs following infection 
with EHV-1, EHV-4 and EAV. All three viruses are endotheliotropic, meaning they target 
endothelial cells during infection resulting in vasculitis which is the underlining etiology 
for the disease conditions caused by these three viruses [5; 6; 19; 52; 170]. A characteristic 
of vasculitides is the dysregulated production of cytokines by immune and endothelial cells 
which often leads to inflammation of blood vessels followed by ischemia that results in 
damage to the organ being supplied with [255; 256]. This study utilized two EHV-1 strains 
(T953 and T262). EHV-1 is a prototypic neuropathogenic strain with an ORF30 G2254 
genotype whereas the T262 strain of EHV-1 is a non-neuropathogenic yet abortogenic 
strain with an ORF30 A2254 genotype. This study also included EHV-4 (T445) which is 
very closely related to EHV-1 and the virulent Bucyrus strain of EAV which is a highly 
pathogenic and endotheliotropic virus of horses. 
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Results of the study demonstrated the production of progeny virus by EECs 
followed a similar pattern for the three EHV strains was different for EAV. This should 
not surprising since EHV-1 and -4 strains are closely related DNA viruses whereas EAV 
is an RNA virus. However, as demonstrated by the virus growth curves, the amount of 
virus particles remaining in EHV-1 (T262) and EAV infected EECs following 3 washes is 
relatively higher than in EHV-1 and EHV-4 (T445) infected EEC monolayers. One 
possible reason for this could be that 3 washes may not be sufficient to remove excess virus 
particles.     
During natural infection, EHV-1 strains can cause abortion and occasionally EHM 
by inducing viral vasculitis. However, such disease manifestations are rare following 
natural EHV-4 infection, which is primarily regarded as a respiratory pathogen. This is 
because leukocyte associated viremia is not common following EHV-4 infections [178; 
275] and in cases where viremia is detected following EHV-4 infections, viral DNA 
remains in low amounts in PBMCs and only for a short period of time [276]. These factors 
might be preventing the successful transfer of EHV-4 from its primary sites of infection to 
endothelial cells of the pregnant uterus or the CNS where it can infect and induce viral 
vasculitis. Studies including this one have demonstrated that EHV-4 is capable of infecting 
EECs at least in-vitro [277]. Furthermore, this study demonstrates that the cellular response 
of EECs towards EHV-1 and EHV-4 infections, for the most part, remains the same with 
regards to the proinflammatory gene expression and the production of proinflammatory 
cytokines and chemokines. Therefore, it is reasonable to assume that if EHV-4 strains 
infect endothelial cells in vivo the vasculitis process and the following disease 
manifestations in the form of abortions or EHM might be the same as in EHV-1 strains. 
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The results of this study indicate that the lack of such disease manifestations is most 
probably due to the virus not being transported to endothelial cells of blood vessels of the 
pregnant uterus and the CNS rather than EHV-4 strains not being able to infect endothelial 
cells and induce an inflammatory response. Therefore, the results of this study strongly 
point towards inefficient leukocyte associated viremia as a major factor in the mild disease 
outcomes associated with EHV-4 infections.  
Results from this study indicate that compared to the three herpesviruses infected 
EECs, EAV infected EECs elicit a relatively lower proinflammatory response. The 
secretion of CXCL10, which is a proinflammatory chemokine, by EAV infected EECs was 
significantly lower when compared with the three herpesviruses infected EECs. CXCL10 
activates CXCR3 receptors which are predominantly expressed on T and B lymphocytes, 
natural killer cells, dendritic cells and macrophages which induces chemotaxis [278-280]. 
As such CXCL10 plays an important role in inflammation and protection against virus 
infections. Therefore, reduced production of CXCL10 relative to herpesvirus infected 
EECs suggests a suppressed proinflammatory response in EAV infected EECs. 
Furthermore, CXCL10 aids herpes simplex virus type 2 infections by stimulating virus 
replication [281]. Therefore, the higher CXCL10 production in EHV infected EECs may 
be an adaptation by the EHVs to facilitate their replication in host cells.    
The production of IFNα, was undetected at both 6 and 12 hpi timepoints in EAV 
infected EECs. Flow cytometry analysis showed that at 2 MOI in-vitro infection, the 
percentage of EAV infected EECs are higher than EHV-1 (T953 or T262) infected EECs 
ruling out lower EEC infection by EAV as the cause for the absence of an IFNα response. 
Go et al. (2014) has shown that EAV suppresses IFNβ production in EECs due to the 
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interference caused by EAV nsp1 on IRF3 and NF-𝜅B [138]. As such, the observation 
made by Go et al. (2014) taken together with the relative gene expression and Luminex 
data from this study makes a strong case for the same interference mechanism by EAV 
nsp1 to be at play in IFNα inhibition in EAV infected EECs. 
Go et al. (2014) has shown that EAV suppresses IFNβ production in infected EECs. 
Here, we show that EAV suppresses IFNα production as well, indicating the suppression 
of the type I interferon pathway in EECs. The porcine reproductive and respiratory 
syndrome virus, which is another member of the family Arteriviridae, is also known to 
suppress the type I interferon system [136; 282]. Being a component of the innate immune 
system, type I (IFNα and IFNβ) and type II (IFNɣ) interferons are essential for the host 
antiviral response towards invading viruses [135; 283]. The results of this study have also 
shown that EECs do not express IFNɣ mRNA or secrete IFNɣ following infection by any 
of the four viruses used in this study indicating that EECs may not be a source for IFNɣ 
production during viral infections. Sarkar et. al. (2015) has shown that T953 strain of EHV-
1 suppress IFNβ production from EECs. However, this study indicates that the production 
of IFNα remains intact in EHV-1 and EHV-4 infected EECs. In accordance, other studies 
have demonstrated the induction of IFNα from EHV-1 infected PBMCs [284] and airway 
epithelial cells [285; 286] suggesting that the EHV-1 suppression of the type 1 interferon 
system may be limited to just IFNβ. During EHV-1 infections, the lesions are restricted to 
the uterus, CNS and the upper respiratory tract with no evidence of systemic lesions such 
as pan vasculitis observed during EAV infections. The fact that at least one arm of the type 
I interferon system remaining intact during EHV-1 infections maybe a contributing factor 
in preventing systemic lesions whereas the complete suppression of the type I interferon 
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system in EECs during EAV infections maybe contributing to the much more severe 
systemic vascular lesions observed during EAV infections. 
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Table 2.1: Average virus titers of the three EHV-1 strains and EAV used in this study at 
different timepoints. These values were obtained from 3 independent experiments. 
 
Table 2.2: The p values of statistically significant virus titers (p<0.05) among different 
virus strains (three EHV-1 strains and EAV) at 3-24 hpi. Statistical analysis was done using 
the natural log values of the log 10 TCID50 values obtained from cell culture supernatants. 
NS indicates timepoints with no statistical significance 
Timepoint 
(hpi) 
VBS v 
T445 
VBS v 
T262 
VBS v 
T953 
T262 v 
T445 
T262 v 
T953 
T953 v 
T445 
3 p=0.014 NS p=0.023 p=0.006 p=0.09 NS 
6 p=0.02 NS NS p=0.004 p=0.024 NS 
9 p=0.0004 p=0.004 p=0.003 p=0.02 NS NS 
12 p<0.0001 p=0.008 p=0.0004 p=0.002 NS p=0.04 
18 p<0.0001 NS NS p<0.0001 p=0.03 p=0.0005 
24 p=0.0005 NS NS p=0.0003 NS p=0.002 
 
 
 
 
 
 
 
 
Virus 3 hpi 6 hpi 9 hpi 12 hpi 18 hpi 24 hpi 
EHV-1 
(T262) 
102.6 ± 
100.1 
102.6 ± 
100.1 
102.8 ± 
100.38 
103.6 ± 
100.1 
106 ± 
100.5 
106 ± 
100.6 
 
EHV-1 
 
100.5 ± 
100.9 
 
100.9 ± 
100.9 
 
101.8 ± 
100.7 
 
102.4 ± 
100.6 
 
104.75 ± 
100.5 
 
105.25 ± 
100.4 
 
EHV-4 
(T445) 
 
100.3 ± 
100.6 
 
100.3 ± 
100.6 
 
100.9 ± 
100.9 
 
100.9 ± 
100.9 
 
102.25 ± 
100.5 
 
102.9 ± 
100.5 
 
EAV 
 
102.25 ± 
100.4 
 
102.1 ± 
100.3 
 
104.5 ± 
100.25 
 
105.6 ± 
100.1 
 
105.6 ± 
100.1 
 
105.8 ± 
100.4 
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Table 2.3: Average fold change in gene expression ± SD in EECs following EHV-1 (T953 and T262), EHV-4 (T445) and EAV. This 
data is from three independent biological replicates for each of the virus strains. Bold texts show where the increase of fold change from 
6 to 12 hpi was statistically significant (p≤0.05) 
  Virus 
  EHV-1 (T262) EHV-1 EHV-4 (T445) EAV 
Gene 6hpi SD 12hpi SD 6hpi SD 12hpi SD 6hpi SD 12hpi SD 6hpi SD 12hpi SD 
IL6 19.4 18.7 28 25.9 14.2 14.7 31.2 31.5 15.6 9.4 16.7 11.2 3.1 3.3 5.8 7.0 
IL-8 1.7 0.2 3.8 1.3 2.4 1.1 1.8 2.3 1.6 0.2 1.4 0.9 0.2 0.2 1.5 0.6 
IL-17 1.7 0.5 13.8 13.9 1.7 0.6 5.2 1.4 2.0 0.7 7.2 2.1 1.3 0.5 4.1 0.9 
IL-18 1.6 0.2 1.3 1.2 0.7 0.4 0.3 0.0 1.6 1.0 1.4 1.3 1.8 0.3 0.8 0.0 
CXCL9 156.3 259.6 230.7 196.3 172.6 282.6 182.4 283.6 173.8 164.7 753.3 692.9 38.4 54.0 154.9 22.1 
CXCL10 111 167.4 101.5 71.9 137.2 193.2 219.7 184.6 1075.6 1560.7 2011.5 3250.5 52.7 51.8 54.2 68.7 
CXCL11 130.5 174.7 345.5 304.7 204.3 292.4 265.7 377.9 561.5 417.7 622.2 216.4 14.5 21.7 115.2 38.1 
TNFα 11.3 13.1 112.8 124.5 4.9 4.8 34.1 26.4 8.1 9.3 18.0 12.3 1.2 1.0 25.2 14.8 
IFNα 96.1 84.1 251.6 207 129.6 114.8 404.6 343.5 198.1 275.6 517.5 575.2 6.9 5.3 57.3 43.8 
IFNω 57.3 49 115.7 72.8 87.4 37.5 169.5 135.7 138.7 120 48.6 32.2 20.1 17.2 129.3 118.4 
IFNɣ 1.7 0.0 0.7 1.0 0.8 1.2 0.0 0.0 0.8 1.2 1.0 1.4 0.6 0.8 1.6 0.5 
GM-
CSF 
2.9 2.9 4.5 1.0 1.5 0.4 3.3 2.0 1.3 0.9 1.6 0.7 0.7 0.4 4.4 2.3 
CCL3 2.4 1.1 4.1 1.5 1.9 0.3 3.6 0.7 2.1 0.4 1.5 0.4 0.6 0.1 0.4 0.3 
CCL4 11.7 9.3 66.1 38.2 12.9 9.7 57.3 57.6 15.0 18.4 42.3 14.0 1.6 0.2 12.5 8.5 
CCL5 22.8 24.4 151.7 135.3 20.6 20.7 163.6 195.1 82.9 70.7 1488.5 1953.8 3.7 3.7 8.5 1.2 
CXCL16 1.4 0.7 2.2 0.9 1.3 0.7 2.0 0.5 1.1 0.2 1.5 0.3 0.7 0.2 1.6 0.2 
CXCR6 1.6 0.0 1.1 0.2 1.8 0.4 1.2 0.6 1.7 0.4 1.3 0.3 1.1 1.1 1.0 0.9 
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Table 2.4: Average gene expressions that are significantly different between EHV-4 
(T445) and EAV at 6 and 12 hpi. Bold texts indicate the higher fold change. 
Gene 6hpi 12hpi 
 EHV-4 
(T445) 
EAV p value EHV-4 
(T445) 
EAV p value 
IL6 15.6 3.1 0.025 - - - 
CXCL11 561.5 14.5 0.036 622.2 115.2 0.007 
IFNα 198.1 6.9 0.049 - - - 
IL17 - - - 7.2 4.1 0.038 
CXCL10 - - - 2011.5 54.2 0.033 
CCL5 - - - 1488.5 8.5 0.025 
 
Table 2.5: Average gene expressions that are significantly different between EHV-1 
(T262) and EAV at 6 and 12 hpi. Bold texts indicate the higher fold change. 
Gene 6hpi 12hpi 
 EHV-1 
(T262) 
EAV p value EHV-1 
(T262) 
EAV p value 
CXCL11 130.5 14.5 0.041 - - - 
IFNω 57.3 20.1 0.025 - - - 
IFNα    251.6 57.3 0.004 
 
Table 2.6: Average gene expressions that are significantly different between EHV-1 and 
EAV at 6 and 12 hpi. Bold texts indicate the higher fold change. 
Gene 6hpi 12hpi 
 EHV-1 EAV p value EHV-1 EAV p value 
CXCL11 204.3 14.5 0.022 - - - 
IFNα 129.6 6.9 0.02 - - - 
CCL4 12.9 1.6 0.028 - - - 
IL6 - - - 31.2 5.8 0.014 
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Figure 2.1: Virus growth curves of EHV-1 (T262), EHV-1, EHV-4 (T445) and EAV in 
EECs.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.2: IFNα production by EECs infected with EHV-1 (T262 and T953), EHV-4 (T445) and 
EAV. * indicates statistically significant increase from mock at 12hpi (p≤0.05). #* indicates the 
increase in IFNα production from 6 to 12 hpi is statistically significant (p ≤0.05)  
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 Figure 2.3: IL17 production by EECs infected with EHV-1 (T262 and T953), EHV-4 (T445) and 
EAV. The increase in IL17 production from 6 to 12 hpi is statistically not significant (p ≥0.05) 
 
Figure 2.4: CXCL10 production by EECs infected with EHV-1 (T262 and T953), EHV-4 (T445) 
and EAV. # indicates statistically significant increase from mock at 6hpi (p≤0.05). * indicates 
statistically significant increase from mock at 12hpi (p≤0.05). #* indicates statistically significant 
increase from 6 to 12 hpi (p≤0.05).   
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Figure 2.5: Flow cytometry results of the percentage of virus infected EECs when compared to 
uninfected EECs (A). EHV-1 (T262) infected EECs (B) with a 41.21% infection rate, EHV-1 infected 
EECs (C) with a 29.35% infection rate and EAV infected EECs (D) with a 45.43 % infection rate. 
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CHAPTER THREE 
 
RNA SEQUENCE ANALYSIS OF EQUINE ENDOTHELIAL CELLS 
FOLLOWING IN VITRO INFECTION WITH EQUINE HERPESVIRUS-1 AND 
EQUINE ARTERITIS VIRUS STRAINS 
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3.1. SUMMARY 
Equine herpesvirus-1 is double stranded DNA virus in the genus Varicellovirus of 
the subfamily Alphaherpesvirinae. Equine arteritis virus is a positive sense single stranded 
RNA virus in the order Arteriviridae and genus Alphaarterivirus 
(https://talk.ictvonline.org/taxonomy/). Both these viruses are endotheliotropic and pose a 
significant threat to the $102 billion US equine industry. In the previous chapter we 
investigated the gene expression of proinflammatory cytokines and chemokines in EHV-
1, EHV-4 and EAV infected EECs. The results of that study indicated that the expression 
of proinflammatory cytokine and chemokine genes are higher in EHV-1 infected EECs 
compared to EAV infected EECs, and also that EAV downregulates the expression of IFNα 
in EECs following infection. In this study we investigated the transcriptome of EHV-1 and 
EAV infected EECs at 6 and 12 hpi timepoints using RNA-Seq. The differentially 
expressed genes were used in combination with gene ontology software to reveal a complex 
pattern of gene regulation and cellular pathways related to cellular immune, inflammatory 
and apoptotic responses. The results revealed clusters of differentially expressed genes in 
EHV-1 and EAV infected EECs. Furthermore, the “gonadotrophin hormone releasing 
receptor pathway”, “CCKR signaling map” and the “Inflammation mediated by cytokine 
and chemokine pathway” was differentially expressed frequently in EECs infected with 
both EHV-1 and EAV.      
Key words: RNA-seq, EHV-1, EAV, EECs, PANTHER, Gene ontology 
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3.2. INTRODUCTION 
Equine herpesvirus-1 (EHV-1) and the equine arteritis virus (EAV) are two 
endotheliotropic equine viruses that pose a significant threat to the $102 billion US equine 
industry. EHV-1 is a double stranded DNA virus in the genus Varicellovirus of the 
subfamily Alphaherpesvirinae [18; 28]. Its type D DNA genome is about 150 kb with about 
57% G+C content [18; 287]. The genome of EHV-1 is arranged into a long unique region 
covalently linked to a short unique region which is flanked by internal and terminal repeat 
sequences [288; 289]. Furthermore, EHV-1 strains have 80 open reading frames (ORFs) 
containing 76 genes capable of coding for 77 different viral proteins [18]. EAV is a positive 
sense single stranded RNA virus in the genus Equarterivirus of the family Arteriviridae 
[290]. The genome of EAV strains include a 5’ leader sequence and at least 10 ORFs which 
encodes for 13 non-structural and 8 structural proteins (7 envelope proteins and 1 
nucleocapsid protein). The size of the EAV genome varies between 12,704 and 12,731 bp 
among different viral strains [5; 6; 291]. In horses, these two viruses are associated with 
respiratory and reproductive diseases. Upon infection, both EHV-1 and EAV strains cause 
mild upper respiratory tract infections and abortions in pregnant mares [5; 6; 17-19]. 
However, neuropathogenic strains of EHV-1, such as the T953 (Findlay) strain [14], can 
cause a rare but fatal neurologic condition in horses called equine herpes 
myeloencephalopathy (EHM) [15; 18; 52; 178]. A single nucleotide polymorphism (SNP) 
in the DNA polymerase gene (ORF30) of neuropathogenic EHV-1 strains has been linked 
with the development of EHM in infected horses [51]. EHV-1 strains with a Guanine (G) 
residue at the nucleotide position 2254 in the ORF 30 are categorized as neuropathogenic 
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while strains that have an Adenine (A) residue at this position are considered non-
neuropathogenic [51]. However, EAV is not linked with the development of any 
neurological diseases. 
As mentioned earlier, these two viruses are endotheliotropic, meaning endothelial 
cells are their main target. Several studies have investigated the gene expression of 
endothelial cells following in-vitro infection by these two viruses [138; 263; 292]. Gene 
expression studies of equine endothelial cells (EECs) infected with EAV and EHV-1 has 
shown that both these viruses suppress the production of IFNβ [138; 292]. Furthermore, a 
study done by our group has demonstrated that EAV suppresses IFNα production in 
infected EECs but not EHV-1 and the upregulation of proinflammatory cytokines and 
chemokines in EHV-1 infected EECs is relatively higher than EAV infected EECs 
(mentioned in chapter 2). Furthermore, PCR array studies done on EECs infected with 
EHV-1 have demonstrated the upregulation of proinflammatory cytokines [263]. 
Therefore, we wanted to further investigate the interferon and proinflammatory cytokine 
gene expression and production in EECs by these two virus strains. However, no study has 
been done to extensively investigate the transcriptome changes induced by EHV-1 and 
EAV in infected EECs and to elucidate the host biological pathways most affected by the 
infection of these two virus strains. Therefore, the purpose of this study was to elucidate 
the transcriptome changes in EECs following infection with either EHV-1 or EAV.  
In this study, we utilized RNA-seq to further investigate the transcriptome of EHV-
1 and EAV infected EECs. The complete set of transcripts in a cell and its quantity is 
referred to as the transcriptome and understanding the transcriptome is important in 
understanding disease conditions [293]. Most of the widely used methods available to 
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investigate the cellular transcriptome profile are based on hybridization or sequence-based 
approaches [293]. Hybridization-based approaches utilize the incubation of fluorescently 
labelled cDNA with custom-made microarrays or commercial high-density oligo 
microarrays [293]. However, the use of hybridization-based approaches are limited by the 
existing knowledge about genome sequences and high background levels caused by cross-
hybridization [294; 295], and it is difficult to compare the expression levels among 
different experiments [293]. However, with the development of high-throughput DNA 
sequencing, mapping and quantifying transcriptomes have become much efficient and 
accurate. Termed RNA-Seq (RNA sequencing), this approach utilizes recently developed 
deep sequencing technologies [293]. Compared to other methods, RNA-seq has several 
advantages since it allows the investigation of all unique sequences of the genome and it is 
a method that is very sensitive and offers a large dynamic range. This makes RNA-seq the 
better method to detect and quantify levels of RNAs expressed at very low levels over 
microarrays [296].   
 
3.3. MATERIALS AND METHODS 
3.3.1. Cells 
Endothelial cells derived from the pulmonary artery of the horse (EECs) [264] 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Corning, New York, 
NY) with 10% bovine calf serum (BCS, Hyclone Laboratories, Inc., Logan, UT), 100 
U/mL penicillin–streptomycin, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids 
and 200 mM l-glutamine (Life Technologies, Carlsbad, CA) in a humidified incubator at 
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37 °C with 5% CO2. All experiments were performed in EECs with passage numbers 15-
20.  
3.3.2. Viruses and purification 
The horse adapted virulent Bucyrus strain of EAV (VBS, VR-796; ATCC) and the 
neuropathogenic T953 (Findlay) strain (Henninger et al., 2007) were used in this study. 
The EHV-1 strain was kindly provided by the late Dr. George Allen at the Maxwell H. 
Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky. All viruses 
were propagated in EECs to generate high titer working stocks. Briefly, triple decker cell 
culture flasks (Nunc, Rochester, NY) containing EECs were infected with each of the 
above-mentioned viruses. The flasks were frozen at -80 °C when a 100% cytopathic effect 
(CPE) was observed. Cell lysates were clarified by centrifugation (2000 x g) at 4 °C for 15 
min, followed by ultracentrifugation (Beckman Coulter, Miami, FL) at 121,600 x g through 
a 20% sucrose cushion in NET buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 
7.5) at 4 °C for 4 h to pellet the virus. Purified preparations of each virus strain were 
resuspended in phosphate-buffered saline (PBS; pH 7.4) and frozen at -80 °C. Virus stocks 
were titrated by standard plaque assay in EECs, and titers were expressed as the number of 
Plaque forming units (PFU) per milliliter (38). 
3.3.3 In-vitro infection 
EECs (Passage 15-20) were plated in 6 well plates (3×106 cells per well) with 
Dulbecco’s Modified Eagle’s Medium as mentioned above and left overnight in a 
humidified incubator at 37 °C with 5% CO2 for the cells to attach to the bottom of the wells 
and form a monolayer. After overnight incubation, the media was aspirated, and the EEC 
monolayer was washed once with 1 mL of Dulbecco’s Modified Eagle’s Medium without 
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bovine calf serum. The cell monolayer was then infected with 200 µL of Minimum 
Essential Media (MEM, Corning, New York, NY) containing either EHV-1 or EAV at a 
multiplicity of infection (MOI) of 2 and incubated in a humidified incubator at 37 °C with 
5% CO2 for 1 hour to complete the infection of EECs. Following the 1 h incubation period, 
the media containing the virus was removed and the EEC monolayer was washed three 
times with warm PBS and pre-warmed Dulbecco’s Modified Eagle’s Medium (DMEM, 
Corning, New York, NY) with 10% bovine calf serum (BCS, Hyclone Laboratories, Inc., 
Logan, UT), 100 U/mL penicillin–streptomycin, 1 mM sodium pyruvate, 0.1mM    
nonessential amino acids and 200 mM L-glutamine (Life Technologies, Carlsbad, CA) was 
added to the wells and was incubated in a humidified incubator at 37 °C with 5% CO2. 
Cells were harvested at 6- and 12-hours post infection (hpi) timepoints for total RNA was 
extraction. Total RNA from uninfected EECs cultured under identical conditions 
mentioned above was used as the negative control.  
3.3.4. Total RNA extraction 
EHV-1, EAV or mock infected EECs were used for total RNA extraction following 
6 and 12 hpi. Total RNA was extracted using the miRNeasy mini kit (Qiagen, Hilden, 
Germany). Total RNA was extracted from three biological replicates for every sample at 
every timepoint. Any contaminating genomic DNA present was removed by performing 
DNase I digestion (RNase free DNase set, Qiagen, Hilden, Germany). The total RNA 
quality and quantity was assessed using a Bioanalyzer (Agilent technologies, Santa Clara, 
CA). All samples had an RNA integrity number > 8.0. 
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3.3.5. Sample submission 
A minimum of 300 ng of total RNA was submitted to Exiqon (Exiqon, South 
Korea) for whole transcriptome sequencing with single end sequencing with 75 bp read 
lengths and 30 million read counts. Library preparation was performed using the TruSeq 
Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA) per manufacturer’s 
instructions.   The adapter for read 1 was; 
AGATCGGAAGAGCACACGTCTGAACTCCAGTCACNNNNNNATCTCGTATGCC
GTCTTCTGCTTG, with NNNNNN being the index sequence.  
The read 2 adapter was;  
AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGT
ATCAT.  The libraries were quantified by qPCR.  Sequencing was performed on a HiSeq 
4000 (Illumina) using a HiSeq 4000 sequencing kit version 1, generating 150 bp single end 
reads. FASTQ files were generated and demultiplexed using bcl2fastq v2.17.1.14 
Conversion Software (Illumina).   
3.3.6. Data analysis:   
For RNA-seq data analysis, the reads were initially trimmed for adapters and 
quality using TrimGalore Version 0.4.4 (Babraham Bioinformatics; 
www.bioinformatics.babraham.ac.uk), then trimmed reads were aligned to the horse 
reference genome (EquCab3.0) using STAR (Release 2.5.2b) [32], and annotated to the 
equine reference transcriptome available in NCBI database  using Cufflinks (Release 2.2.1; 
http://cole-trapnell-lab.github.io/cufflinks/) [33]. Differential expression analysis was 
performed on the normalized read count (FPKM; fragments per kilobase of exon per 
million mapped reads) [34]. we used Cuffdiff 2.2.1  to calculate differently expressed genes 
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(DEG) between samples from the mock and virus infected groups [297]. Significance level 
was set at FDR-adjusted p value of the test statistic < 0.1 using a Benjamini-Hochberg 
correction. 
For all data analyses, separate databases were created for EHV and EAV samples. 
Differentially expressed genes were determined within tissue.  Principal components 
analysis was performed on all genes included in either database to verify clustering. Initial 
identification of differentially expressed genes was performed using one-way ANOVA, 
using the Benjamini-Hochberg correction for false discovery rate (FDR P < 0.1). 
PANTHER (version 13.1, http://www.pantherdb.org/) was used to annotate DEG in 
relation to biological process, molecular function, cellular component and pathways [298].   
 
3.4. RESULTS 
RNA-seq data obtained for this study came from a total of 18 libraries sequenced 
from EECs. These were EHV-1 infected EECs at 6 (3 samples) and 12 (3 samples) hpi 
timepoints, EAV infected EECs at 6 (3 samples) and 12 (3 samples) hpi timepoints and 
mock infected EECs at 6 (3 samples) and 12 (3 samples) hpi timepoints.   
3.4.1 Gene clustering and arrangement 
A heatmap with dendrograms and a principal component analysis (PCA) was done 
to identify the arrangement and clustering of differentially expressed genes of the EHV-1 
infected EECs at 6 and 12 hpi timepoints, EAV infected EECs at 6 and 12 hpi timepoints 
and mock infected EECs at 6 and 12 hpi timepoints (Figures 4.1 and 4.2). Based on the 
heatmap and the PCA the 3 RNA seq libraries generated from the 3 replicates of EHV-1 
infected EECs at the 6 and 12 hpi timepoints clustered together and did not show a 
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significant variance (Figures 4.1 and 4.2). With EAV infected EECs, the RNA seq libraries 
generated by the 3 replicates at the 12 hpi timepoint clustered together but did not at the 6 
hpi timepoint and showed a significant variance among the replicates (Figures 4.1 and 4.2).  
When considering the differential gene expression of EHV-1 infected EECs, at the 
6 hpi timepoint majority of the genes were upregulated compared to mock infected EECs 
(Figure 4.3A). At the 12 hpi timepoint, however, only about 50% of the genes were 
upregulated in EHV-1 infected EECs (Figure 4.3B). Furthermore, between 6 and 12 hpi 
timepoints, most of the genes were upregulated at the 6 hpi timepoint in EHV-1 infected 
EECs (Figure 4.3C). When considering the differential gene expression of EAV infected 
EECs, similar to EHV-1 infected EECs, the majority of the differentially expressed genes 
were upregulated at the 6 hpi timepoint when compared with mock infected EECs (Figure 
4.3D). At the 12 hpi timepoint, most of the genes that were differentially expressed were 
downregulated in EAV infected EECs when compared with mock infected EECs (Figure 
4.3E). Furthermore, between 6 and 12 hpi timepoints, similar to EHV-1 infected EECs, 
most of the genes were upregulated at the 6 hpi timepoint in EAV infected EECs (Figure 
4.3F).    
3.4.2 Differential expression of genes and pathways in EAV vs Mock-infected EECs  
The PANTHER 14.1 database (http://www.pantherdb.org/) was used to map the 
differentially expressed genes in EECs to canonical pathways. When considering the EAV 
and mock-infected EECs, at the 6 hpi timepoint, 544 genes showed statistically significant 
differential expression (q≤0.05). Out of those, 367 genes were upregulated while 177 genes 
were downregulated in EAV infected EECs compared to the mock infected. Out of the 544 
differentially expressed genes, 466 could be mapped to the PANTHER 14.1 database to 
 
97 
 
assign gene ontology. The top five canonical pathways differentially expressed in EAV 
infected EECs when compared to mock EECs at the 6 hpi timepoint included the 
“Cholecystokinin receptor (CCKR) signaling map”, “Inflammation mediated by 
chemokine and cytokine signaling pathway” and the “Wingless-integrated (Wnt) signaling 
pathway” with 10 differentially expressed genes each, and the “Epidermal growth factor 
(EGF) receptor signaling pathway” and the “Gonadotropin-releasing hormone receptor 
pathway” with 9 differentially expressed genes each” (Table 4.1). The 10 genes 
differentially expressed in the “Inflammation mediated by chemokine and cytokine 
signaling pathway” were all upregulated. Therefore, the “Inflammation mediated by 
chemokine and cytokine signaling pathway” appears to be predominantly upregulated in 
EAV infected EECs when compared to mock EECs at the 6 hpi timepoint. The genes 
upregulated in the “Inflammation mediated by chemokine and cytokine signaling pathway” 
included CCL13 and CCL26 (Table 4.1) which play roles in T cell monocyte and 
macrophage Chemoattraction. Also upregulated in the same pathway was NFKB2 which 
functions as an inhibitor of NF-κB and aids in controlling the inflammatory response [299; 
300] and PREX1, PLA2G4A and GNG4 which are associated with anti-inflammatory 
effects (Table 3.1) [301-303]. The “Wnt signaling pathway” is known to stimulate the 
expression of many inflammatory molecules during bacterial infections suggesting it plays 
a role during the host inflammatory response during infections [304]. Furthermore, 
increased Wnt pathway signaling is associated with inflammatory disorders [304-306]. 
Among the upregulated genes in this pathway is WNT9A which is a gene usually 
upregulated during endotoxemia driven inflammation and inflammatory bowel disease 
(Table 4.1) [304; 307]. Out of the 10 genes in the “CCKR signaling map” 5 genes each 
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were up as well as down regulated. Activation of  the “CCKR signaling map” is usually 
associated with anti-apoptotic and inflammatory effects [308]. The “EGF receptor 
signaling pathway” is associated with virus entry into cells and inflammation [309-311]. 
Out of the 9 differentially expressed genes in the “EGF receptor signaling pathway” 3 were 
upregulated and 6 were downregulated while the “Gonadotropin-releasing hormone 
receptor pathway” had 2 upregulated genes while 7 were downregulated indicating these 
two pathways were predominantly downregulated at this timepoint. Therefore, at the 6 hpi 
timepoint, the top canonical pathways showing differential gene expression are linked to 
the host inflammatory and immune responses.  
At the 12 hpi timepoint between EAV and mock-infected EECs, 3109 genes 
showed statistically significant differential expression (q≤0.05) and out of those, 1621 
genes were upregulated while 1488 genes were downregulated in EAV infected EECs 
compared to the mock-infected. Out of the 3109 differentially expressed genes, 2675 could 
be mapped to the PANTHER 14.1 database to assign gene ontology. Among the top 5 
canonical pathways differentially expressed at this timepoint were the “Gonadotropin-
releasing hormone receptor pathway”, “CCKR signaling map” and the “Inflammation 
mediated by chemokine and cytokine signaling pathway” and they were differentially 
expressed at the 6 hpi timepoint as well (Table 4.2). 
However, at the 12 hpi timepoint more genes were differentially expressed in these 
pathways compared to the 6 hpi timepoint (Table 4.2). For the “Gonadotropin-releasing 
hormone receptor pathway” 51 genes were differentially expressed and out of them 37 
were upregulated while 14 were downregulated. The upregulated genes in this pathway 
includes MAP3K2, MAP3K5, MAP3K11, MAP3K14, MAP2K3 and MAPK8 (Table 4.2) 
 
99 
 
which are associated with the mitogen-activated protein kinases (MAPK) signaling 
cascade. MAPK is associated with promoting inflammation and apoptosis [312; 313]. 
“CCKR signaling map” pathway had 39 differentially expressed genes out of which 30 
were upregulated and 9 were downregulated. As mentioned before, the “CCKR signaling 
map” is associated inflammatory and anti-apoptotic effects [308]. The “Inflammation 
mediated by chemokine and cytokine signaling pathway” had 36 differentially expressed 
genes and 25 of them were upregulated while 11 were downregulated. Among the 
important genes upregulated at this timepoint is JAK2, STAT1, STAT3 and STAT6. These 
genes are associated with the Janus kinase/signal transducer and activator of transcription 
(Jak/STAT) signaling pathway [314] which promotes inflammation during diseases [315]. 
The “Platelet-derived growth factor (PDGF) signaling pathway” and the “Apoptosis 
signaling pathway” were also among the top five pathways differentially expressed in EAV 
vs mock infected EECs at the 12 hpi timepoint. The “PDGF signaling pathway” had 44 
differentially expressed genes out of which 33 were upregulated and 11 were 
downregulated. Vascular endothelial cells are one of the main sites expressing the PDGF 
receptors (PDGFRs) which initiates the downstream “PDGF signaling pathway” which is 
involved with vascular inflammation and chemotactic activity [316; 317]. Among the 
upregulated genes in this pathway is PDGFB which is known to be expressed in endothelial 
cells and encodes the B chain of PDGF (Table 3.2) [318; 319]. The “Apoptosis signaling 
pathway” which plays a role in cell death is a cellular defense mechanism against virus 
infections to prevent the spread of progeny virus [320]. This pathway had 34 differentially 
expressed genes and out of them 31 were upregulated while 3 were downregulated. EAV 
promotes cellular apoptosis via caspase-8 and caspase-9 [321] and at this timepoint the 
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CASP8 and CASP10 genes were upregulated in EAV infected EECs compared to mock 
infected cells (Table 4.2). Furthermore, MAPK8 (Table 4.2) was also among the 
upregulated genes associated with this pathway known to promote apoptosis [312] 
confirming the involvement of caspase genes in promoting apoptosis as well as the 
triggering of apoptosis in EECs by EAV. Therefore, at the 12 hpi timepoint the top 5 
pathways differentially expressed in EAV infected EECs compared to mock infected EECs 
were associated with the host inflammatory, immune and apoptotic responses. This was 
similar to the 6 hpi timepoint and these differentially expressed pathways in EECs 
correlates with EAV pathogenesis.   
3.4.3 Differential expression of genes and pathways in EAV 6 hpi vs EAV 12 hpi in 
EECs  
As mentioned above, 544 and 3109 genes were differentially expressed in EAV 
infected EECs at the 6 and 12 hpi timepoints respectively when compared with mock-
infected EECs. Out of these differentially expressed genes 240 (7%) was differentially 
expressed at both 6 and 12 hpi timepoints while 304 and 2869 genes were exclusively 
differentially expressed at the 6 and 12 hpi timepoints respectively (Figure 4.4A). Out of 
the 240 differentially expressed genes common to both 6 and 12 hpi timepoints, 213 could 
be mapped to the PANTHER 14.1 database to assign gene ontology. The top 5 
differentially expressed pathways associated with these genes were “CCKR signaling 
map”, “EGF receptor signaling pathway”, “PDGF signaling pathway” “Apoptosis 
signaling pathway” and the “Gonadotrophin-releasing hormone receptor pathway” (Table 
4.3A). Therefore, at both 6 and 12 hpi timepoints, cellular pathways differentially 
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expressed in EECs infected EAV are associated with host inflammatory, immune and 
apoptotic responses.  
3.4.4 Differential expression of genes and pathways in EHV-1 vs Mock-infected EECs  
When considering the EHV-1 and mock-infected EECs, at the 6 hpi timepoint 4737 
genes showed statistically significant differential expression (q≤0.05). Out of those, 4003 
genes were upregulated while 734 genes were downregulated in EHV-1 infected EECs 
compared to the mock-infected. Out of the 4737 differentially expressed genes, 4196 could 
be mapped to the PANTHER 14.1 database to assign gene ontology. The top five canonical 
pathways differentially expressed in EHV-1 infected EECs when compared to mock EECs 
at the 6 hpi timepoint included the “Gonadotropin-releasing hormone receptor pathway” 
with 59 differentially expressed genes out of which 41 were upregulated and 18 were 
downregulated (Table 4.3B). The upregulated genes in this pathway included MAP4K5, 
MAP3K5, MAP2K1, MAPK11 and MAPK14 (Table 4.3B) and as mentioned before, these 
genes are associated with the MAPK signaling cascade which is associated with promoting 
inflammation and apoptosis [312; 313]. The “CCKR signaling map” had 50 differentially 
expressed genes out of which 35 were upregulated and 15 were downregulated (Table 
4.3B). Activation of the “CCKR signaling map” is associated inflammatory and anti-
apoptotic effects [308]. The “Integrin signaling pathway” had 48 differentially expressed 
genes and out of those 30 were upregulated while 18 were downregulated (Table 4.3B).  
Integrins are cell surface receptors critical for cell to cell and cell to extra cellular matrix 
communication. The Herpesviridae family is known to utilize integrins as entry receptors 
[322]. However, a study done by Van de Walle et al (2008) has shown that integrins might 
not be utilized by EHV-1 during infection of EECs. In the transcriptome data we obtained 
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for EHV-1 infected EECs, at the 6 hpi timepoint, only the α integrin subunit ITGAE was 
upregulated while the β subunits ITGB3 and ITGB4 were downregulated suggesting a 
lesser involvement of integrins during infection of EECs by EHV-1 as mentioned by Van 
de Walle et al (2008). Furthermore, several studies have indicated the importance of MHC 
class I molecule as an entry receptor for EHV-1 infections in several cell lines [196; 323]. 
At the 6 hpi timepoint, transcriptome data indicates the upregulation of EQMHCC1 which 
encodes for the equine MHC class I heavy chain in EHV-1 infected EECs which bolsters 
the observation of the involvement of MHC class I molecules in EHV-1 entry into EECs. 
Furthermore, the cell adhesion molecules ICAM-1 and VCAM-1 were also upregulated in 
EHV-1 infected EECs at the 6 hpi timepoint. The upregulation of these molecules are 
important for the firm adhesion of leukocytes to the endothelium [324] which may facilitate 
the transfer of EHV-1 virus particles from EHV-1 infected leukocytes to endothelial cells 
[17] and may also play a role in the development of thrombosis which is an important 
factors associated with EHV-1 pathogenesis [17; 18; 52; 170]. The “Inflammation 
mediated by chemokine and cytokine signaling pathway” had 47 differentially expressed 
genes and out of those 38 were upregulated and 9 were downregulated (Table 4.3B).  
Upregulated genes included IL6, IL18, IL15, IL11, CCL13, CCL26 and CXCL8, (Table 
4.3B) which play important roles in acute inflammation, immunity against infections, T 
cell, monocyte and macrophage chemoattraction as well as promote systemic vasculitis 
diseases such as the Churg–Strauss Syndrome [325-329]. Finally, the “Wnt signaling 
pathway” had 46 differentially expressed genes with 22 of them upregulated while 24 being 
downregulated (Table 4.3B) and as mentioned before, increased Wnt pathway signaling is 
associated with inflammatory disorders [304-306]. Therefore, similar to EAV infected 
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EECs, EHV-1 infected EECs differentially express cellular pathways associated with host 
inflammatory and immune responses   
At the 12 hpi timepoint between EHV-1 and mock-infected EECs 2503 genes 
showed statistically significant differential expression (q≤0.05) and out of those, 1046 
genes were upregulated while 1457 genes were downregulated in EAV infected EECs 
compared to the mock-infected. Out of the 2503 differentially expressed genes, 2109 could 
be mapped to the PANTHER 14.1 database to assign gene ontology. The top five canonical 
pathways differentially expressed in EHV-1 infected EECs when compared to mock EECs 
at the 12 hpi timepoint included the following: The “Integrin signaling pathway” had 47 
differentially expressed genes. Out of those 47 genes, 8 were upregulated and 39 were 
down regulated (Table 3.4B).  Similar to the 6 hpi timepoint the integrin subunit genes 
were among the downregulated genes. These included the integrin α subunit genes ITGA2, 
ITGA5, ITGA11, and ITGAX, and the integrin β subunit genes ITGB3, ITGB4, and ITGB5 
(Table 3.4B), indicating a lesser involvement of integrins during infection of EECs by 
EHV-1 as mentioned by previous studies [330]. Furthermore, at the 12 hpi timepoint the 
cell adhesion molecules ICAM-1 and VCAM-1 were among the upregulated genes just as 
it was at the 6 hpi timepoint. These molecules play important roles in the firm adhesion of 
leukocytes to the endothelium which may facilitate the transfer of EVH-1 particles from 
infected leukocytes to the endothelium and may also contribute to the development of 
thrombosis [17; 18; 52; 170; 324]. Similar to the 6 hpi timepoint, the “Gonadotropin-
releasing hormone receptor pathway” was among the top 5 differentially expressed 
pathways at the 12 hpi timepoint (Table 4.4B). This pathway had 46 differentially 
expressed genes out of which 16 were upregulated and 30 were downregulated. The 
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upregulated genes in this pathway included MAP3K5, MAPK4, MAPK6 and MAPK11 
which are associated with the MAPK signaling cascade that promotes inflammation and 
apoptosis [312; 313]. The “Angiogenesis” pathway had 35 differentially expressed genes 
out of which 8 were upregulated and 27 were downregulated (Table 4.4B). Based on the 
amounts of upregulated genes in these three pathways, we can conclude that these three 
pathways are downregulated in EHV-1 infected EECs compared to uninfected EECs at the 
12 hpi timepoint. The “Inflammation mediated by chemokine and cytokine signaling 
pathway” and the “CCKR signaling map” was also among the top 5 pathways (Table 4.4B). 
The “Inflammation mediated by chemokine and cytokine signaling pathway” had 44 
differentially expressed genes and 23 of them were upregulated while 21 were 
downregulated. Among the upregulated genes were CCL2, CCL5, CCL13, CCL20, CXCL8 
and IL6 which play important roles in acute inflammation, immunity against infections, T 
cell monocyte and macrophage chemoattraction as well as be involved in systemic 
vasculitis diseases such as the Churg–Strauss Syndrome [325; 326; 328; 331]. The “CCKR 
signaling map” had 37 differentially expressed genes out of which 21 were upregulated 
and 16 were downregulated. Therefore, at the 12 hpi timepoint as well, EECs infected with 
EHV-1 differentially express cellular pathways associated with host immune and 
inflammatory responses.    
3.4.5 Differential expression of genes and pathways in EHV-1 6 hpi vs EHV-1 12 hpi 
in EECs  
As mentioned above, 4737 and 2503 genes were differentially expressed in EHV-
1 infected EECs at the 6 and 12 hpi timepoints respectively when compared with mock-
infected EECs. Out of these differentially expressed genes, 1315 (22.2%) were common to 
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both 6 and 12 hpi timepoints while 3422 and 1188 genes were exclusively differentially 
expressed at the 6 and 12 hpi timepoints respectively (Figure 4.4B). Out of the 1315 
differentially expressed genes common to both 6 and 12 hpi timepoints, 1076 could be 
mapped to the PANTHER 14.1 database to assign gene ontology. The top 5 differentially 
expressed pathways associated with these genes were “Gonadotrophin-releasing hormone 
receptor pathway”, “Integrin signaling pathway”, “CCKR signaling map”, “Inflammation 
mediated by chemokine and cytokine signaling pathway”, and the “Angiogenesis pathway” 
(Table 4.5A). Therefore, in EHV-1 infected EECs genes that were commonly differentially 
expressed were associated with host immune and inflammatory responses.    
3.4.6 Differential expression of genes, pathways and biological functions in EHV-1 vs 
EAV infected EECs  
When considering the differentially expressed genes in EHV-1 and EAV infected 
EECs, at the 6 hpi timepoint, 518 genes (10.9%) were common while 4217 and 26 genes 
were exclusively differentially expressed in EHV-1 and EAV infected EECs respectively 
(Figure 4.4C). Out of the 518 common genes, 443 could be mapped to the PANTHER 14.1 
database to assign gene ontology. The top 5 differentially expressed pathways associated 
with these genes were the “Inflammation mediated by chemokine and cytokine signaling 
pathway”, “CCKR signaling map”, “Wnt signaling pathway”, “EGF receptor signaling 
pathway” and the “Gonadotrophin-releasing hormone receptor pathway” (Table 4.5A) 
suggesting the host cellular pathways associated with immune and inflammatory responses 
are the top pathways differentially expressed in EECs following infection with these two 
viruses.      
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At the 12 hpi timepoint, out of the differentially expressed genes in EHV-1 and 
EAV infected EECs, 910 genes (19.4%) were common while 1593 and 2199 genes were 
exclusively differentially expressed in EHV-1 and EAV infected EECs respectively 
(Figure 4.4D). Out of the 910 common genes, 785 could be mapped to the PANTHER 14.1 
database to assign gene ontology. The top 5 differentially expressed pathways associated 
with these genes were the “Gonadotrophin-releasing hormone receptor pathway”, “CCKR 
signaling map”, “Apoptosis signaling pathway”, “Inflammation mediated by chemokine 
and cytokine signaling pathway” and the “Integrin signaling pathway” (Table 4.5B).    
 
3.5. DISCUSSION 
This study elucidates the transcriptome of EECs infected with EHV-1 and EAV.  
3.5.1 Gene clustering and arrangement 
According to the heat map and the PCA, the differentially expressed genes in EHV-
1, infected EECs at the 6 and 12 hpi timepoint were clustered together indicating no 
significant differences in the differential gene expression among the replicates. In EAV 
infected EECs, at the 12 hpi timepoint, the differentially expressed genes were clustered 
together indicating no significant differences among the replicates. Two out of the three 
replicates of EAV infected EECs at the 6 hpi timepoint clustered together but one replicate 
did not, even though virus from the same EAV stock and EECs with the same passage 
number was used throughout the experiment. Several reasons may have contributed to this 
including differences in virus infection efficiency of EECs to the single ended sequencing.  
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3.5.2Differential gene expression and cellular pathways 
When considering the differential gene expression in EHV-1 and EAV infected 
EECs, more genes were upregulated at the 6 hpi timepoint when compared with the 12 hpi 
timepoint. Virus infections of mammalian cells activates a myriad of gene expression 
pathways that may assist the host cells in overcoming invading pathogens [332]. 
Furthermore, it has been demonstrated that with the herpes simplex type I (HSV-1) virus 
infections, a vast number of host genes get transcriptionally activated even though they do 
not get translated [333]. These observations fit well with the activation of the 
transcriptional machinery at the 6 hpi timepoint in EHV-1 infected EECs. However, the 
innate immune system of host cells also has a tendency to shut down cellular protein 
synthesis as a measure to control viral replication [334-336] and members of many 
different virus families too, follow the same trend in shutting down host gene expression 
and mRNA translation while promoting the translation of viral mRNAs [335]. It has been 
suggested that the downregulation of host gene transcription by viruses is not merely to 
acquire more cellular resources for viral biogenesis but to inhibit the host anti-viral 
response [335]. Therefore, downregulation of the host gene expression in order to 
circumvent the host antiviral response can be taken as an important factor in viral 
pathogenesis [335]. A previous study done by Sarkar et al. (2016) has shown that EHV-1 
can downregulate the production of IFNβ in infected EECs and studies done by Go et al. 
(2014) taken together with the results obtained during the course of this study indicates 
EAV maybe downregulating the type I IFN response (IFNα and IFNβ) altogether in 
infected EECs. The type I interferon system is an essential component of the innate immune 
system providing protection against invading viruses [135; 136]. As such, the 
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downregulation of the host gene expression of EAV and EHV-1 infected EECs at the 12 
hpi timepoint appears to be a direct consequence of the mechanism taken by some virus 
families to downregulate the host anti-viral response. Furthermore, the porcine 
reproductive and respiratory syndrome virus, which is another member of the family 
Arteriviridae, is also known to suppress the type I interferon system [136; 337] suggesting 
that the suppression of the host antiviral response maybe a common mechanism utilized by 
members of the Arteriviridae family.  
When considering the differentially expressed genes and pathways in EAV infected 
EECs, at the 6 hpi timepoint, the “CCKR signaling map”, “Inflammation mediated by 
chemokine and cytokine signaling pathway” and the “Gonadotropin-releasing hormone 
receptor pathway” were differentially expressed at both 6 and 12 hpi timepoints. In a 
previous study, we demonstrated that the infection of EECs with EAV induces the 
expression of proinflammatory cytokine and chemokine mRNA. The upregulation of the 
“Inflammation mediated by chemokine and cytokine signaling pathway” at both 6 and 12 
hpi timepoints in EAV infected EECs confirms these results and indicates an active role 
played by proinflammatory cytokines and chemokines during EAV infection of EECs. At 
the 12 hpi timepoint, the “apoptosis signaling pathway” is differentially expressed in EAV 
infected EECs when compared to uninfected EECs. Caspase-8 and caspase-9 genes have 
been shown to be involved in the induction of apoptosis during EAV infections [338]. The 
transcriptome data of EAV infected EECs obtained during this study shows that Caspase-
8 gene is upregulated confirming previous studies. However, we did not see a differential 
expression on the caspase-9 gene. In addition to caspase-8, caspase-10 and MAPK8 genes 
were also upregulated at the 12 hpi timepoint suggesting these two apoptosis promoting 
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genes may also play a role in inducing apoptosis in EAV infected EECs [312]. EAV 
infections in horses results in  abortions in pregnant mares and even fatalities due to 
endothelial cell injury and increased vascular permeability caused by severe necrotizing 
panvasculitis [339; 340]. As such, vasculitis plays major roles in the pathological outcomes 
associated with EAV infections. Vasculitis is the inflammation of the walls of the blood 
vessels which can be influenced by many factors. The transcriptome results at the 6 hpi 
timepoint for EAV VBA infected EECs suggest the upregulation of the host inflammatory 
and immune responses when compared to uninfected EECs. Interestingly, the 
“Gonadotropin-releasing hormone receptor pathway” was differentially expressed in EAV 
and EHV-1 infected EECs. Signaling by this pathway is necessary for the normal secretion 
of the gonadotropin-releasing hormone (GnRH) and the gonadotropins LH and FSH. Even 
though GnRH, LH and FSH are proinflammatory by nature [341], it is unlikely that 
activation of the “Gonadotropin-releasing hormone receptor pathway” in endothelial cells 
will have an effect on inducing the release of these hormones by the pituitary gland. 
However, the upregulated genes in this pathway such as MAP3K2, MAP3K5, MAP3K11, 
MAP3K14, MAP2K3 and MAPK8 are associated with the mitogen-activated protein 
kinases (MAPK) signaling cascade which is associated with promoting inflammation and 
apoptosis [312; 313]. 
Similar to EAV infected EECs, the “Inflammation mediated by chemokine and 
cytokine signaling pathway” in EHV-1 infected EECs is differentially expressed at both 6 
and 12 hpi timepoints. Vasculitis is one of the important underlying causes in the 
pathogenesis of these two viruses and pro inflammatory cytokines and chemokines 
produced by endothelial cells and PBMCs play a key role in inducing vasculitis. The 
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upregulation of the “Inflammation mediated by chemokine and cytokine signaling 
pathway” in both EAV and EHV-1 infected EECs suggest that this pathway plays a key 
role in promoting vasculitis following infection by these two viruses.   
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Table 3.1: List of the top 5 pathways and the differentially expressed genes in EAV 6 hpi vs mock 6 hpi comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EAV 6 hpi vs. mock 6 hpi 
PANTHER pathways Number 
of genes 
Genes 
CCKR signaling map 10 PIK3R1, ITPR1, PRKD1, MEF2D, FOXO1, ODC1, SERPINE1, EGR1, 
HBEGF, PLA2G4A 
 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway 
10 ITPR1, GNG10, PREX1, CCL13, RGS17, CCL26, NFKB2, ARPC5, 
PLA2G4A, GNG4 
 
 
Wnt signaling pathway 10 ITPR1, GNG10, WNT9A, EP400, SRCAP, PPP2R5E, ARID1A, EP300, 
CREBB, GNG4 
 
EGF receptor signaling 
pathway 
9 CBLB, PRKD1, STAT4, STAT5A, PPP2R5E, PHLDB2, HBEGF, GAB1, 
SPRY4 
 
Gonadotropin-releasing 
hormone receptor pathway 
9 PIK3R1, ITPR1, IGF1R, BMP2, NR5A1, EGR1, EP300, CREBBP, PLA2G4A 
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Table 3.2: List of the top 5 pathways and the differentially expressed genes in EAV 12 hpi vs mock 12 hpi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EAV 12 hpi vs. mock 12 hpi 
PANTHER 
pathways 
Number 
of genes 
Genes 
Gonadotropin-
releasing hormone 
receptor pathway 
51 HSPA1A, ACVR2B, FOSB, CREB1, MAPK8, BMP2, IRS2, BMPR2, TGFBR3, GNB3, 
ID2, VCL, ATF3, SMAD3, TGIF1, FOS, SP1, MAP3K8, ELK1, PRKAG2, NR4A1, ISL1, 
ANXA5, EGR1, MAP3K11, MAP3K14, ITPR2, JUND, SDF4, MAP3K5, PLA2G4A, 
STAT3, JUN, JUNB, MAP3K9, SRF, ID3, INHBB, MAP2K3, MAPK14, BMP4, PER1, 
PIK3R1, ITPR1, MAP3K2, GATA2, SLC2A1, YBX3, ADIPOR1 
PDGF signaling 
pathway 
44 FLI1, RPS6KC1, MAPK8, ELF1, STARD8, MAPKAPK2, ARHGAP5, EPHB2, STAT4, 
FOS, RAB11B, STAT5A, MTOR, SHC1, ELK1, PDGFB, NINL, ERF, CDK2, OPHN1, 
NRAS, JAK2, GABPA, MKNK2, MYCBP, RPS6KB2, ITPR2, MYC, GAB1, STAT3,  
PDGFRA, ARHGAP12, JAK1, JUN, SRF, STAT6, RASA2, MAPK6, VAV2, PIK3R1, 
ITPR1, MAP3K2, STAT1, DLC1 
CCKR signaling 
map 
39 CREB1, MAPK8, BCAR1, CXCL1, PTEN, BIRC3, FOS, SP1, FOXO1, SHC1, FOXO3, 
ELK1, YES1, NR4A1, CXCL8, ODC1, MCL1, SERPINE1, JAK2, EGR1, IER3, PLAU, 
MAP3K11, MAP3K14, KLF4, SNAI1, PTGS2, HBEGF, MYC, RGS2, CLU, PLA2G4A, 
STAT3, JUN, SRF, CXCL2, MAPK14, PIK3R1, ITPR1 
Inflammation 
mediated by 
chemokine and 
cytokine signaling 
pathway 
36 GNG12, RELB, RAC3, PLCL2, ACTB, GNB3, PTEN, SHC1, KRAS, CXCL8, PLCD1, 
NRAS, JAK2, NFKB2, ACTG1, PTGS2, ITPR2, JUND, MYH3, REL, PLA2G4A, 
STAT3, PLCD4, JUN, JUNB, NFKBIE, STAT6, PLA2G4B, CCL3, PLCL1, MYLK3, 
ITPR1, STAT1, MYH10, NFKB1, ITGA2 
Apoptosis signaling 
pathway 
34 HSPA1A, CREB1, MAPK8, RELB, FADD, EIF2AK2, HSPA8, HSPA6, ATF4, ATF3, 
BCL2L11, BCL2L2, AIFM1, BIRC3, FOS, PRKRA, HSPA14, TNFRSF10B, TRAF2, 
MCL1, BIK, BAG3, NFKB2, MAP3K14, TNFRSF1B, REL, MAP3K5, CASP10, APAF1, 
JUN, CASP8, MAP2K3, NFKB1, HSPA5, TNFRSF10B, TRAF2, MCL1, BIK, BAG3, 
NFKB2, MAP3K14, TNFRSF1B, REL, MAP3K5, CASP10, APAF1, JUN, CASP8, 
MAP2K3, NFKB1, HSPA5 
 
 
 
 
 
1
1
3
 
Table 3.3: List of the top 5 pathways and the differentially expressed genes in EAV 6 hpi vs EAV 12 hpi (A) and EHV 6 hpi vs 
mock 6 hpi (B) comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Table 3.3 continued… 
A. EAV 6 hpi vs. EAV 12 hpi 
PANTHER pathways Number 
of genes 
Genes 
CCKR signaling map 8 PIK3R1, ITPR1, FOXO1, ODC1, SERPINE1, EGR1, HBEGF, PLA2G4A 
EGF receptor signaling 
pathway 
7 CBLB, STAT4, STAT5A, PPP2R5E, PHLDB2, HBEGF, GAB1 
PDGF signaling pathway 6 PIK3R1, ITPR1, DLC1, STAT4, STAT5A, GAB1 
Apoptosis signaling pathway 5 HSPA5, HSPA8, HSPA6, NFKB2, TNFRSF1B 
Gonadotropin-releasing 
hormone receptor pathway 
5 PIK3R1, ITPR1, BMP2, EGR1, PLA2G4A 
 
B. EHV 6 hpi vs. mock 6 hpi 
PANTHER pathways Number 
of genes 
Genes 
Gonadotropin-releasing 
hormone receptor pathway 
59 HSPA1A, KSR1, BMP2, IRS2, BMPR2, GNAI3, PRKAG1, ITPR3, ATF3, TGIF1, 
NR5A1, RAP1B, NR4A1, ISL1, MMP14, EGR1, SMAD9, CREBBP, GUCY1B1, 
PXN, ESRRA, NFATC2, NAB1, CDC42, JUNB, FST, ID3, BMP4, MAP4K5, 
ITPR1, SMAD5, GATA2, IGF1R, MAP2K1, TCF7L1, DUSP1, GNB4, ADIPOR1, 
CTNNB1, MAPK11, GNB5, FOS, SP1, HRAS, PRKAB2, SNRPN, NAB2, 
PRKCA, PPP3CA, EP300, TUBA1A, SOS1, SDF4, MAP3K5, PLA2G4A, 
PKNOX1, POU2F1, MAPK14, CAV1 
 
CCKR signaling map 50 MEF2D, CREM, CALM1, BCAR1, TACR1, CPE, ACAT1, BIRC3, FOXO1, 
MOB1A, ELK4, NR4A1, ODC1, MCL1, SERPINE1, EGR1, CRK, HBEGF, 
RGS2, PXN, NFATC2, CDC42, PRKD2, PLCG1, AP2M1, PRKACB, ITPR1, 
PRKD1, EIF4E, MAP2K1, CTNNB1, SLC18A2, FOS, SP1, PRKACA, YES1, 
CXCL8, RHEB, RPS6, HDAC7, PRKCH, PRKCA, PPP3CA, KLF4, SOS1, 
PLA2G4A, PDPK1, PAK1, MAPK14, TPCN1 
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B. EHV-1 6 hpi vs. mock 6 hpi 
PANTHER pathways Number 
of genes 
Genes 
Integrin signaling pathway 48 COL8A1, BCAR1, ARF1, RAP2B, LAMA5, PIK3C3, RND3, LIMS1, RAP1B, 
ITGB4, COL4A2, ITGAE, NRAS, COL5A2, LAMA4, RAP2C, ARF6, CRK, 
ACTN4, ARPC3, ARPC1A, COL18A1, PXN, COL2A1, CDC42, RAP2A, RHOC, 
MAPK6, ASAP1, ABL1, MAP2K1, NTN4, ILK, COL6A2, COL5A1, PIK3C2B, 
ARL1, LAMB1, ARPC1B, HRAS, ARPC5, SOS1, ITGB3, MAP3K5, COL1A1, 
ARFGAP1, CAV1, PIK3R2 
 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway 
47 PREX1, GNAI3, ITPR3, IFNGR2, TYK2, AKT3, CAMK2D, MYH9, RGS17, 
NRAS, IL10RB, RRAS2, REL, GNG4, ARPC3, ARPC1A, NFATC2, CDC42, 
IL15, JUNB, RHOC, PLCG1, PRKACB, CHUK, SOCS5, ITPR1, GNG10, STAT1, 
MYH10, COL6A2, CYTH2, CCL13, RGS4, PRKACA, CXCL8, ARPC1B, CCL26, 
NFKB2, ARPC5, IL6, GNG5, SOS1, VWF, PLA2G4A, STAT6, PDPK1, PAK1 
 
Wnt signaling pathway 46 PPP2R5A, SMARCC1, SMARCA5, DVL3, ITPR3, HDAC3, SMARCE1, CDH5, 
SMARCD2, ADSS, FBXW11, LRP5, ARID1B, SMAD9, CREBBP, TLE2, GNG4, 
NFATC2, APC, PPP3CB, FAT1, ITPR1, SMAD5, GNG10, FZD6, PPP2CB, BCL9, 
TCF7L1, GNB4, CTNNB1, PPP3CC, EP400, SRCAP, SMARCC2, B4GALT7, 
PPP2R5E, ARID1A, PRKCH, TCF7L2, PRKCA, PPP3CA, EP300, GNG5, 
DCHS1, SMARCA4, CTNNAL1 
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       Table 3.4: List of the top 5 pathways and the differentially expressed genes in EHV 12 hpi vs mock 12 hpi (A) and EHV 6 hpi vs    
EHV 12 hpi (B) comparison. 
 
A. EHV-1 12 hpi vs. mock 12 hpi 
PANTHER 
pathways 
Number of 
genes 
Genes 
Integrin signaling 
pathway 
47 FLNB, ITGA5, PIK3R2, COL8A1, DOCK1, COL6A2, MAP3K3, COL5A1, ACTB, 
COL14A1, ITGA2, LAMA5, RND1, RND3, PIK3C2B, RHOA, RAP1B, ITGB4, 
COL16A1, COL4A2, LAMB2, ITGB5, LAMB1, HRAS, LAMC2, COL12A1, COL5A2, 
ARPC5, ITGAX, ARF6, PARVA, SOS1, COL6A1, ACTN4, ITGB3, TLN1, MAP3K5, 
COL18A1, PXN, COL1A1, LAMC1, COL1A2, RHOB, MAPK6, PTK2B, ASAP1, 
ITGA11 
 
Gonadotropin-
releasing hormone 
receptor pathway 
46 BMPR1A, ACVR2B, FOSB, GATA2, NCOA3, IGF1R, SLC2A1, KSR1, IRS2, 
MAP3K3, DUSP1, GNAI2, BMPR2, TGFBR3, ID2, ATF3, MAPK11, FOS, SP1, 
RAP1B, NR4A1, HRAS, MAP4K2, MMP14, MAP2K7, ANXA5, EGR1, PBX1, 
SMAD9, PRKCA, EP300, CREBBP, JUND, SOS1, EIF2A, MAP3K5, PXN, GNB2, 
JUNB, MAP3K9, SRF, FST, POU2F1, PTK2B, EIF2AK3, BMP4 
 
Inflammation 
mediated by 
chemokine and 
cytokine signaling 
pathway 
44 GNG12, GNG10, CCL5, RELB, STAT1, NFKBIA, MYH10, COL6A2, GNAI2, ACTB, 
COL14A1, ITGA2, IFNGR2, TYK2, NFAT5, AKT3, CCL13, RHOA, INPPL1, 
PRKACA, MYH9, CXCL8, PLCD1, COL12A1, RGS17, JAK2, PAK2, NFKB2, 
ARPC5, IL6, RRAS2, PTGS2, JUND, SOS1, VWF, COL6A1, CCL2, CCL20, REL, 
ROCK1, JUNB, NFKBIE, PDPK1, PTK2B 
 
CCKR signaling 
map 
37 PRKD1, MEF2D, CREM, HSPB1, NFKBIA, BIRC2, BIRC3, RHOA, FOS, SP1, 
FOXO1, FOXO3, PRKACA, TPST1, NR4A1, CXCL8, ODC1, MCL1, SERPINE1, 
JAK2, RPS6, EGR1, IER3, HDAC7, PRKCA, KLF4, SNAI1, PTGS2, HBEGF, SOS1, 
CLU, ROCK1, PXN, SRF, PRKD2, PDPK1, PTK2B 
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Angiogenesis 
signaling pathway 
35 PIK3R2, PRKD1, HSPB1, EFNB2, SPHK2, STAT1, PRR5, DVL3, NOTCH1, 
TGFB1I1, PIK3C2B, AKT3, RHOA, FOS, BIRC5, JAG1, HRAS, PDGFRB, 
ARHGAP1, PAK2, PRKCA, CRYAB, F3, SOS1, PXN, PDGFRA, PTPRB, PRKD2, 
APC, NOS3, VEGFA, NOTCH2, RHOB, MAPK6, JAG2 
 
Table 3.4 continued… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. EHV-1 6 hpi vs. EHV 12 hpi 
 
PANTHER pathways Number 
of genes 
Genes 
Gonadotropin-releasing 
hormone receptor 
pathway 
26 GATA2, IGF1R, KSR1, IRS2, DUSP1, BMPR2, ATF3, MAPK11, FOS, SP1, 
RAP1B, NR4A1, HRAS, MMP14, EGR1, SMAD9, PRKCA, EP300, CREBBP, 
SOS1, MAP3K5, PXN, JUNB, FST, POU2F1, BMP4 
 
Integrin signaling 
pathway 
24 PIK3R2, COL8A1, COL6A2, COL5A1, LAMA5, RND3, PIK3C2B, RAP1B, ITGB4, 
COL4A2, LAMB1, HRAS, COL5A2, ARPC5, ARF6, SOS1, ACTN4, ITGB3, 
MAP3K5, COL18A1, PXN, COL1A1, MAPK6, ASAP1 
 
CCKR signaling map 22 PRKD1, MEF2D, CREM, BIRC3, FOS, SP1, FOXO1, PRKACA, NR4A1, CXCL8, 
ODC1, MCL1, SERPINE1, RPS6, EGR1, HDAC7, PRKCA, KLF4, HBEGF, SOS1, 
PXN, PDPK1 
 
Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway 
21 GNG10, STAT1, MYH10, COL6A2, IFNGR2, TYK2, AKT3, CCL13, PRKACA, 
MYH9, CXCL8, RGS17, NFKB2, ARPC5, IL6, RRAS2, SOS1, VWF, REL, JUNB, 
PDPK1 
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Table 3.5: List of the top 5 pathways and the differentially expressed genes in EHV 6 hpi vs EAV 6 hpi (A) and EHV 12 hpi vs EAV 
12 hpi (B) comparison.  
 
 
 
 
 
 
 
A. EHV-1 6 hpi vs. EAV 6 hpi 
PANTHER pathways Number 
of genes 
Genes 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway 
10 ITPR1, GNG10, PREX1, CCL13, RGS17, CCL26, NFKB2, ARPC5, PLA2G4A, GNG4 
CCKR signaling map 9 ITPR1, PRKD1, MEF2D, FOXO1, ODC1, SERPINE1, EGR1, HBEGF, PLA2G4A 
 
Wnt signaling pathway 9 ITPR1, GNG10, EP400, SRCAP, PPP2R5E, ARID1A, EP300, CREBBP, GNG4 
 
EGF receptor pathway 8 CBLB, PRKD1, STAT4, STAT5A, PPP2R5E, HBEGF, GAB1, SPRY4 
 
Gonadotropin-releasing 
hormone receptor pathway 
8 ITPR1, IGF1R, BMP2, NR5A1, EGR1, EP300, CREBBP, PLA2G4A 
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B. EHV-1 12 hpi vs. EAV 12 hpi 
PANTHER pathways Number 
of genes 
Genes 
Gonadotropin-releasing hormone 
receptor pathway 
21 ACVR2B, FOSB, GATA2, SLC2A1, IRS2, DUSP1, BMPR2, TGFBR3, ID2, 
ATF3, FOS, SP1, NR4A1, ANXA5, EGR1, JUND, MAP3K5, JUNB, MAP3K9, 
SRF, BMP4 
CCKR signaling map 19 BIRC3, FOS, SP1, FOXO1, FOXO3, NR4A1, CXCL8, ODC1, MCL1, 
SERPINE1, JAK2, EGR1, IER3, KLF4, SNAI1, PTGS2, HBEGF, CLU, SRF 
 
Apoptosis signaling pathway 15 RELB, EIF2AK2, HSPA8, HSPA6, ATF4, ATF3, BCL2L11, BIRC3, FOS, 
HSPA14, MCL1, BIK, NFKB2, REL, MAP3K5 
 
Inflammation mediated by 
chemokine and cytokine signaling 
pathway 
15 GNG12, RELB, STAT1, MYH10, ACTB, ITGA2, CXCL8, PLCD1, JAK2, 
NFKB2, PTGS2, JUND, REL, JUNB, NFKBIE 
Integrin signaling pathway 14 COL5A1, ACTB, ITGA2, RND1, RND3, COL4A2, LAMB2, COL5A2, ITGAX, 
ITGB3, MAP3K5, COL18A1, LAMC1, MAPK6 
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Figure 3.1: Heatmap of the gene expression of EHV-1, EAV and mock infected EECs.    
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Figure 3.2: Principal components analysis of genes of EHV-1, EAV and mock infected EECs at 
both 6 and 12 hpi timepoints. The clustering of the genes of EAV infected EECs at the 6 hpi 
timepoint shows significant variance. No such variance observed in the clustering of EHV-1 or 
mock infected EECs. 
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Figure 3.3: Differential gene expression of EHV-1 infected EECs when compared with mock 
infected EECs at the 6 (A) and 12 (B) hpi timepoints and when compared among 6 and 12 hpi 
timepoints (C). Differential gene expression of EAV infected EECs when compared with mock 
infected EECs at the 6 (D) and 12 (E) hpi timepoints and when compared among 6 and 12 hpi 
timepoints (F). 
  Upregulated  Downregulated  
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Figure 3.4: Venn diagram illustrating the distribution of differentially expressed genes in EECs 
infected with; EAV at 6 and 12 hpi timepoints (A), EHV-1 at 6 and 12 hpi timepoints (B), EAV 
and EHV-1 at the 6 hpi timepoint (C) and EAV and EHV-1 at the 12 hpi timepoint (D).     
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CHAPTER FOUR 
 
 
INVOLVEMENT OF TOLL-LIKE RECEPTORS IN THE INNATE IMMUNE 
RESPONSE OF EQUINE ENDOTHELIAL CELLS FOLLOWING EHV-1 AND 
EAV INFECTIONS 
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4.1. SUMMARY 
Equid herpesvirus–1 (EHV-1) is a double-stranded DNA virus whereas equine 
arteritis virus (EAV) is a positive sense, single stranded RNA virus. Both these viruses 
have a worldwide distribution and collectively, are a significant threat to the global and US 
equine industry. One of the most important pathological conditions underlying the disease 
manifestations associated with EAV and EHV-1 infections is vasculitis. The vasculitis 
induced by EHV-1 is restricted to either the vasculature of the pregnant uterus or the central 
nervous system while in the case of EAV it can be systemic. In the 2nd chapter 
proinflammatory cytokine and chemokine response of EHV-1 and EAV infected EECs 
were investigated and the expression of proinflammatory cytokine and chemokine genes 
was found to be higher in EHV-1 infected EECs compared to EAV infected EECs, 
furthermore, EAV downregulates the expression of IFNα in EECs following infection 
suggesting that toll-like receptors (TLRs) are involved in the induction of the 
proinflammatory response in the infected EECs. Here we report an active role played by 
TLR 3 in inducing the proinflammatory response in EHV-1 infected EECs at early stages 
and also that TLR 3 is not the main pattern recognition receptor in inducing a 
proinflammatory response in EAV infected EECs. 
Keywords: EHV-1, EECs, TLRs, TLR3, Horses, siRNA, Electrophoresis  
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4.2. INTRODUCTION 
Equid herpesvirus–1 (EHV-1) is a DNA viruses of the subfamily 
Alphaherpesvirinae and genus Varicellovirus [28]. Equine arteritis virus (EAV) is a 
positive sense, single stranded RNA virus belonging to the order Arteriviridae and genus 
Alphaarterivirus (https://talk.ictvonline.org/taxonomy/)[290]. Both these viruses have a 
worldwide distribution [5; 6] and collectively, are a significant threat to the global and US 
equine industry. These two genetically very different viruses share some interesting 
similarities in their disease manifestation and clinical outcomes (establishment of latent or 
persistent infections[5; 6; 342], respiratory and/or reproductive tract diseases[5; 6; 15; 17-
19; 27; 34; 38; 88; 89; 169] and abortions in pregnant mares[5; 6; 17; 19; 27; 38; 88; 89; 
166; 198; 343; 344]). One of the most important pathological conditions underlying the 
disease manifestations associated with EAV and EHV-1 infections is viral vasculitis [5; 6; 
17; 19; 52; 170]. In the case of EHV-1 infections, the viral vasculitis is restricted to either 
the vasculature of the pregnant uterus or the central nervous system (CNS) resulting in 
abortions and a neurological condition termed equine herpesvirus myeloencephalopathy 
(EHM) [15; 17; 18; 52; 170; 345]. Viral vasculitis induced by EAV infection affects the 
pregnant uterus which can result in abortion [5; 6; 19; 88]. However, it can also become 
systemic (Systemic panvasculitis) leading to fatalities [5; 6; 19; 89; 261]. Yet, in contrast 
to EHV-1 infections, EAV infections do not induce any form of neurological disease.  
In a previous study, we investigated the cytokine response of EECs following 
infection with EHV-1, EHV-4 and EAV. The results of that study indicated that both EHV-
1 and EAV infected EECs upregulate the gene expression of proinflammatory cytokines 
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and chemokines. However, the expression levels of these genes were relatively higher in 
EHV-1 infected EECs when compared with EAV infected EECs (Unpublished data). 
Following these results, whole transcriptome sequencing of EHV-1 and EAV infected 
EECs was conducted. The results indicated the differential expression of the “Inflammation 
mediated by cytokine and chemokine” pathway as well as other pathways associated with 
the host immune, inflammatory and apoptotic responses in EECs following infection by 
EHV-1 and EAV. 
Inflammation is a coordinated cellular response evolved over time that can result 
in positive or sometimes negative effects for the host [227]. The cellular inflammatory 
response is advantageous to the host during infections or cellular damage but becomes 
disadvantageous when directed at a wrong stimulus or when reacting in excess [227]. The 
immune system consists of two arms, the innate and the adaptive immune systems [226; 
229]. The innate immune system is the first line of defense against invading pathogens and 
it senses the presence of invaders through pathogen associated molecular patterns (PAMPs) 
or damage associated molecular patterns (DAMPs) [226; 229]. Host cells use a specialized 
group of structurally diverse cell surface and intra-cellular receptors known as pattern 
recognition receptors (PRRs) to sense these PAMPs or DAMPs and one such extensively 
studied group of PRRs are the Toll-like receptors (TLRs) [229]. TLRs sense PAMPs and 
DAMPs and initiate an immune and inflammatory response via proinflammatory cytokines 
and chemokines. Virus replication in endothelial cells causes cell injury and virus 
infections that damage blood vessels are known to induce vasculitis [346]. Upon sensing 
PAMPs and DAMPs, the innate immune system triggers an inflammatory response and 
this is mediated by proinflammatory cytokines and chemokines [226]. As such, TLRs are 
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important in the initiation of the host inflammatory response and to this point, no 
investigation has been carried out to elucidate the TLRs involved with the inflammatory 
response induced by EHV-1 and EAV in EECs. The purpose of this study was to elucidate 
the involvement of TLRs in the immune and inflammatory response against EHV-1 and 
EAV infections in EECs.   
 
4.3 MATERIALS AND METHODS 
4.3.1 Transcriptome data analysis 
For RNA-seq data analysis, the reads were initially trimmed for adapters and 
quality using TrimGalore Version 0.4.4 (Babraham Bioinformatics; 
www.bioinformatics.babraham.ac.uk), then trimmed reads were aligned to the horse 
reference genome (EquCab3.0) using STAR (Release 2.5.2b) [32], and annotated to the 
equine reference transcriptome available in NCBI database  using Cufflinks (Release 2.2.1; 
http://cole-trapnell-lab.github.io/cufflinks/) [33]. Differential expression analysis was 
performed on the normalized read count (FPKM; fragments per kilobase of exon per 
million mapped reads) [34]. We used Cuffdiff 2.2.1 (Trapnell, Roberts et al. 2012) to 
calculate differentially expressed genes (DEG) between samples from mock and virus 
infected groups. Significance level was set at FDR-adjusted p value of the test statistic < 
0.1 using a Benjamini- Hochberg correction. For all data analyses, separate databases were 
created for EHV and EAV samples. Differentially expressed genes were determined within 
tissue.  Initial identification of differentially expressed genes was performed using one-
way ANOVA, using the Benjamini-Hochberg correction for false discovery rate (FDR P < 
0.1). 
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4.3.2 Cells 
Equine endothelial cells (EECs) were derived from the pulmonary artery of a horse 
as previously described [264]. The EECs were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Corning, New York, NY) with 10% bovine calf serum (BCS, Hyclone 
Laboratories, Inc., Logan, UT), 100 U/mL penicillin–streptomycin, 1 mM sodium 
pyruvate, 0.1 mM nonessential amino acids and 200 mM L-glutamine (Thermo Fisher 
Scientific, Waltham, MA) in a humidified incubator at 37 °C with 5% CO2. All experiments 
were performed in EECs between passage numbers 15-20.  
4.3.3 Viruses 
Two viruses were used in this study. The horse adapted virulent Bucyrus strain of 
EAV (VBS; VR796; ATCC) and the neuropathogenic EHV-1 (Findlay) strain [14]. The 
EHV-1 virus was kindly provided by the late Dr. George Allen, Maxwell H. Gluck Equine 
Research Center, University of Kentucky, Lexington, Kentucky. All viruses were 
propagated in EECs to generate high titer working stocks. Briefly, triple-decker cell culture 
flasks (Nunc, Rochester, NY) containing EEC monolayers were infected with each of the 
four viruses. The flasks were frozen at -80°C when a 100% cytopathic effect (CPE) was 
observed. Cell lysates were clarified by centrifugation (2000 x g) at 4 °C for 15 min, 
followed by ultracentrifugation (Beckman Coulter, Miami, FL) at 121,600 x g for EAV 
and 100,000 x g for EHVs through a 20% sucrose cushion in NET buffer (150 mM NaCl, 
5 mM EDTA, 50 mM Tris-HCl, pH 7.5) at 4°C for 4 h to pellet the virus. Purified 
preparations of each virus strain were resuspended in Dulbecco’s phosphate buffered saline 
(DPBS, Thermo Fisher Scientific, Waltham, MA), briefly sonicated and 50 µL aliquots 
were frozen at -80 °C until further use. Virus stocks were titrated by standard plaque assay 
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in EECs, and titers were expressed as the number of plaque forming units (PFU) per 
milliliter (PFU/mL).  
4.3.4 siRNA transfection 
EECs (Passage 15-20) were used for TLR3 siRNA transfection. In brief, 1×105 cells 
were transfected with either 0.5 pmol of TLR3 siRNA or negative control using the Lonza 
4D nucleofector X unit system (Basel, Switzerland) following the manufacturers protocol. 
The sequence of the TLR3 siRNA is; sense: 5’ AGAUCAAACUCUCAAGUUUtt 3’ 
antisense: 5’ AAACUUGAGAGUUUGAUCUtg 3’ (Silencer™ Select, Thermo Fisher 
Scientific, Waltham, MA). The negative control siRNA used was a commercially available 
product (MISSION® siRNA Universal Negative Control, Sigma-Aldrich, St. Louis, MO).    
4.3.5 Virus infection, RNA extraction and cDNA generation 
siRNA transfected EECs (Passage 15-20) were seeded in 24 well plates (1×105 cells 
per well) and incubated for 24 hours. At 24 hours post transfection (hpt) timepoint, the 
cells were infected with either EHV-1 or EAV virus strains at a MOI of 2 and incubated 
for 6 and 12 hours. Following 6 and 12 hours of infection with virus strains total RNA was 
extracted using the miRNeasy mini kit (Qiagen, Hilden, Germany). Any contaminating 
genomic DNA present was removed by performing DNase I digestion (RNase free DNase 
set, Qiagen, Hilden, Germany). The total RNA quality and quantity was assessed by 
OD260/OD280 measurement using a NanoDrop (Thermo Scientific, Wilmington, DE). 0.5 
micrograms of total RNA were reverse transcribed to generate cDNA using the High 
capacity reverse transcription kit (Applied Biosystems, Foster city, CA).  
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4.3.6 RT-qPCR:  
Real-Time PCR amplification was carried out using 1:1 diluted cDNA to assess the 
relative expression of different pro-inflammatory cytokine and chemokine genes using 
commercially available TaqMan™ primers and probes (Thermo Fisher Scientific, 
Waltham, MA) in a 7500 Fast Real-Time PCR system (Thermo Fisher Scientific, Waltham, 
MA). The panel of TLR genes investigated in this study were TLRs 1, 2, 3, 4, 7, 8 and 9. 
The proinflammatory cytokine and chemokine panel investigated was IL6, IL17, CXCL10 
and IFNα. All reactions were performed in triplicate. EECs grown in identical conditions 
absent virus infection was used as the mock control. Equine β- glucuronidase gene was 
used as the endogenous control to normalize the quantitative RT-qPCR data as has been 
described in previous studies [64]. PCR efficiency for all reactions was assessed using 
LinRegPCR [271]. For relative quantification, fold changes in gene expression were 
calculated using the ΔΔCT method [272].   
 
4.3.7. Statistical analysis 
The statistical analysis of RT-qPCR analysis was performed using the means of fold 
changes employing t tests. The significant level (p-value) was set at 0.05 for all tests. 
Statistical analysis was performed using the JMP pro 13 software (JMP®, Version 13 SAS 
Institute Inc., Cary, NC, 1989-2019). 
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4.4. RESULTS 
4.4.1 Transcriptome profile of TLR expression 
As mentioned in chapter 3, the RNA-seq data obtained for this study came from a 
total of 18 libraries sequenced from EECs. Transcriptome data obtained from EHV-1, EAV 
and mock infected EEC libraries was analyzed for TLR expression. Transcriptome data 
from EHV-1 infected EECs showed that at the 6 hpi timepoint there was no detectable 
expression of TLRs 2 and 4 in either EHV-1 or mock infected EECs (Figure 3.1A). TLRs 
1, 3, 7, 8 and 9 were expressed in both EHV-1 and mock infected EECs but did not show 
any significant differences from each other (Figure 3.1A). Only the expression of TLR 3 
in EHV-1 infected EECs was statistically significantly increased from mock infected EECs 
at the 6 hpi timepoint (Figure 3.1A). Similar to the 6 hpi timepoint, the expression of TLRs 
2 and 4 was not detected in EHV-1 infected or mock infected EECs at the 12 hpi timepoint 
(Figure 3.1B). The expression of the TLRs 1, 3, 8, and 9 was detected in EHV-1 infected 
EECs, but no significant differences from mock was observed (Figure 3.1B). The 
expression of TLRs 7 and 9 was not detected in EHV-1 infected EECs but was detected in 
mock infected EECs at the 12 hpi timepoint, but this downregulation in expression was not 
statistically significant (Figure 3.1B). similar to findings at the 6 hpi timepoint, TLR 3 
expression was detected in EHV-1 infected EECs at the 12 hpi timepoint and it was 
significantly higher when compared with mock infected EECs.   
In EAV infected EECs at the 6 hpi timepoint, transcriptome data revealed that TLRs 
2 and 4 was not expressed either in EAV or mock infected EECs (Figure 3.2A). Moreover, 
TLRs 1, 3, 7, 8 and 9 were expressed in both EAV and mock infected EECs but did not 
show any significant differences from each other (Figure 3.2A). Only TLR 3 expression in 
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EAV infected EECs was significantly increased from mock infected EECs at the 6 hpi 
timepoint (Figure 3.2A).  
Similarly, at the 12 hpi timepoint, TLRs 2 and 4 were not expressed in either EAV 
or mock infected EECs (Figure 3.2B). The expression of the TLRs 1, 3, 7, 8 and 9 were 
expressed in both EAV and mock infected EECs, neither differed significantly from each 
other (Figure 3.2B). Only TLR 3 expression in EAV infected EECs significantly increased 
from mock infected EECs at the 6 hpi timepoint (Figure 3.2B).      
4.4.2 RT-qPCR validation of transcriptome results 
In EHV-1 infected EECs gene expression was detected for TLRs 1, 2, 3, 4, 7, 8 and 
9 at both 6 and 12 hpi timepoints (Figure 3.3A). The gene expression of the TLRs 1, 2, 4, 
8 and 9 did not show a statistically significant difference at both 6 and 12 hpi timepoints 
when compared with mock infected EECs (Figure 3.3A). The gene expression level of TLR 
7 was significantly upregulated in EHV-1 infected EECs at the 6 hpi timepoint but was not 
significant at the 12 hpi timepoint (Figure 3.3A). The gene expression level of TLR 3 was 
significantly upregulated at both 6 and 12 hpi timepoints in EHV-1 infected EECs 
compared to the mock infected EECs (Figure 3.3A). Furthermore, gene expression 
significantly increased from 6 to 12 hpi timepoints suggesting EHV-1 infection of EECs 
promote the expression of the TLR 3 gene (Figure 3.3A). Furthermore, the RT-qPCR data 
validates the transcriptome results for TLR 3 gene expression in EHV-1 infected EECs. 
Similar to EHV-1 infected EECs, gene expression was detected for TLRs 1, 2, 3, 
4, 7, 8 and 9 at both 6 and 12 hpi timepoints in EAV infected EECs (Figure 3.3B). The 
gene expression of the TLRs 1, 2, 3, 4, and 8 was not significantly different at both 6 and 
12 hpi timepoints when compared with mock infected EECs (Figure 3.3B). The gene 
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expression of TLR 7 was significantly upregulated in EAV infected EECs at both 6 and 12 
hpi timepoints (Figure 3.3B). However, the gene expression level was lower at the 12 hpi 
timepoint compared to the 6 hpi timepoint. The gene expression of TLR 9 was significantly 
upregulated in EAV infected EECs at both 6 and 12 hpi timepoints (Figure 3.3B). These 
RT-qPCR results suggest that TLRs 7 and 9 are differentially expressed in EAV infected 
EECs. Furthermore, the data does not confirm the transcriptome results for TLR 3 
expression in EAV infected EECs.  
4.4.3 Involvement of TLR 3 in the innate immune response against EHV-1 and EAV 
infections    
In order to investigate the involvement of TLR 3 in promoting the inflammatory 
response in EHV-1 and EAV infected EECs, we used siRNA sequences generated against 
equine TLR 3 mRNA. The downregulation of equine TLR 3 and the proinflammatory 
cytokine (IL6, IL17, CXCL10 and IFNα) mRNA was assessed using RT-qPCR.  
The siRNA sequence generated against equine TLR 3 downregulated equine TLR 
3 mRNA expression significantly at the 6 hpi timepoint (Figure 3.4A). Furthermore, 
parallel to the downregulation of TLR 3 mRNA, the IFNα mRNA level was significantly 
downregulated compared to mock infected EECs. This suggests that TLR 3 plays a role in 
IFNα production in EHV-1 infected EECs at the 6 hpi timepoint (Figure 3.4A). However, 
the gene expression levels of IL6, IL17 and CXCL10 was not significantly downregulated, 
suggesting the expression of these proinflammatory cytokines and chemokines are not 
induced by TLR 3 (Figure 3.4A). Similarly, at the 12 hpi timepoint, the siRNA sequence 
generated against equine TLR 3 downregulated equine TLR 3 mRNA expression 
significantly (Figure 4.4B). I n contrast to the results obtained at the 6 hpi timepoint 
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however, none of the proinflammatory cytokines and chemokines used in the experiment 
was significantly downregulated, suggesting that at the 12 hpi timepoint the importance of 
TLR 3 in inducing an inflammatory response in EHV-1 infected EECs is reduced (Figure 
3.4B).  
The same experiment was performed using EAV infected EECs to investigate the 
involvement of TLR 3 in inducing an inflammatory response in infected cells at both 6 and 
12 hpi timepoints. Similar to the observations in EHV-1 infected EECs, the siRNA 
sequence generated against equine TLR 3 downregulated equine TLR 3 mRNA expression 
significantly in EAV infected EECs at both 6 and 12 hpi timepoints (Figure 3.5 A&B). 
However, the downregulation of TLR 3 mRNA did not induce the downregulation of any 
of the proinflammatory cytokines and chemokines investigated in this study, suggesting 
that TLR 3 is of lesser importance in inducing an inflammatory response in EAV infected 
EECs compared to EHV-1 infected EECs (Figure 3.4B).  
 
4.5 DISCUSSION 
Eleven known TLRs have been identified in mammalian cells and the expression 
of these TLRs are cell type dependent [347]. To date, studies have reported the expression 
of TLR 4 and 2 in equine lungs and bronchial epithelial cells [236; 239], TLR 9 in equine 
lungs, spleen, lymph nodes, and peripheral blood leukocytes [234; 238] and TLRs 2, 3, 4, 
6 and 9 in equine cornea, limbus, and the conjunctiva [237]. Here, we report the expression 
of TLRs 1, 2, 3, 4, 7, 8 and 9 in equine endothelial cells. The transcriptome results of this 
study indicated gene expression of TLRs 1, 3, 7, 8 and 9 in EECs but did not detect any 
gene expression for TLRs 2 and 4. However, RT-qPCR results indicated gene expression 
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for TLRs 2 and 4 as well, indicating that EECs express mRNA for at least TLRs 1, 2, 3, 4, 
7, 8 and 9. This is the first study to investigate the expression of TLRs in equine pulmonary 
artery endothelial cells. Furthermore, in the transcriptome profiles of infected and 
uninfected EECs, no expression was detected for TLRs 2, 4 and 5. However, RT-qPCR 
results indicated the presence of gene expression for these TLRs as well. This could be due 
to the higher sensitivity of RT-qPCR in detecting gene expression with low copy numbers 
compared to Next-generation sequencing and microarrays.  
The transcriptome and RT-qPCR results of EHV-1 infected EECs indicate the 
upregulation of TLR 3 gene expression at both 6 and 12 hpi timepoints. Furthermore, the 
downregulation of TLR 3 mRNA using siRNA induced a downregulation of IFNα mRNA 
at the 6 hpi timepoint in EHV-1 infected EECs suggesting TLR 3 has a role to play in 
induction of IFNα during EHV-1 infection of EECs. TLR 3, together with TLRs 7, 8 and 
9 are located intracellularly in endosomal membranes and they sense nucleic acids of 
invading pathogens [348; 349]. TLR 3 specifically recognizes double-stranded RNA which 
is an intermediate produced during the replication of most viruses including herpesviruses 
[348]. Several studies have shown the importance of TLR 3 in sensing infections by herpes 
simplex type 1 virus [234; 350]. Therefore, this study indicates that just as it is in herpes 
simplex viruses, TLR 3 is important for the sensing of EHV-1 and for the induction of 
IFNα in EECs at the early stages of infection. This is the first study to demonstrate the 
importance of TLR 3 in the infection of EECs by EHV-1 strains. However, at the 12 hpi 
timepoint, the downregulation of TLR 3 mRNA did not induce IFNα mRNA 
downregulation indicating that the importance of TLR 3 in inducing IFNα during the initial 
stages of infection has become redundant. Recent studies have demonstrated that the capsid 
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of DNA viruses such as HSV and adenoviruses to become ubiquitinated and degraded in 
the cytoplasm by proteasomal pathways [351; 352]. This proteasomal degradation of the 
capsid maybe a mechanism utilized by DNA viruses which replicate in the cytoplasm of 
host cells to avoid capsid sensing as well as to release the viral genomic DNA into the 
cytoplasm [353], what it also does is expose the viral DNA to innate DNA sensors such as 
DAI, RNA polymerase III, RIG-I and STING [353-358]. These cytosolic DNA sensors are 
capable of inducing a type I IFN response when exposed to DNA in the cytoplasm [353; 
355-357]. This mechanism may be able to compensate for the downregulation in TLR 3 
and induce the production of IFNα.  
One thing that needs to be mentioned here is the downregulation of TLR3 mRNA 
brought about by siRNA is relatively low when compared with other such RNA silencing 
experiments [359; 360]. This could be because not all cells get transfected with the anti-
TLR 3 siRNA during the siRNA transfection process. Transfection with fluorescently 
labelled siRNA followed by cell sorting will aid in acquiring a uniformly transfected cell 
population with a relatively higher downregulation of TLR 3 mRNA and increase the 
sensitivity of the experiment.  
It is well established that up or downregulation of mRNA doesn’t always reflect in 
protein translation and the subsequent expression of a protein. As such, TLR 3 mRNA 
downregulation demonstrated by RT-qPCR alone is not sufficient to confirm the 
downregulation of TLR 3 protein expression in EECs. In most experiments this 
confirmation of protein downregulation can be made with the use of western blots. 
However, it proved a difficult task in this situation as we ran into difficulty finding a 
monoclonal or a polyclonal anti-equine TLR 3 antibody.     
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The downregulation of TLR 3 mRNA in EAV infected EECs did not reduce the 
expression of any of the cytokine and chemokine genes analyzed during this study 
indicating that the induction of the proinflammatory response in EAV infected EECs may 
not be coming from TLR 3 but from a different TLR. 
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Figure 4.1: Transcriptome results (FPKM values) of TLR expression in EHV-1 and mock infected 
EECs at 6 hpi (A) and 12 hpi (B) timepoints. * indicates a statistically significant increase from 
mock infected EECs (p≤0.05).  
 
Figure 4.2: Transcriptome results (FPKM values) of TLR expression in EAV and mock infected 
EECs at 6 hpi (A) and 12 hpi (B) timepoints. * indicates a statistically significant increase from 
mock infected EECs (p≤0.05).  
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Figure 4.3: Relative quantification values of TLR in EHV-1 (A) and EAV infected EECs. The red 
line marks the basal level of expression (RQ=1). * indicates a statistically significant increase from 
mock infected EECs (p≤0.05).  
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Figure 4.4: Relative quantification values of TLR expression in TLR 3 siRNA transfected and 
EHV-1 infected EECs at 6 hpi (A) and 12 hpi (B) timepoints. The red line marks the basal level 
of expression (RQ=1). * indicates a statistically significant decrease in gene expression from 
negative control transfected EECs (p≤0.05).  
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Figure 4.5: Relative quantification values of toll-like receptor expression in TLR 3 siRNA 
transfected and EAV infected EECs at 6 hpi (A) and 12 hpi (B) timepoints. The red line marks 
the basal level of expression (RQ=1). * indicates a statistically significant decrease in gene 
expression from negative control transfected EECs (p≤0.05).  
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CHAPTER FIVE 
 
GENOME-WIDE ASSOCIATION STUDY (GWAS) TO IDENTIFY HOST 
GENETIC FACTORS ASSOCIATED WITH EQUID HERPESVIRUS TYPE-1 
(EHV-1) INDUCED MYELOENCEPHALOPATHY (EHM) IN HORSES 
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5.1. SUMMARY 
Equid herpesvirus (EHV-1) infections in horses can lead to equine herpesvirus 
myeloencephalopathy (EHM), characterized by neurological clinical signs. We 
investigated the importance of the host genetic background in the development EHM using 
a genome-wide association study (GWAS). Genomic DNA from 28 horses with neurologic 
signs due to EHV-1 infection (EHM) and 67 control horses without any neurologic signs 
but infected with EHV-1 were included in this study. DNA samples were tested with the 
Affymetrix Axiom 670K SNP array to identify single nucleotide polymorphisms (SNPs) 
associated with EHM. Results from this study did not identify significant SNPs or 
haplotype associations for the development of EHM following EHV-1 infections and did 
not corroborate with a previously published study. The results exclude the involvement of 
a recessive genetic factor in the susceptibility to develop EHM but do not have the power 
to exclude the involvement of other, complex host genetic factors. 
Key words: EHV-1, EHM, GWAS, Horses, SNPs 
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5.2. INTRODUCTION  
             Equid herpesvirus 1 (EHV-1) is a double-stranded DNA virus in the family 
Herpesviridaein the genus Varicellovirus [28]. EHV-1 has a global distribution and at some 
time during their lives almost all domesticated horses will become infected with the virus 
resulting in a wide spectrum of clinical signs including an acute upper respiratory tract 
disease, abortion, neonatal death, retinopathy and severe neurological disease (also known 
as equine herpesvirus myeloencephalopathy [EHM]) [18; 172]. This neurologic form has 
a 15-50% case-fatality rate and poses a significant threat to the $102 billion equine industry 
in the United States [48; 49].  Unfortunately, the occurrence of EHM has increased 
dramatically over the past fifteen years, with extensive outbreaks reported in the United 
States, South Africa, New Zealand and several European nations, including the United 
Kingdom. Susceptibility to EHM appears to be determined by several host factors 
including age, physical condition, immune status and whether the infection is a primary 
exposure [48; 50]. It has also been reported that the neuropathogenic phenotype of EHV-1 
can result from a single nucleotide substitution within ORF30 (A→G2254 [amino acid 
N→D752] ) in the viral DNA polymerase [51]. However, data recently generated in our 
laboratory and other laboratories have demonstrated this interpretation is probably overly 
simplistic and the development of EHM cannot be solely explained by studying the viral 
determinants of virulence [361]. An experimental infection study with a neuropathogenic 
EHV-1 strain (Ab4) resulted in 0-35% EHM cases [185]; similar rates have been reported 
for natural outbreaks in the US and Europe (3-45%) [362]. These observations suggest that 
host genetics may play an important part in the development of EHM. Thus, the rationale 
for this research is to understand the host genetic factors conferring the risk of developing 
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EHM following infection with EHV-1. A recent genome-wide association study (GWAS) 
study suggested an association of a single nucleotide polymorphism  
  
 5.3. MATERIALS AND METHODS 
5.3.1 Animals:  
We tested 95 DNA samples from horses that had EHM (n=28) and horses that were 
infected with EHV-1 but did not develop EHM (n=67). The DNA was extracted from nasal 
swabs or whole blood samples that were received fresh or had been archived at -80°C. 
These samples were obtained from several EHV-1 outbreaks in the US during the time 
period of 2013-2018.  
5.3.2 Clinical Characterization:  
The case definition of EHM for the selection of these samples involved horses that 
had clinical signs of neurologic disease consistent with EHM. The neurological signs 
included dysmetria, ataxia and paresis of limbs, toe dragging, hypotonia of the tail and 
recumbency. Licensed veterinarians performed the clinical diagnosis of EHM. The horses 
included in the control group showed signs of EHV-1 infection (fever, swollen legs and 
lymph nodes, nasal discharge and abortions) without any neurological signs.    
5.3.3 Genome Wide Association Studies:  
Genomic DNA was extracted from samples using the QIAamp® DNA blood mini 
kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. Extracted 
genomic DNA was stored at -80°C until further use. Genotyping was carried out using the 
Axiom® Equine Genotyping Array (Affymetrix, Santa Clara, CA, USA) which contains a 
total of 670,796 markers (Neogen Corporation-GeneSeek Operations, Lincoln, NE, USA). 
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The SNP data analysis was done using the Golden Helix SNP & Variation Suite 8.8.3 
(SVS, Bozeman, MT, USA). Affymetrix quality control for the samples validated 582,598 
SNPs. The call rate for one horse was less than 80% and it was dropped from the analyses. 
The remaining 94 horses had call rates higher than 95%.  
SNP data were removed for call rates below 95%, greater than two alleles or minor 
allele frequency less than 0.05 leaving 382,529 SNPs for analyses. Further analysis was 
done with only Thoroughbreds, Paints and Quarter Horses resulting in 55 samples (17 cases 
and 38 controls). Filtering left 369,064 SNPs for subsequent analyses. The Genotype 
Association Tests (Basic, Genotype, Additive, Dominant and Recessive), Haplotype 
Association Tests (moving window of 6 SNPs).  In addition, tests were conducted for Runs 
of Homozygosity (ROH) based on regions of varying minimum sizes, numbers of samples 
and number of SNPs, allowing for 1 heterozygous position in the run.  Probabilities were 
calculated using chi-square or correlation tests.  To control for repeated analyses, 
probability values were corrected using the Bonferroni correction. 
 
5.4. RESULTS 
5.4.1 Association Tests 
None of the association tests (Basic, Genotypic, Additive, Dominant and 
Recessive) identified SNPs with significant differences in distribution when comparing 
cases and controls.   Figure 5.1 shows the Manhattan Plot for the investigation of the 
recessive mode of inheritance.  Investigations for haplotype associations were conducted 
using sliding windows of 6 SNPs and, again, no associations were found.  The distribution 
of genotypes did not indicate an influence by population substructure; however we did 
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repeat the association tests using a subset of Thoroughbred, Paint and Quarter horses based 
on the close relationship among those breeds Again, no significant associations (using 
Bonferroni corrections) were uncovered for the genotype or haplotype association tests.  
5.4.2 Runs of Homozygosity (ROH):   
Traits with recessive modes of inheritance may be missed based on recessive 
genotypic studies due to absence of individual SNPs which distinguish cases and controls.  
Therefor analyses were conducted for runs of homozygosity.  The conditions used for this 
study ranged from 20 samples to 5 samples required to have lengths of homozygosity from 
400kb to 1000kb with an expectation of 6- 10 SNPs per kb.   None of these showed 
statistical association with EHM. A Manhattan plot for a test of recessive association this 
data is shown in Figure 5.2.  Conditions for this figure were requirements for minimum of 
400kb runs with no more than 1 heterozygote found among 5 of the 94 horses with at least 
60 SNPs.  The assay identified 307 runs distributed throughout the genome with none 
achieving statistical significance.  
5.4.3 Testing BIEC2-946397:   
The single SNP identified as having a statistically significant association with EHM 
by Brosnahan et al., (2018) was BIEC2-946397. This SNP was included in the Affymetrix 
array used in this study. The locus was polymorphic in this assay with two alleles, G and 
A. However, the level of polymorphism was low with only 5 horses being heterozygous 
for the two alleles, 2 cases and 3 controls.   
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5.5. DISCUSSION 
The sporadic nature for the occurrence of EHM among horses previously infected 
with EHV-1 led to the speculation that some host factor may play a role in the occurrence 
of EHM. Brosnahan et al. (2018) reported an association between a SNP and the 
occurrence of EHM in a manner suggesting a recessive mode of inheritance.   In this current 
study we examined 382,529 SNPs using a population of 94 horses (28 cases and 66 
controls).  In contrast to the report by Brosnahan et al. (2018), (129 horses with 37,173 
SNPs) we did not find evidence for a genetic association with EHM.  The power of our test 
was sufficient to reject a hypothesis of genetic effect by recessive alleles.   We did not see 
any evidence for trends in the data identifying other possible modes of inheritance although 
we would not have sufficient power to detect complex genetic causes based on multiple 
loci.   
Our assay included the SNP identified in the previous work by Brosnahan et al. 
(2018), BIEC2- 946397. The marker exhibited a low level of variation in our study and 
there were no statistical differences between the cases and controls for the presence of 
variants.  While most SNPs test the same regardless of assay used, some SNPS do not.   We 
did not use other assays to assess the variation for the SNP and it is possible that the 
Affymetrix assay was not reliable for this SNP. Brosnahan and co-workers confirmed their 
tests with a second assay, so it is more likely that our results under-represent the variation 
for this SNP.  Nevertheless, we did not find any evidence with other SNPs in the region, 
or with runs of homozygosity implicating genes on chromosome 6 (Figures 1 and 2).  
The difference between the two studies may have several explanations.  The test is 
statistical, and it may be that either of the reports failed, either in detecting or not detecting 
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the association. There were also a few differences in the nature of the two studies that could 
have had an impact.  In this study all cases came from natural infections while Brosnahan 
and co-workers (2018) used cases from both experimental and natural infections.  Other 
differences could be related to the genetic background of the horses. In order to obtain 
enough horses for the GWAS study, we included horses of diverse breeds (Supplemental 
Table 1).  We do not know what breeds were used in the other study, but such differences 
also could have an impact on the statistical evaluations.  
In conclusion, based on the results of this study, we do not see any evidence for a 
recessive allele being determinative for the development of EHM following EHV-1 
infection for any genetic locus. More complex host-pathogen interactions are possible, and 
discovery will require testing a larger number of horses with EHM. 
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Table 5.1: List of case and control samples used in this study indicating their geographical location, 
breed and case/control classification. Samples were generously provided for this study by Anoka 
Equine Veterinary Services, MN, Equine Diagnostic Solutions, KY, Virginia Department of 
Agriculture and Consumer Services, VA, Alpine Veterinary Hospital, CO, Animal Health Clinic, 
ID, Eastern Lancaster Veterinary Clinic, PA, Oklahoma State University-Department of Veterinary 
Clinical Sciences, OK, Veterinary Integrative Performance Services, IA, and Dr. Nicola Pusterla 
School of Veterinary Medicine, University of California, Davis, CA.  
Sample 
No. 
Location Case/Control Breed 
1 Virginia Case Warmblood 
2 Virginia Case Thoroughbred 
3 Virginia Case Quarter Horse 
4 Virginia Case Thoroughbred 
5 Virginia Case Thoroughbred 
6 California Case Warmblood 
7 California Case Warmblood 
8 California Case Quarter Horse 
9 California Case Quarter Horse 
10 California Case Thoroughbred 
11 California Case Thoroughbred 
12 California Case Quarter Horse 
13 California Case Warmblood 
14 California Case Thoroughbred 
15 California Case Paint 
16 California Case Thoroughbred 
17 California Case Quarter Horse 
18 California Case Thoroughbred 
19 Kentucky Case Thoroughbred 
20 Kentucky Case Thoroughbred 
21 Minnesota Case Quarter Horse 
22 Minnesota Case Quarter Horse 
23 Minnesota Case Quarter Horse 
24 Minnesota Case Not mentioned 
25 Iowa Case Not mentioned 
26 Idaho Case Thoroughbred 
27 Pennsylvania Case Not mentioned 
28 Wisconsin Case Not mentioned 
29 Minnesota Control Not mentioned 
30 Minnesota Control Not mentioned 
31 Minnesota Control Not mentioned 
32 Minnesota Control Not mentioned 
33 Minnesota Control Not mentioned 
34 Minnesota Control Not mentioned 
35 Minnesota Control Not mentioned 
36 Minnesota Control Not mentioned 
 
 
149 
 
Table 5.1 continued... 
37 Minnesota Control Quarter Horse 
38 Minnesota Control Quarter Horse 
39 Minnesota Control Quarter Horse 
40 Colorado Control Not mentioned 
41 Virginia Control Thoroughbred 
42 Virginia Control Dutch Warmblood 
43 Virginia Control Draft cross 
44 California Control Quarter Horse 
45 California Control Quarter Horse 
46 California Control Quarter Horse 
47 California Control Quarter Horse 
48 California Control Quarter Horse 
49 California Control Quarter Horse 
50 California Control Quarter Horse 
51 California Control Quarter Horse 
52 California Control Quarter Horse 
53 California Control Quarter Horse 
54 California Control Quarter Horse 
55 California Control Quarter Horse 
56 California Control Crossbred 
57 California Control Warmblood 
58 California Control Quarter Horse 
59 California Control Mustang 
60 California Control Thoroughbred 
61 California Control Crossbred 
62 California Control Crossbred 
63 California Control Quarter Horse 
64 California Control Lusitano 
65 California Control Warmblood 
66 California Control Warmblood 
67 California Control Not mentioned 
68 California Control Pony 
69 California Control Paint 
70 California Control Crossbred 
71 California Control Welsh pony 
72 California Control Welsh pony 
73 California Control Welsh pony 
74 California Control Quarter Horse 
75 California Control Quarter Horse 
76 California Control Pony 
77 California Control Thoroughbred 
78 California Control Warmblood 
79 Kentucky Control Thoroughbred 
80 Kentucky Control Thoroughbred 
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Table 5.1 continued…. 
81 Kentucky Control Thoroughbred 
82 Kentucky Control Thoroughbred 
83 Kentucky Control Thoroughbred 
84 Kentucky Control Thoroughbred 
85 Kentucky Control Thoroughbred 
86 Kentucky Control Thoroughbred 
87 Kentucky Control Thoroughbred 
88 Kentucky Control Thoroughbred 
89 Kentucky Control Thoroughbred 
90 Kentucky Control Thoroughbred 
91 Kentucky Control Thoroughbred 
92 Iowa Control Not mentioned 
93 Iowa Control Not mentioned 
94 Iowa Control Not mentioned 
95 Oklahoma Control Paint 
  (SNP) in horse chromosome 6 (ECA6) with the occurrence of EHM [363]. In the study 
described below, we were unable to find this association on ECA6, or any other association.   
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Figure 5.1: Manhattan plot of the -log10 P values for correlation of SNPs with EHM based on recessive model genome-wide association (GWAS) 
study using 94 horses with 382,529 markers were analyzed using the Ecab 3.0 data. No significance was observed after adjusting for Bonferroni 
corrections.  
 
 
Figure 5.2: Genome plot (Ecab 3.0) of -log10 P values for association test of runs of homozygosity (ROH; minimum 5 samples with minimum 
homozygosity length of 400 kb with at least 60 SNPs) Association test.  No significant associations were found for any ROH.   
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CHAPTER SIX 
 GENERAL DISCUSSION 
 
EHV-1, EHV-4 and EAV are among the most important viruses infecting horse 
populations around the world and pose a significant threat to the global as well as the U.S. 
equine industry which is estimated to be approximately 122 billion dollars 
(https://www.horsecouncil.org/resources/economics/). Characteristic to EHV-1, EHV-4 
and EAV is their endotheliotropic nature which plays a major role in inducing vasculitis. 
Induction of vasculitis in the blood vessels of the pregnant uterus is the underlying reason 
for abortions in pregnant mares following EHV-1 or EAV infections [5; 6; 17-19; 61]. 
EHV-4 is primarily regarded as a respiratory pathogen of equids yet on rare occasions 
EHV-4 infect and replicate in endothelial cells of local capillaries of lymph nodes and 
pulmonary vessels. Vasculitis is the inflammation of the walls of the blood vessels and 
several factors including the production of proinflammatory cytokines and chemokines by 
immune and endothelial cells play significant roles [255]. However, the proinflammatory 
cytokine and chemokine response mounted by EECs in response to EHV-1, EHV-4 and 
EAV infections have not been extensively characterized.  
The proinflammatory cytokine and chemokine profile of virus infected EECs revealed 
the gene expression levels of IL18, GM-CSF, CXCL16, IFNɣ (proinflammatory cytokines) 
and IL8 and CCL3 (proinflammatory chemokines) were expressed less than two-fold in 
most instances (Table 2.3) suggesting that, at least in the case of virus infections, the 
expression of these genes were not being induced in EECs. Furthermore, It is well 
established that EHV-1 and EAV infected PBMCs upregulate IFNɣ gene expression [64; 
364; 365]. However, IFNɣ gene expression or secretion was not detected in EECs 
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following infection with EHV-1, EHV-4 or EAV as demonstrated by RT-qPCR and 
Luminex data suggesting EECs may not be a good source of IFNɣ following virus 
infections (Table 2.3). The gene expression of the rest of the proinflammatory cytokines 
and chemokines (IL6, IL17, CXCL9, CXCL10, CXCL11, TNFα, IFNα, IFNω, CCL4 and 
CCL5) analyzed during this study were upregulated 5-folds or higher in virus infected 
EECs (Table 2.3). Interestingly, it was observed that the relative gene expression as well 
as the secretion of these proinflammatory cytokines and chemokines were relatively lower 
in EECs infected with EAV, suggesting a relatively lower induction of the host 
inflammatory response by EAV compared to EHV-1 and EAV infected EECs (Table 2.3).  
Moreover, as is evident from the RT-qPCR and Luminex data, EAV infected EECs 
induces a lower gene expression as well as a lower secretion of CXCL10 and IFNα relative 
to EHV-1 and EHV-4 infected EECs (Table 2.3, Figures 2.2 & 2.4). Previous studies done 
in our lab has unequivocally demonstrated EAV suppresses the production of IFNβ 
secretion from EECs and this is brought about by the action of EAV nsp1 on IRF3 and NF-
𝜅B [138]. Therefore, the relatively lower IFNα gene expression as well as secretion might 
be a result of the same suppression mechanism since IFNα, similar to IFNβ, is also 
stimulated by IRF3 and NF-𝜅B [222]. As such, the data from this study together with the 
study previously done in our lab by Go et.al. (2012) [138] makes a strong case for the 
reduction of type I interferon ( IFNα and IFNβ) gene expression as well as their secretion 
from EECs following EAV infection. Moreover, EAV infected EECs has a relatively lower 
gene expression for CXCL10 which is a proinflammatory chemokine that induces T and B 
lymphocytes, natural killer cells, dendritic cells and macrophages [278-280].    
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Interestingly, as demonstrated by the RT-qPCR and Luminex results, the 
proinflammatory cytokine and chemokine gene expression and secretion from EECs 
following EHV-1 and EHV-4 infections, for the most part, did not show significant 
differences (Table 2.3, Figures 2.2 & 2.4). Furthermore, the growth curves for EHV-1 and 
EHV-4 in EECs followed a similar pattern as well (Figure 2.1). During natural infection, 
EHV-1 strains cause abortions and occasionally EHM by inducing vasculitis in the 
pregnant uterus and the CNS. However, such disease manifestations are rare following 
natural EHV-4 infections due to the absence of CAV [178; 275]. On instances CAV is 
detected following EHV-4 infections, viral DNA remains in low amounts in PBMCs and 
only for a short period of time [276]. This appears to be a major limitation in EHV-4 
pathology that prevents the efficient transfer of virus particles from its primary sites of 
infection to endothelial cells of the pregnant uterus or the CNS where it can infect and 
induce viral vasculitis. Studies including this one have demonstrated that EHV-4 is capable 
of infecting and replicating in EECs in-vitro and occasionally in-vivo [37; 277]. 
Furthermore, this study demonstrates that the cellular response of EECs towards EHV-1 
and EHV-4 infections, for the most part, remains the same with regards to the 
proinflammatory cytokine and chemokine gene expression as well as secretion (Table 2.3, 
Figures 2.2 & 2.4). Therefore, it is reasonable to assume that if EHV-4 strains infected 
endothelial cells in-vivo, the vasculitis process and the following disease manifestations in 
the form of abortions or EHM might be the same as with EHV-1 strains. The results of this 
study indicate the lack of such disease manifestations is probably due to the inefficient 
transportation of the virus to endothelial cells of blood vessels of the pregnant uterus and 
the CNS rather than EHV-4 strains not being able to infect endothelial. Therefore, the 
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results of this study strongly point towards inefficient leukocyte associated viremia as a 
major reason for the mild disease outcomes associated with EHV-4 infections.  
Global transcriptomic analysis of EAV and EHV-1 infected cells provided valuable 
insights about the molecular pathways and genes associated with the host response against 
EHV-1 and EAV infections. The pathway analysis revealed that EECs infected with both 
EHV-1 and EAV differentially expressed the CCKR signaling map”, “Inflammation 
mediated by chemokine and cytokine signaling pathway” and the “Gonadotropin-releasing 
hormone receptor pathway” during the first 12 h of infection (Tables 4.1, 4.2, 4.3, 4.4A&B 
and 4.5A&B). These 3 pathways are associated with the host Inflammatory responses 
against infections [308; 325; 326]. As such, the data from this study reveals both viruses 
stimulate pathways that contribute to the local inflammatory response in EECs. This, 
together with the relative gene expression and Luminex data indicates the molecular 
pathways as well as the proinflammatory cytokines and chemokines that play key roles in 
inducing vasculitis which is the major pathological condition that drives the disease 
outcomes associated with both EHV-1 and EAV infections.  
Global transcriptome analysis together with RT-qPCR revealed the upregulation of 
TLR3 mRNA in EECs following EHV-1 infection suggesting the involvement of TLR3 in 
the induction of the inflammatory response associated with EHV-1 infections (Figure 4.1). 
interestingly, siRNA silencing of TLR3 in EECs revealed that TLR3 plays a key role in the 
upregulation of IFNα mRNA during the first 6 h of EEC infection. However, no such 
involvement for TLR3 following EAV infection of EECs was made (Figure 4.3A&B).  
The GWAS analysis of horses with EHM was done in order to investigate host 
genetic factors that may play a role in EHM development following EHV-1 infection. In 
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this current study we examined 382,529 SNPs using a population of 94 horses (28 cases 
and 66 controls), however, we did not find evidence for a host genetic association with 
EHM development following EHV-1 infections (Table 5.1, Figures 5.1&5.2). The power 
of our test was sufficient to reject a hypothesis of genetic effect by recessive alleles. 
Furthermore, we did not see any evidence for trends in the data identifying other possible 
modes of inheritance (Figure 5.2). However, the power of our test was not sufficient to 
detect complex genetic causes involving multiple loci. One of the major limitations to this 
test was the lower sample size and this may have affected the detection of genetic loci 
associated with EHM development. Furthermore, we failed to corroborate the results 
obtained by Brosnahan et al. (2018) that reported an association between a SNP and the 
occurrence of EHM in a manner suggesting a recessive mode of inheritance [363]. 
Future directions 
The results presented here provide novel insights about the modulation of the innate 
immune response of EECs against EHV-1 and EAV infections. In particular, our data taken 
together with the observations of Go et.al. (2012), makes a strong case for the suppression 
of type I interferon (IFNα and IFNβ) gene expression as well as their secretion from EECs 
following EAV infection (Table 2.3 & Figure 2.2). Furthermore, the secretion of CXCL10 
as well as the gene expression of proinflammatory cytokines and chemokines were also 
relatively lower in EAV infected EECs when compared with EHV-1 infected EECs (Table 
2.3 & Figure 2.4). However, the mechanism utilized by EAV to influence this relatively 
lower proinflammatory response from EECs remains to be further elucidated. Go et.al. 
(2012) has demonstrated that EAV nsp1 influences the suppression of IFNβ production 
from EAV infected EECs by interfering with the action of IRF3 and NF-𝜅B [138]. 
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Therefore, further investigations are warranted to elucidate if EAV nsp1 is responsible for 
the lower proinflammatory response as well as the mechanism that bring about this lower 
inflammatory response. 
Data from this study also demonstrated the involvement of TLR 3 in inducing IFNα 
from EHV-1 infected EECs during the first 6 h of infection. However, TLR 3 was not 
involved in IFNα stimulation after the initial stages of infection even though IFNα gene 
expression as well as secretion was observed (Figure 3.3A&B). However, what molecules 
and pathways are involved in this process remains to be elucidated and warrants further 
investigations. Furthermore, TLR 3 was not deemed to be involved in the proinflammatory 
response induced by EAV in EECs. Therefore, it is important to further investigate the role 
played by TLRs during EAV infection of EECs.  
The transcriptomic analysis of EHV-1 and EAV infected EECs displayed distinct 
clusters of up and downregulated genes as well as pathways (Tables 4.1, 4.2, 4.3, 4.4A&B 
and 4.5A&B and Figure 4.1). Among others, the “gonadotrophin hormone releasing 
receptor pathway”, “CCKR signaling map” and the “Inflammation mediated by cytokine 
and chemokine pathway” was differentially expressed frequently in EECs infected with 
both EHV-1 and EAV (Tables 4.1, 4.2, 4.3, 4.4A&B and 4.5A&B). Since this study was 
only focused on elucidating these differentially expressed genes and pathways in-silico, 
further work is required to confirm these results with functional studies.  
The GWAS study investigated the involvement of host genetic factors in the 
development of EHV-1 induced EHM but found no evidence for a genetic association 
(Figure 5.1). However, the biggest limitation in that study was the sample size (94 
samples). Even though the power of our test was sufficient to reject a hypothesis of genetic 
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effect by recessive alleles it wasn’t sufficient to detect complex genetic causes based on 
multiple loci. Therefore, a repeated experiment with a higher sample number has the 
potential to reveal more promising results. 
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Appendix 1 
EXPERIMENTAL METHODS 
TLR siRNA Transfection Method to EECs 
siRNA stock solution preparation 
1. Dilute 5 nmols of siRNA in 100 µL of nuclease free water to make a 50 µM stock
solution. Store the stock solution in -20 °C until further use. Prepare fresh working
solutions from the stock solution for siRNA transfection.
siRNA transfection into EECs 
1. Prewarm 24 well cell culture plates with complete DMEM media
2. Harvest cells by trypsinizing (1×105 cells/well) and centrifuge at 90g for 10 minutes
3. Remove the supernatant and resuspend the cell pellet in 4DNucleofector™
Solution.
4. Prepare master mixes (4DNucleofector™ Solution+cells+siRNA) by dividing cell
suspension according to number of substrates
5. Add required amount of substrates to each aliquot
6. Transfer master mixes into the Nucleocuvette™ Vessels
7. Place the Nucleocuvette™ Vessels inside the Lonza 4D nucleofection unit.
8. Use the program for BHK21 to electroporate cells
9. Remove the Nucleocuvette™ Vessels from the Lonza 4D nucleofection unit
10. Mix 500 µL of prewarmed media with the electroporated cells in Nucleocuvette™
Vessels and transfer the cells into 24 well cell culture plates
11. Incubate the cell culture plates for 24 h in a 37 °C incubator in the presence of 5%
CO2.
In-vitro infection of siRNA transfected EECs 
1. Prepare fresh working stocks of virus by diluting concentrated stocks in MEM. All
in-vitro infections are carried out at 2 MOI.
2. Remove cell culture media from siRNA transfected cell containing 24 cell culture
plates by aspiration
3. Add the virus containing MEM onto cell monolayers and incubate the plates for 1
h in a 37 °C incubator in the presence of 5% CO2.
4. After 1 h remove the MEM medium containing the virus through aspiration and
add 1 mL of fresh complete DMEM medium to each well.
5. Incubate the cell culture plates for 6 and 12 h in a 37 °C incubator in the presence
of 5% CO2.
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Luminex Assay for Cell Culture Supernatant 
Preparation of antibody-immobilized beads     
1. Sonicate antibody-bead vials for 30 seconds followed by vortexing for 1 minute.
Add 60 μL from each antibody-bead vial to the mixing bottle and bring final volume
to 3.0 mL with bead diluent. Vortex the final bead mix thoroughly.
Preparation of quality controls 
1. Reconstitute quality controls 1 and 2 by adding 250 μL of deionized water. Invert
the vial several times to mix.
Preparation of wash buffer 
1. Dilute 60 mL of 10X wash buffer with 540 mL deionized water.
Preparation of equine cytokine standard 
1. Reconstitute the equine cytokine standard with 250 μL deionized water. Invert and
mix the vial several times. Vortex the vial for 10 seconds.
Preparation of samples 
1. Thaw samples on ice and centrifuge the sample to remove debris.
Luminex assay for cell culture supernatant 
1. Add 200 μL of wash buffer into each well of the plate. Seal the plate and mix on a
plate shaker for 10 minutes at room temperature.
2. Invert the plate and decant the wash buffer.
3. Add 25 μL of each standard and control into the appropriate wells.
4. Add 25 μL of assay buffer to the sample wells.
5. Add 25 μL of complete DMEM to the background, standards, and control wells.
6. Add 25 μL from each sample to appropriate wells.
7. Add 25 μL of mixed beads to each well.
8. Seal the plate with a plate sealer and wrap the plate with foil. Incubate with agitation
on a plate shaker overnight (16-18 hours) at 2-8°C.
9. Following incubation, remove well contents and wash the plate 3 times with the
wash buffer.
10. Add 25 μL from the detection antibodies into each well.
11. Seal the plate with a plate sealer and cover with foil. Incubate with agitation on a
plate shaker for 1 hour at room temperature.
12. Add 25 μL of Streptavidin-Phycoerythrin to each well containing the detection
antibody mix.
13. Seal the plate with a plate sealer and cover with foil. Incubate with agitation on a
plate shaker for 30 minutes at room temperature.
14. Gently remove the well contents and wash the plate 3 times with wash buffer.
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15. Add 150 μL of sheath fluid into all the wells. Resuspend the beads on a plate shaker
for 5 minutes.
16. Run the plate on a Luminex® 200™ machine.
Transcriptome Analysis of Virus Infected EECs 
In-vitro infection of EECs with EHV-1 and EAV 
1. Seed 1×106 EECs in 6 well cell culture plates and incubate in a 37 °C incubator in
the presence of 5% CO2 to form cell monolayers.
2. Calculate the volume of virus needed for a MOI of 2. Mix the virus with MEM
medium and add onto cell monolayers. Adsorb for 1 h at 37 °C in the presence of
5% CO2.
3. After 1 h, remove the virus containing medium and add fresh complete DMEM
medium to cell monolayers.
Total RNA extraction 
1. Total RNA was extracted from EHV-1 and EAV infected EECs at 6 and 12 hpi
timepoints using the miRNeasy mini kit (Qiagen, Hilden, Germany) following the
manufacturers protocol.
2. Extracted RNA was quantified using a bioanalyzer.
3. 300 ng of total RNA was submitted for whole transcriptome sequencing.
Data analysis 
1. Reads were initially trimmed for adapters and quality using TrimGalore Version
4.4.
2. Trimmed reads were aligned to the horse reference genome (EquCab3.0) using
STAR (Release 2.5.2b).
3. Cufflinks (Release 2.2.1) was used to annotate to the equine reference
transcriptome available in NCBI database.
4. Cuffdiff 2.2.1  was used to calculate differently expressed genes between samples
from the mock and virus infected groups.
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